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1. INTRODUCTION 
1.1 BREAST CANCER: MOTIVATION AND STATISTICS 
 Cancer is a disease characterized by uncontrolled growth of cells. Though 
herculean efforts have been put up by various researchers in understanding the 
dynamics of cancer, treatment still remains a distant solution. Breast cancer is the 
most common cause of cancer death among women (522 000 deaths in 2012), 
making it a major global health concern. In 2008, breast cancer caused 458,503 
deaths worldwide (13.7% of cancer deaths in women) and in 2012 the number 
shot up to 522, 000 [1]. Since the 2008, the incidence of number of patients 
affected by breast cancer has increased by more than 20%, while mortality has 
increased by 14% which clearly indicates the dangers associated with it. Early 
diagnosis of cancer can be treated either by surgery or chemotherapy or local 
irradiation. But, unfortunately patients are diagnosed from breast cancer at a stage 
where the dissemination of cancerous cells to the adjacent lymph nodes has 
already begun by metastasis. Even after extended mastectomy, the tumour can 
recur due to metastasis of tumor cells to the sentinel lymph nodes [2].  
1.2 METASTASIS OF BREAST CANCER AND THE ROLE OF 
 LYMPHATICS IN ASSISTING THE SPREAD 
Breast cancer originates in the lobular or ductal epithelial cells as a result of a 
series of genetic events which leads to inhibition of normal apoptotic responses 
and aberrant regulation of the cell cycle. Several genes and signalling pathways 
are involved in the development of breast cancer including the germ-line or 
somatic mutations in tumor-suppressor genes (e.g., p53, BRCA1, BRCA2, and 
PTEN), disturbance in the signalling pathways or estrogen receptors, and over 
expression of proto-oncogenes like HER2/neu. Additionally, breast cancer also 
promotes metastasis [3,4]. 
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 Metastasis is the spread of cancer from one organ or tissue to distant organ 
environments. More than 90% of the cancer deaths are as a result of metastatic 
spread [5]. When cancer is diagnosed at an early stage, before it has spread, it can 
often be treated by surgery or chemotherapy or local irradiation. But, when cancer 
is detected after it is known to have metastasized, treatments are much less 
successful. Also, in patients where metastasis is not observed in the initial 
diagnosis, it can occur at a later time.  
 Cancer cells escape from the primary tumour site to the secondary organs 
through the blood vessels and lymphatic vessels. For some cancers like breast, 
prostate, colon and lung, dissemination via lymphatics precedes dissemination 
through blood vessels. Generally metastasis starts within the regional lymph nodes 
and facilitates the migration of tumour cells to other organs of the body by 
lymphangiogenesis. Figure 1 represents the pathway for the metastatic 
dissemination of cancerous cells and the process of metastasis to different organs 
in the body [4]. Lymphangiogenesis is a process that generates new lymphatic 
vessels from the pre-existing lymphatics or lymphatic endothelial progenitors. 
Lymphatic vessels are comparatively more favourable for the transport of pre- 
metastatic cancerous cells than the blood vessels because of the following reasons: 
 Discontinuous basement membrane and loose cell- cell junctions of the 
 endothelial cells 
 Lower flow rate of the lymph that increases survival by minimizing shear 
 stress 
 A 1000-fold high concentration of hyaluronic acid, a molecule with potent 
 cell protecting and pro- survival properties [4] 
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Figure 1. Metastatic dissemination of cancerous cells through the lymphatics 
 Figure 2 represents the metastasis of breast cancer to different organs 
Thus, inhibiting lymph node metastases by targeting the anticancer drugs to the 
regional lymph nodes will not only reduce the tumour burden, but will also 
prevent the cancer metastasis through the lymphatics. This can ultimately lead to 
an improvement in the quality of patients’ life and survivability [6]. Application 
of targeted delivery of anticancer nanotherapeutics to the cancer cells in the 
regional lymph nodes is a good option to inhibit metastases of breast cancer. 
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Figure 2. Diagrammatic steps representing the metastasis of 
breast cancer to different organs. 1) proliferation 2) lymphangiogenesis  
20 migration and invasion 4) intravasation 5) metastasis to secondary sites 
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1.3 LYMPHATICS AND THEIR ROLE 
 The discovery, study and evolution of lymphatics have a great history, 
spinning across centuries. Initial description about lymphatics was first made by 
the ancient Greeks in 300 B.C and thereafter several theories and treaties have 
propped up. It was only in 1622 that the lymphatic system came into prominence 
through various works of Gasparo Aselli [7]. Then, only by 19th century a clear 
picture about lymphatics came into existence owing to the works of the Hunter 
brothers, William Hewson, William Cruikshank and Paolo Mascagni [7]. 
 The lymphatic system, found in all tissues of the body, is a one- way 
transport system for the collection, filtration and returning of interstitial fluid and 
proteins to the blood circulation. Apart from maintaining the tissue fluid balance, 
it also plays a major role in the trafficking of immune cells and dissemination of 
tumour cells. The lymphatic system consists of circulating lymph, network of 
lymphatic pathways like lymphatic capillaries, collecting vessels, trunks and ducts 
and lymphatic organs like lymph nodes, thymus, bone marrow, spleen, tonsils, 
Peyers patches and mucosa associated lymphoid tissue (MALT) [8].  
 During the passage of blood through its vessels, plasma fluid and proteins 
come out to the interstitial spaces owing to the hydrostatic and pressure gradients. 
This exudate is termed as interstitial fluid and a part of this is reabsorbed into post 
capillary venules. The uptake of the remaining fraction occurs through the thin 
endothelium of the initial lymphatic capillaries through intracellular junctions, 
which is termed lymph. As lymph originates from the blood, the chemical 
composition, amount of lipids, enzyme activity and proteins composition is 
usually same as that of plasma, but vary only in terms of their concentration. 
Lymph from the initial lymphatic capillaries is drained into the lymphatic vessels 
and may possibly encounter lymph nodes which filter the lymph. Then, it enters 
into the lymphatic vessels and large lymphatic vessels through numerous 
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lymphatic trunks which collects lymph from different parts of the body. Finally, 
the lymph from the lymphatic ducts will be returned back to the blood circulation. 
During the course of passage of lymph through the lymphatic structure, lymph is 
encountered by lymph nodes. The lymph nodes acts as mechanical filters by 
filtering the lymph and also acts as immunological mediators by producing 
antibodies and proliferating lymphocytes [9]. Figure 3 represents an overview of 
the lymphatic system. 
 
Figure 3. Overview of the lymphatic system 
1.4 NANOTHERAPEUTICS FOR CANCER CHEMOTHERAPY 
 Nanotherapeutics involves application of nanotechnology in the field of 
medicine to aid treatment for diseases at the nanoscale, where majority of the 
biological molecules exist and function. Advances in nanotechnology are being 
applied in the development of novel therapeutics which can address a number of 
shortcomings of conventional drugs/ molecules. Additionally, using 
nanotherapeutics, problems of conventional anticancer drugs such as dose related 
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toxic effects (haemolytic a naemia, bone marrow toxicity, etc), nonselective 
killing of non tumor cells and drug resistance has been addressed. Recently, 
numerous investigations have been concentrated on biodegradable 
nanotherapeutics (using lipids and polymers) for the delivery of anticancer drugs 
to the desired target, which has great potential to revolutionize the future of cancer 
therapy [6,10,11]. Some of the complex issues solved using nanotherapeutics are, 
enhanced permeation across the complex blood brain barrier [12]; the ability of 
the multi drug resistant cancer cells to overcome the drug resistance for anticancer 
drugs  and selective targeting of the nanotherapeutics to the cancerous cells  [13]. 
Some of the nanotherapeutics approved by FDA in treating cancer like 
DaunoXome (Lipid based daunorubicin for Kaposis sacoma), Doxil (lipid based 
Doxorubicin for various cancers), Abraxane (Albumin bound paclitaxel for breast 
cancer and metastatic pancreatic cancer), etc have shown great potential and the 
window remains wide open for further development of nanotherapeutics for 
treating cancer and other ailments [14]. 
 1.5 LIPID BASED NANOTHERAPEUTICS 
 Lipids are a chemically diverse group of compounds with high solubility 
in non polar solvents and poor solubility in water. They are chemically complex in 
nature and play a crucial role by forming the basic structural elements of the 
biological membranes, vitamins, hormones, intracellular messengers, enzyme 
cofactors, emulsifying agents in the digest tract, electron carriers, etc. Apart from 
being a major part of our diet, lipids form a major constituent of our body. This 
clearly indicates that lipids are biocompatible, non toxic to our body. Hence, if 
used wisely, lipids can form an excellent carrier for drug delivery in terms of 
acceptability to the body, safety and scalability [15–17] . Lipids are usually either 
fatty acids and/ or their derivatives, and substances related to these compounds. 
They are generally amphiphilic in nature because of the presence hydrophilic head 
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portion to which the lipophilic fatty acid(s) tail portion is esterified [14–19]. The 
melting point of lipids normally increases with an increase in its molecular weight 
(hydrocarbon chain length) and decreases with unsaturation (presence of double 
bonds) of the fatty acid. Each lipid is uniquely identified by their fatty acid 
composition, melting point, hydrophilic-lipophilic balance (HLB), and solubility 
in non-polar organic solvents. Over the past few decades there has been a surge in 
the application of lipids to cater the needs of drug delivery. Owing to the unique 
properties of lipids viz., their physiochemical diversity, affordability, 
biocompatibility, ease of metabolism, biodegradability and proven ability to 
enhance oral bioavailability of poorly water soluble have made them preferred 
candidates for various drug delivery applications [16,20–22]. 
1.6 VARIOUS KINDS OF LIPID BASED COLLOIDAL DRUG 
 CARRIERS 
 Lipid-based colloidal drug carriers like liposomes, solid lipid 
nanoparticles, nanostructured lipid carriers, lipid based micelles, lipid polymer 
hybrids, lipid emulsions, lipid nanospheres, cubosomes, ethosomes, phytosomes, 
etc have been used to improve the therapeutic efficacy of drugs and plant extracts 
[16,20,23–28].   
 Liposomes are compact vesicles which are composed of one or more 
phospholipid bilayers enclosing an aqueous phase. They can be briefly classified 
as small unilamellar vesicles, large multilamellar vesicles, large unilamellar 
vesicles depending on the size and number of lipid bilayers present. They are 
excellent drug carriers and are capable of carrying hydrophilic drugs in their inner 
aqueous phase or hydrophobic drugs in their hydrophobic lipid bilayers. As 
liposomes are composed of the biomembranes, they are biodegradable, non-toxic 
and widely used [29]. Liposomes can also evade phagocytosis against 
macrophages by imparting stealth character and consequently enhance the half life 
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of drugs. They can also increase the solubility and absorption of poorly water-
soluble drugs. Although some group of researchers are of the view that liposomes 
are capable of protecting the drugs in the gastrointestinal tract against the hostile 
conditions, other group of researchers showed that the enzymatic activity in the 
duodenum and bile salts can destroy the lipid bilayers of the liposomes. But, 
liposomes which are prepared from phospholipids (with a phase transition 
temperature above 37ºC) and cholesterol are most resistant to degradation [30,31].  
 Solid lipid nanoparticles (SLNs) are colloidal carriers consisting of a solid 
lipid core at room temperature, dispersed in an aqueous solution of stabilizers. 
They are produced by replacing the liquid lipid (oil) part of an emulsion with solid 
lipids which exist as solids at both room and body temperature. The minute size of 
SLNs (20- 500 nm) enables efficient uptake of drugs into the intestine via the 
lymphatic route [32]. The main advantages offered by SLNs are, controlled 
release of drugs, improved stability of drugs, good drug loading, ability to entrap 
both hydrophilic and lipophilic drugs. These solid lipid nanoparticles, after being 
converted to powder by freeze drying can be filled in hard gelatin capsules or can 
also be incorporated as a suspended form in PEG and filled into soft gelatin 
capsules. The spray-dried or lyophilized powders can even be filled into sachets 
[19,30,33–36].  
 
 Nanostructured lipid carriers (NLCs) are similar to SLNs, but additionally 
contain liquid oil component (mostly unsaturated fatty acids) along with solid 
lipid component. They have been introduced to overcome the limitations of SLNs 
i.e., limited drug loading capacity and drug expulsion during storage. It is an 
established fact that longer fatty acid triglycerides require higher energy (i.e., the 
higher the temperature) for melting. The oil inside the NLC system will provide a 
uniform heating medium in melting the lipid and will result in an efficient 
emulsification. Their size varies from 100- 500 nm and has been frequently used 
for enhancing bioavailability and drug targeting purposes also [37–42]. 
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 Lipid--polymer hybrid nanoparticles contain a hydrophobic polymeric core 
along with the drug, a lipid monolayer and an outer layer made of PEG eg. PEG-
DSPE. This polymer-drug mixture is encapsulated in a lipid layer (lecithin), which 
is further covalently conjugated to DSPE-PEG. Lipid--polymer hybrids have 
found applications in cancer therapeutics. They offer good promise owing to their 
biodegradability, biocompatibility, sustained drug-release profile, stealth nature 
and excellent stability in blood [43,44]. 
 
 Lipid based micelles are formed by self-assembly of amphiphilic block 
copolymers. When dispersed in water, the amphiphilic block copolymers 
assemble into 30- 50 nm spheres with a core-shell structure. The hydrophobic 
segments form the core and the hydrophilic segments protrude into the aqueous 
medium. Lipids micelles are formed by adding surfactants (like phospholipids or 
PEG-phosphatidylethanolamine) at a concentration above the critical micellar 
concentration. They are easy to prepare and offer good stability [45,46].  
 
 Lipid emulsions are parenteral products containing vegetable oils which 
are emulsified with lecithin. The droplet size of the lipid emulsion varies from 200 
to 300 nm. Apart from using lipid nanoemulsions for nutraceutical purpose, they 
are used for drug delivery purpose due to the ability of oils to solubilise low water 
soluble drugs and to reduce toxicity of intravenously administered drugs. 
Generally, medium chain triglycerides and long chain triglycerides are used in the 
preparation of lipid emulsions [47]. 
 
 Lipid nanospheres are based on the logical selection of individual lipid 
components and ratios of drug and lipids using a complex formulation 
composition. They are generally less toxic with small particle size. These 
formulation factors allow better interaction with lipids for hydrolysis and favours 
rapid in vivo drug release [48].  
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 Cubosomes are discrete, sub-micron or nanostructured particles formed 
from fragmentation and steric stabilization of inverse bi-continuous cubic phases 
of lipids. Cubosomes have high internal surface area along with cubic crystalline 
structures. The cubic phases possess a very high solid like viscosity, which is a 
unique property because of their intriguing bicontinuous structures which enclose 
two distinct regions separated by the bilayer. They exhibit different internal cubic 
structure and composition with different drug loading modalities [49,50].  
1.7  LIPID BASED NANOTHERAPEUTICS FOR PREVENTION OF 
 CANCER METASTASIS BY TARGETING THE LYMPAHTICS 
 Recently, numerous investigations have been concentrated on the 
development of lipid based nanotherapeutics for the delivery of anti-cancer drugs 
to the desired target which has great potential to revolutionize the future of cancer 
therapy. It is a rapidly progressing field which can solve several limitations of 
conventional drug delivery. Herculean efforts have also been made to target 
various compounds to specific regions like brain, eye, breast, lungs, liver, colon 
etc. But attempts to target or deliver a specific compound to the lymphatics are 
comparatively less and this might owe to the simple fact that the lymphatics are 
present throughout the body and the medium is dynamic. Though the problems 
associated with targeting compounds to the lymphatics are challenging, the advent 
of nanotechnology has made the complex science appear simpler. In order to 
reach the lymphatics, the size of the particles should be in the range of  
10- 100 nm, the uptake rate into the lymphatics should be high and the route of 
delivery route should be appropriate [9]. Extensive literature survey suggests that 
solid lipid based nanoparticles can be selectively absorbed into the lymphatic 
system when administered subcutaneously [51,52].  
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1.8  SOLID LIPID NANOPARTICLES 
  Solid lipid nanoparticles (SLNs) are a relatively new class of spherical 
drug carriers which are of submicron size (10 to 1000 nm) [19]. They are made 
from physiological lipids (lipid acids, mono, di, or triglycerides, glyceride 
mixtures or waxes) that remain in a solid state at room and body temperature. 
Usually cytotoxic drugs show poor specificity, high toxicity and multi drug 
resistance. But, SLNs can solve these problems by enhanced permeability and 
retention effect (EPR) and by imparting specific targeting property to the 
cancerous cells [53]. Also, stealth character can be imparted to the SLNs by 
coating with non ionic surfactants to evade macrophage uptake and enhance their 
circulation time in the body [51,52]. Further, SLNs show controlled release, better 
stability and low drug leakage compared to other nanocarriers upon long term 
storage. Recently, researchers have also worked on specifically targeting solid 
lipid nanoparticles of lopanivir [54], methotrexate [55], etc to the lymphatics 
using SLNs. Their results have been promising which showed higher amounts of 
drug enter the lymphatics after administration through SLNs.  
 In order to reduce the toxic effect of anticancer drugs to the healthy cells 
and to impart targeting nature to the cancer cells, the surface of the SLNs has been 
modified (by conjugation or adsorption) using ligands like transferrin (an iron-
binding glycoprotein that binds to the transferrin receptors present on breast 
cancer cells) [12], folic acid [56,57], hyaluronic acid (it binds specifically to 
CD44 receptors, an extracellular protein on cell membranes that is over expressed 
only in tumors) [58]. Finally, the industrial scale up of solid lipid nanoparticles is 
very feasible and has been successfully attempted to scale up from laboratory to 
industrial level [19,59].  
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1.9  ADVANTAGES OF SLNs 
  SLNs combine the advantages of nanoparticles prepared using polymers and also 
avoid their disadvantages [14,19,37]. The numerous advantages of SLNs are: 
 SLNs in the range of below 200 nm (or sometimes 100 nm) are not taken 
up by the cells of Reticulo Endothelial System (RES) and thus evade liver 
and spleen filtration [21,60]. 
 Controlled release of the loaded drug can be achieved for several  
 weeks [61].  
 Drug targeting to specific cells/organs can be achieved [7,62].  
 SLNs are stable for longer time when compared to other colloidal drug 
 delivery systems [63].  
 SLNs prepared by high pressure homogenization are highly reproducible 
 and economically inexpensive [19]. 
 SLNs formulations have the feasibility of incorporating both hydrophilic 
 and hydrophobic drugs [60].  
 The lipid carriers are biodegradable and safe [64]. 
 Organic solvents are avoided in the SLN preparation. 
 Large scale production and sterilization are feasible [65]. 
1.10 TOXICITY AND REGULATORY STATUS OF LIPID EXCIPIENTS
 The Food and Drug Administration (FDA) has published listings in the 
Code of Federal Regulations (CFR) for generally regarded safe (GRAS) category 
substances and a separate list entitled Inactive Ingredient Guide (IIG) for 
excipients was approved and incorporated in the marketed products. As excipients 
play an integral part in the formulation, it is necessary to have a proper system to 
obtain regulatory clearance before using them in the formulation. This is very true 
for lipid excipients in view of their distinct physicochemical properties and 
potential complex interactions with other ingredients or physiological 
environment that may occur in vivo. 
Chapter 1  Introduction  
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  14 
 In the past, excipients like diluents, fillers, binders, lubricants, coatings, 
solvents, and dyes, were considered inert without any interactions with the drug, 
packaging material and biological environment. Off late, great deal of excipient 
research has delivered several novel exicpients with some toxicities and 
interactions. Thus, it is necessary to evaluate the toxicity and interaction profile of 
the excipients.  
 Toxicity and the status of excipients safety are some of the major issues 
for the development and usage of a product. One can have an excellent delivery 
system, but if the excipients are toxic, it is not possible to introduce them into the 
clinic setup. Fortunately, as lipids are present in the body and in all the foods 
which we take, the problem of safety owing to lipids will generally not arise and 
majority of the lipids are GRAS. But the final safety of the formulation may vary 
due to the usage of surfactants or co-surfactants which may be toxic (like 
Cremophor). Thus, for the preparation of various lipid formulations, surfactants of 
GRAS status must be used [33,66–68].  
 The status of excipients of lipids has to be discussed as a function of the 
administration routes. Usage of lipids for topical and oral administration of solid 
lipid nanoparticles, nanostructured lipid carriers, etc is absolutely safe with respect 
to lipids. Almost all the lipids can be used in the formulation of topical 
pharmaceutical and cosmetic products. Additionally, lipids from the food industry 
can also be used in the pharmaceutical industry after getting the due clearance 
from the regulatory bodies. Usage of a specific lipid in the food industry does not 
allow its direct usage for the preparation of pharmaceutical products. But, the 
toxicity data of a new lipid used in the food sector can be used for getting 
clearance from the pharmaceutical regulatory bodies [69–71].  
 For parenteral purpose, the category of lipids used for drug delivery 
applications change with respect to the type of lipid based formulation. Liposomes 
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have been traditionally administered by parenteral route for treating various 
ailments without any problem. Although SLNs and NLCs have been deemed safe 
on paper without any toxicity issues, they have not been the preferred carrier for 
administration of drugs via parenteral route. A good tolerability (without any 
changes to liver and spleen) was also observed even after administration of  
6 bolus injections of lipid (cetyl palmitate) at a dose of 1.33 g lipid/kg body 
weight. Surprisingly, there are also no products available in the market for 
parenteral purpose. But, glycerides which are composed of fatty acids as in oils of 
have been used for parenteral fat emulsions for nutraceutical purpose [33,46].  
 Lipids also commonly reduce the toxicity of several anticancer drugs by 
making them less toxic to the body and thereby protecting the healthy cells. In a 
nut shell, lipids are totally biocompatible without any toxicity owing to its natural 
origin.  
1.11 METHODS OF PREPARATION OF SOLID LIPID 
 NANOPARTICLES  
Preparation of solid lipid nanoparticles can be broadly categorised into hot 
melt and cold melt methods based on whether the lipid is melted by application of 
heat energy. Various methods of preparations of solid lipid nanoparticles have 
been proposed to meet different objectives [72]. The following are the general 
methods used for the preparation of SLNs.  
 
1.11.1 High pressure homogenization technique: 
 This technique was first developed by Muller and Lucks. High pressure 
homogenization technique can be employed for both hot and cold homogenization 
processes where the initial common step involves dispersing or dissolving the 
drug in a melted lipid phase [65]. 
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Hot High Pressure Homogenization: 
 Initially the lipid is melted approximately above 5°C it’s melting point 
followed by dispersing or dissolving the drug in the melted lipid to produce an oil 
phase. Simultaneously, a suitable surfactant is dissolved in water to produce an 
aqueous phase which is also heated to maintain at a temperature similar to the oil 
phase. Then the melted lipid phase is dispersed by the addition of aqueous phase 
using a high speed stirrer to form a pre emulsion. This pre emulsion is passed 
through a high pressure homogenizer with optimized conditions of pressure and 
cycles to obtain a dispersion of SLNs. 
 
Cold High Pressure Homogenization: 
 Similar to the hot homogenization method, initially the lipid is melted 
approximately above 5°C its melting point, followed by dispersing or dissolving 
the drug in the melted lipid to produce a clear and homogeneous oil phase 
followed by cooling the melt using dry ice or liquid nitrogen to form a solid drug 
dispersed lipid matrix. A high cooling rate will provide dispersion where the drug 
is uniformly distributed in the matrix. Then the solidified lipid matrix is reduced 
to microparticles by ball or mortar milling. This dispersion of lipid microparticles 
is dispersed in a cold aqueous surfactant solution and is allowed to pass through a 
high pressure homogenizer to form a suspension containing SLNs [19]. 
 
 For substances which are thermo labile, cold high speed homogenization is 
the preferred method as the time of exposure to the heat is less when compared to 
the hot high speed homogenization method. Another advantage which the cold 
high speed homogenization method possesses is that it is better suitable for the 
loading of hydrophilic drugs as there won’t be any partitioning of the drug from 
the lipid phase to the aqueous phase. This technique can also be used when the 
lipid matrix consists of lipids with high melting point. This technique is less 
effective in dispersing the lipids as the solid lipid matrix remains in the solid state 
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during homogenisation. Hence, the homogenization needs to be carried out 
slightly below the melting point of the lipid. This can soften the lipid during the 
homogenization process and facilitate dispersion of lipid leading to production of 
SLNs with smaller particle size [35].  
 
1.11.2 Microemulsion technique: 
 This technique was developed by Gasco. Initially, the lipid material is 
melted to form an oil phase. Simultaneously, an o/w surfactant/ co-surfactant is 
added to the aqueous phase and is heated at the same temperature as that of the oil 
phase. The melted lipid and aqueous phases are mixed in such a ratio (1:2 to 
1:100) so that a microemulsion is formed. A special thermostatic syringe can be 
used for the purpose of preparing microemulsion. Once the size of the 
microemulsion region in the phase diagram is fixed, the system needs to be kept at 
elevated temperatures during the production process to avoid conversion to a 
different system. This hot microemulsion is then diluted into excess of cold water 
to convert the microemulsion to an ultrafine nanoemulsion, thereby facilitating the 
internal lipid to re-crystallize. One main disadvantage is dilution of the suspension 
with large volume of water, which produces final product with concentrations 
below 1% particle content. Another disadvantage associated with this technique is 
the removal of large quantities of water in the final stage of processing. Also, the 
addition of high concentrations of surfactants and co-surfactants during the 
formulation may cause toxicity [71]. 
 
1.11.3 Solvent emulsification- evaporation technique: 
 This technique was initially developed by Sjostrom and Bergenstahl in 
1992. The lipid material is initially dissolved in water-immiscible organic solvents 
like cyclohexane or dichloromethane or chloroform or methylene chloride, 
followed by the addition of drug to it. An aqueous phase containing surfactant is 
prepared and added to the organic phase containing lipid to form an emulsion. The 
organic phase evaporated under mechanical stirring at high speeds or reduced 
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pressure to obtain an o/w emulsion consisting of a dispersion of SLNs. The 
solvent evaporation step must be quick for the formation of smaller particles 
without any aggregation. This technique can be best applied for the incorporation 
of hydrophilic molecules such as proteins and peptides [19,73].  
 
1.11.4. Solvent Displacement Technique: 
 The solvent displacement technique was first described by Fessi et al. for 
the production of polymeric nanoparticles and recently this technique has also 
been used to prepare SLNs. In this process, the lipid material is dissolved in a 
partially water- miscible solvent such as ethanol, acetone, or methanol followed 
by the addition of the drug to this organic phase. The aqueous phase is prepared 
by dissolving the o/w surfactant in water. The organic phase is carefully injected 
into the aqueous phase as a fine jet under high speed stirring. Droplets of solvent 
of nanometre size are formed from the o/w interface. The presence of surfactant 
stabilizes the droplets and finally the lipid nanoparticles are formed after complete 
evaporation of the water miscible organic solvent [48].  
 
1.11.5. Emulsification- Diffusion Technique: 
 The emulsification- diffusion techniques patented by Quintanar- Gerrero 
and Fessi is generally used to produce polymeric nanoparticles. Initially, to 
maintain thermodynamic equilibrium, a saturated solvent system of partially 
water- soluble solvents like benzyl alcohol or tetrahydrofuran is prepared by 
adding sufficient water. Then the lipid of choice and drug are dissolved in the 
saturated solvent to produce an organic phase. This organic phase is then 
emulsified under rapid agitation by addition of an aqueous solution containing a 
stabilizer. Finally, the lipid starts precipitating by the diffusion of solvent to the 
external phase to obtain an o/w emulsion of SLNs. The organic solvent is then 
eliminated by suitable method after which an aqueous dispersion of lipid 
nanoparticles of 100 nm and good size distributions is formed [74]. 
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1.11.6. Ultrasonication: 
 High shear homogenization and ultrasonication are the earliest dispersing 
techniques used for the production of SLNs and they can be either used in 
combination or separately. Initially the lipid is melted at a temperature 5°C above 
its melting point. Simultaneously, surfactant is added to the aqueous solution and 
heated to the same temperature of the lipid phase. The surfactant solution is 
dispersed in the lipid phase and homogenized using a high shear homogenizer for 
a predetermined time. Finally, the obtained pre emulsion is homogenised using a 
probe sonicator to obtain SLNs [61]. 
1.12 SCALE UP FEASIBILITY 
 For the success of a technology or a product, the ease of scale up at large 
industrial scale is very important. Fortunately, lipid based formulations are very 
easy to scale up because of the simplicity of the preparation methods and 
availability of equipments (like high pressure homogenisers) which can cater the 
need at industrial level. Using high pressure homogenisers, a GMP unit for large 
scale clinical batch production of solid lipid nanoparticles has already been 
developed and validated for batch sizes between 2 and 10 kg. Additionally, a large 
scale production setup for solid lipid nanoparticles has also been designed with a 
capacity as large as 50–150 kg per hour by placing two homogenisers in series. 
Thus, large scale production of SLNs is possible by discontinuous or continuous 
fashion [33,66,67,75–77]. 
1.13 STABILITY OF SOLID LIPID NANOPARTICLES 
 Formulations of nanoparticles in an aqueous medium results in poor 
stability and hinder the clinical use of the formulation. The physical and chemical 
instability of the nanoparticles arising due to the leakage of drug from the matrix 
and aggregation among the particles are the main obstacles encountered in the 
nanoparticles formulation. To overcome this difficulty, the water component has 
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to be removed and thus freeze drying technique comes into play. Freeze-drying 
(lyophilisation) is a process which removes water from a frozen material by 
sublimation and desorption under vacuum. However, the high stress involved in 
freeze drying and desiccation needs to be avoided and so, cryoprotectants such as 
aerosol, trehalose and mannitol are incorporated [78].  
 Freeze drying is an efficient way to boost the chemical and physical 
stability for a long duration. Freeze drying may be requisite to accomplish long 
term stability for a product containing hydrolysable molecules or a suitable 
product for per-oral delivery. Conversion into the solid state would prevent 
Oswald ripening and avoids hydrolytic reactions. Spray–drying is an alternative 
method to lyophilisation. But the compounds can be destabilized due to the 
elevated temperatures and high shear forces. Additionally, partial melting of the 
lipid phase during spraying can result in particle growth.  
1.14 TARGETING LINGAND AND THEIR RECPTORS 
 Research efforts have been recently shifting from cytotoxic nonspecific 
chemotherapies to molecularly targeted rationally designed drugs. Targeted 
chemotherapies offer a great potential advantage due to their ability to enhance 
specificity to deliver high doses directly to the target site. Anyway, this requires 
the identification of the relevant biomarkers or receptors that are over-expressed 
specifically by diseased cells but not in healthy tissue, so as to attain such 
selective targeted delivery. Information pertaining to the receptors used in the 
current research work has been described below: 
1.14.1 Vitamin B12 and Transcobalamin II Receptors 
 Vitamin B12 (cyanocobalamin) is an essential nutrient in the mammals 
with very poor bioavailability [79,80]. The recommended dietary allowance is 1-5 
μg per day and deficiency can lead to a number of diseases, including weakness, 
fatigue, constipation, and on a more serious scale, megaloblastic anaemia, 
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pernicious anaemia, and neurological malfunctions. Cyanocobalamin is the largest 
and most complex vitamin of all and it can be produced only by certain bacteria 
and archaea; hence, it is accessible in mammals only through diet. Vitamin B 12 
in the bloodstream is transported and taken up in the liver and other tissues by 
transcobalamin II (TCII). The TCII-B12 complex (holo- TCII) is transported into 
the plasma of the tissues by TCII receptor-mediated endocytosis operated by the 
transmembrane proteins. The internalized holo-TCII complex enters the 
lysosomes and dissociates into free cobalamin by lysosomal proteases. Vitamin 
B12 in cells is converted into its biologically-active cofactors, methylcobalamin 
and adenosylcobalamin. As rapidly dividing tumor cells require higher amounts of 
methionine and energy for cell proliferation, they show preferential accumulation 
of vitamin B12 compared with the healthy cells. Thus vitamin B12 helps in 
targeting cancer cells. Moreover, it shows additional features that make it suitable 
for possible therapeutic applications: it is water soluble, has no known toxicity 
and, as an indispensable vitamin for sustaining life, it is unlikely that a mutational 
arrest of vitamin B12 uptake (with concomitant failure of vitamin-mediated 
therapy) could occur. In testis, breast, ovarian, thyroid, uterine and brain tumors, 
there is a greater demand for vitamin B12 along with over expression of TC II 
receptors. Thus vitamin B12 conjugated nanocarriers can be used for targeting 
drugs or imaging agents directly to the tumor site [79].  
1.14.2 Hyaluronic Acid (HA) 
 HA is an extracellular matrix component composing of polyanionic 
glycoaminoglycan with repetitive disaccharide units of D-glucuronic acid and D-
N-acetylglucosamine. It can be used as a targeting ligand in nanomedicine for 
selectively identifying, binding and killing tumors over-expressing CD44 
receptors [58,81]. As CD44 receptors are over expressed in multiple human 
cancer cells with increasing density over progression of different stages of 
cancers, HA can be efficiently targeted to the cancer cells. Additionally, HA is 
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widely available, economic and biocompatible. CD44 receptors functions as a 
bioactive signalling transmitter and plays a role in the invasion and metastasis of 
different tumours including breast carcinomas. CD44 is a ubiquitous 
multistructural and multifunctional cell surface adhesion molecule involved in 
cell-cell and cell-matrix interactions. CD44 also has a role in a variety of 
responses, including lymphocyte homing, hematopoiesis, angiogenesis, 
inflammation and tumorigenesis. Thus, attaching HA to the nanocarriers 
containing anticancer drugs can improve its targeting ability to the tumour cells 
[81,82]. 
1.15 QUILLAJA SAPONIN (QS) AND ITS ROLE AS A SURFACTANT 
 QS is a non-ionic amphiphilic surfactant extracted from the bark of 
Quillaja saponaria (Soap bark tree). QS is a glycoside with a lipophilic backbone 
of Quillaic acid and gypsogenic acid (a triterpene aglycone), to which hydrophilic 
polysaccharide moieties like rhamnose, xylose, arabinose, galactose, fucose and 
glucuronic acid are attached [83]. Thus, QS can perform the role of a surfactant by 
adsorbing at the oil and water interface to form an emulsion [84]. Despite the 
characterisation of the micellar properties of QS as early as1800 AD and approval 
by the US Food and Drug Administration (FDA) [85], its application has not 
gained prominence in the pharmaceutical sector so far. In addition to its 
emulsifying property, QS also possesses many bioactivities (larvicidal, antitumor, 
antimicrobial etc.) and is used as a natural foaming agent in cosmetic products, 
and as an adjuvant in vaccine delivery [86][87][88]. Furthermore, a product based 
on the Quillaja saponaria bark extract is marketed under the trade name  
Q-Naturale and approved by FDA for use as emulsifier in beverages. 
 Thus, in the current research work, HA/ vitamin B12 surface modified 
SLNs of Imatinib mesylate (IM) were prepared to target the metastatic breast 
cancer cells in the lymphatics. Additionally, the efficiency of QS to form SLNs 
was also evaluated.  
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2. AIM AND OBJECTIVES 
 
 In order to reach the lymphatics of the breast, the uptake of nanoparticles 
into the lymphatics should be high and the route of delivery should be appropriate. 
The current doctoral research work has been planned to develop and evaluate 
ligand conjugated SLNs of Imatinib mesylate (IM) which can specifically target 
and kill the tumor cells in the lymphatics. Additionally, the role of lipids in 
solubilising IM and the utility of QS, a natural surfactant obtained from the bark 
of Quillaja saponaria, in the preparation of SLNs has also been evaluated for the 
first time. 
 The specific objectives of the work include: 
Specific objective 1:  
 To predict the solubility of IM in the lipids and to study the various 
properties of lipids which affect its solubilisation. 
Specific objective 2: 
 To develop and optimize SLNs of IM conjugated with ligands (like HA 
and vitamin B12) to facilitate targeting to the cancerous cells in the lymph nodes. 
Specific objective 3:  
 To evaluate the utility of QS, a novel and unexplored natural surfactant 
with anticancer activity, in the preparation of SLNs. 
Specific objective 4:  
 To characterize and evaluate the optimized SLNs for size, surface charge, 
morphology, conjugation efficiency, entrapment efficiency, physical state of the 
entrapped drug and in vitro release studies. 
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Specific objective 5: 
 To assess the cytotoxicity of the SLNs using in vitro cancerous and non 
cancerous cell lines. 
Specific objective 6:  
 To evaluate the concentration of IM in blood and sentinel lymph nodes in 
female Wistar rats after subcutaneous administration of the developed SLNs. 
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Scheme of the work 
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3.  REVIEW OF LITERATURE 
3.1. METASTASIS OF BREAST CANCER 
 Ran et al., 2010 elaborately described on lymphangiogenesis and 
lymphatic metastasis of breast cancer. They stated that metastasis of cancer 
through the lymphatics is the main prognostic factor for survival of patients with 
breast cancer and associated malignancies, which is facilitated by 
lymphangiogenesis. Major proteins which induce lymphangiogenesis have been 
mentioned in detail. The changes which are observed during different stages of 
breast cancer metastasis have also been mentioned. They also summarized the 
newer concepts related to lymphatic metastasis of breast cancer and its 
lymphangiogenesis by addressing some controversial questions [4]. 
 Tayyeb et al., 2014 described the pathogenesis of breast cancer to brain. 
They mentioned the reasons breast cancer, it’s metastasis and the basic 
pathophysiology behind it in a molecular basis. Additionally, they have also 
described various novel approaches for designing targeted based therapies for its 
treatment [89]. 
 Perret et al., 2008 summarised various pharmacological strategies to 
prevent metastasis of cancer. The lack of proper treatment for metastatic breast 
cancer was discussed and information on the available targets has been mentioned. 
Among them, the metastasis suppressor genes seem to be the most promising. In 
spite of this, during recent years, a dozen of molecules, which fulfil the definition 
of a specific metastatic drug that inhibits the metastases without altering the 
growth of the primary tumour (which can be eradicated by surgery), have been 
identified and assessed for the proof of the concept. The continuation of this effort 
would benefit in terms of efficiency, if the objectives were defined more precisely. 
It is particularly important to distinguish molecules that prevent spread of the 
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metastatic cells of the early-stage primary tumour from the ones which induce a 
regression of the established metastases or to inhibit the transition from 
disseminated occult tumour cells to dormant micrometastasis. This second goal is 
a more relevant in the current clinical setting where the detection of early 
metastatic spread is very difficult, and therefore would call for greater effort on 
the part of the scientific community [90]. 
3.2 Lymphatic targeting of drugs using nanoparticles 
 Cho et al., 2014 discussed the importance of targeting various kinds of 
nanoparticles to the lymphatics. They highlighted that targeting anticancer, 
immunotherapeutic drugs and lymphoid contrast agents, to both tumors and the 
lymphatics, has several advantages such as reduced systemic side effects and 
increased efficacy. The mechanism, efficiency and challenges of different 
nanoparticles like polymeric nanoparticles, liposomes, and lipid-based vehicles for 
lymphatic targeting and their clinical perspectives has been discussed [91]. 
 Liu et al., 2013 developed paclitaxel expansile nanoparticles for lymph 
node targeting to prevent the metastasis of breast cancer. In vitro showed a dose-
dependent cytotoxicity and decreased the growth of cancerous cells in vivo against 
human triple negative breast cancer murine models. It also decreased the 
metastasis of nanoparticles from the lymph nodes [92].  
 Reddy et al., 2007 tested in detail whether nanoparticles loaded with 
vaccines can be targeted to the dendritic cells of the lymph nodes and 
consequently activate them to obtain better response. They observed that after 
intradermal injection of the nanovaccines, the interstitial flow assisted in 
transporting them efficiently into the lymphatic capillaries and lymph nodes, 
(dendritic cells) in a size dependent manner. They used a model antigen 
ovalbumin, and successfully obtained higher levels of humoral and cellular 
immunity in mice [93]. 
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 Oussoren et al., 2001 developed liposomes to target the lymphatics by 
subcutaneous administration. They described that the size and anatomical site of 
injection usually influence the lymphatic absorption and lymph node uptake of 
subcutaneously administered. They also demonstrated that phagocytosis by 
macrophages is the major important mechanism for uptake of liposomes to the 
lymph nodes. This is a major finding with respect to targeting nanoparticles to the 
lymphatics [51]. 
 Qin et al., 2013 developed polymeric micelles to enhance its 
concentrations in the lymphatics for treating metastasis of cancers. They prepared 
micelles using polyethylene glycol-phosphatidylethanolamine (PEG-PE) of size 
14.5 nm using doxorubicin and vinorelbine. Their results showed migration of 
PEG-PE micelles into the interstitial tissue of the lymphatic vessels and finally 
accumulated in the lymph nodes. In vivo whole body imaging in rats showed 
reduction in the metastasis rate in murine breast cancer model. They also observed 
enhanced antitumor activity of primary tumors and prevented its metastases to the 
lungs [6]. 
 Hawley et al., 1995 provided vast information on targeting of colloids to 
lymph nodes and described the influence of lymphatic physiology and 
characteristics of colloids. The influence of route of administration to the regional 
lymph nodes was also described [94]. 
 Feng et al., 2010 described the roles of dextrans for improving lymphatic 
drainage using liposomes. They developed novel liposomes containing dextrans to 
reduce undesirable retention of antineoplastic agents and to reduce the damage at 
the local tissue. The liposomes reduced the local retention and enhanced the 
drainage to the lymphatics. Pharmacokinetic studies showed the enhanced 
drainage of liposomes through lymphatics and reversal to systemic circulation. 
Dextrans, efficiently enhanced the drainage of liposomes into the lymphatics and 
can be used as adjuvants with liposomes [95]. 
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 Mortimer et al., 2014 studied the influence of different kinds of plasma 
proteins on opsonisation of nanoparticles and elaborated in detail. They showed 
that plasma proteins (majorly albumin) can form a hard corona around the 
nanoparticles, which is the main criterion for recognition by the mononuclear 
phagocyte system [96].  
 Mueller et al., 2015 attempted to target antigen to the lymph nodes using 
PRINT hydrogels. They developed a platform for the delivery of vaccines using 
hydroxy-poly (ethylene glycol). The developed cylindrical nanoparticles measured 
80 × 180 nm and showed good uptake by antigen presenting cells and also 
stimulated proliferation of CD4+ helper T cells. These PRINT hydrogels can be 
used to target other drugs to the lymphatics [97]. 
 Kaminskas et al., 2009 showed that PEGylated polylysine dendrimers 
improved the absorption and lymphatic targeting following subcutaneous 
administration in rats. The impact of PEGylation on the absorption and lymphatic 
transport of the dendrimers modified by different molecular weights of PEG or  
4-benzene sulphonate after subcutaneous or intravenous administration was 
studied. PEGylation using PEG 200 rapidly and completely absorbed into the 
blood after SC administration. Increasing the chain length of PEG decreased its 
absorption into the blood and consequently enhanced lymphatic uptake [98].  
 
3.3 DIFFERENT TYPES OF NANOPARTICLES 
 Chang et al., 2012 discussed various liposome-based drugs and their 
therapeutic efficacy. They discussed and compared the therapeutic effect of 
clinically approved liposome based drugs and the free drugs. They also 
determined the clinical effect with relationship to the lipid content. Crucial 
preclinical and clinical information about the principal liposomal formulations 
were also discussed [99]. 
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 Geng et al., 2007 studied the effect of filaments shaped nanoparticles 
(filomicelles) versus spherical particles with respect to drug delivery, transport 
and trafficking. The filomicelles remained in the circulation for nearly 1 week 
after intravenous injection, which is nearly ten times longer than the spherical 
shaped nanoparticles [100]. 
 Liu et al., 2016 tried to improve the oral bioavailability of Sorafenib using 
“Spring” and “Parachute” molecular interactions. They noticed that that the 
solubility of sorafenib could be increased by 50-fold with the co-existence of poly 
vinyl pyrrolidone-vinyl acetate and sodium lauryl sulphate (SLS), due to the 
formation of complexes at a low critical aggregation concentration. The ability of 
poly vinylpyrrolidone-vinyl acetate to keep the drug in solution (parachute) was 
impaired by SLS. They concluded that poly vinyl pyrrolidone-vinyl acetate 
enhanced the solubility and super saturation of sorafenib due to the molecular 
interactions between them. In vitro dissolution and dog pharmacokinetic in vivo 
evaluation showed good in vitro-in vivo correlation [101]. 
 Karanam et al., 2014 developed poly (ε-caprolactone) nanoparticles of 
carboplatin and performed characterization and in vitro cytotoxicity studies in U-
87 MG cell lines. Nanoparticles below 100 nm were efficiently taken up by U-87 
MG cells and exhibited significantly higher cytotoxicity than free drug. 
Carboplatin in the form of nanoparticles did not induce haemolysis in rat red 
blood cells [60]. 
 Joshi et al., 2006 formulated and evaluated topical gel based on 
nanostructured lipid carrier of Valdecoxib. The NLCs was suitably gelled and 
characterized with respect to drug content, pH, spreadibility, rheology, and  
in vitro release. The developed gel showed faster onset and also prolonged the 
activity for 24 hours [102]. 
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 Kasongo et al., 2011 worked on the selection and characterization of lipid 
excipients for the manufacture of Didanosine loaded SLNs and NLCs. They 
evaluated the suitability of lipids for the manufacture of solid lipid nanoparticles 
SLNs and NLCs. The crystalline nature and polymorphism of lipids was tested 
using differential scanning calorimetry and wide-angle X-ray scattering. Precirol 
ATO 5 and Transcutol HP showed the good solubilizing potential for the drug. 
DSC and WAXS profiles of DDI/bulk lipids mixture obtained before and after 
exposure to heat showed no interactions between the drug and the lipids [103].  
 Geng et al., 2005 developed Poly (ethylene oxide)-block- 
Polycaprolactone (PEG-PCL) giant and flexible worm micelles for the first time. 
These worm micelles immediately generate spherical micelles due to hydrolysis of 
polycaprolactone hydrolysis. The mechanism behind the hydrolysis and the 
kinetics was described in detail [104].  
 Levchenko et al., 2002 studied the effect of surface charge and polymer 
coating on the biodistribution and clearance of liposomes. Phosphatidylcholine 
(PC)/ cholesterol liposomes were prepared using stearylamine/ phosphatidic acid/ 
phosphatidyl serine/ polyethylene glycol of different molecular weights. The 
chemical nature of the charged lipid is important in vivo. They found out that short 
PEG (750) and longer PEG (5000) inhibited the clearance of positively charged, 
whereas, only longer PEG (5000) inhibited the clearance of negatively charged. 
They also highlighted that opsonins of different molecular size are possibly 
involved in the clearance of differently charged liposomes [105]. 
 Sanna et al., 2014 discussed on target based cancer therapy using 
nanoparticles. They stressed the need for nanotechnology in cancer treatment and 
highlighted the progress made by nanoparticles in other fields of science. 
Different nanoparticles used for treating cancers have been discussed in detail 
with a special focus on increasing the specificity. They also discussed on the 
clearance mechanisms for the nanoparticles and elaborated on various 
nanoformulations which are in phase II clinical trials [106]. 
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 Kamaly et al., 2012 described target based polymeric therapeutic 
nanoparticles with a special focus on its design, development and clinical 
translation. Various polymeric materials ranging from orthopaedic implants, 
resorbable sutures, macroscale and microscale drug delivery systems such as 
microparticles and wafers, multifunctional nanoparticles were discussed in detail. 
The safety, efficacy, solubility, metabolism, plasma binding, biodistribution, 
target tissue accumulation were detailed in depth. Additional information with 
respect to the design and development of target based polymeric nanoparticles and 
the challenges associated with development were discussed [107]. 
 Li et al., 2008 described the pharmacokinetics and bio-distribution of 
nanoparticles. They stated that nanoparticles can be promising for improving the 
efficacy of drugs. The chemical and physical properties of the nanoparticles like 
particles size, zeta potential, surface chemistry and morphology, are major factors 
that determine their pharmacokinetic and bio-distribution. The fate of the 
nanoparticles after cellular internalization and the various strategies for 
overcoming the numerous barriers for intracellular delivery and drug release were 
also discussed with a focus of the future directions [108]. 
 Weissig et al., 2014 discussed elaborately on various nanopharmaceuticals 
which are in the current market. They highlighted the importance offered by some 
internationally acclaimed research bodies who have paved way for the 
development of nanopharmaceuticals. They have detailed the growth of the 
nanopharmaceuticals which are in the market. They provided elaborate 
information on 43 approved nanopharmaceuticals with a special focus on its 
clinical outcomes [109]. 
 Joshi et al., 2008 developed nanostructured lipid carrier gel for topical 
application. The gel was assessed for in vitro release and in vitro skin permeation 
using rat skin. The efficacy of the NLC gel was also tested in aerosil-induced rat 
paw edema model. The NLC gel of celecoxib showed faster onset of action and 
also prolonged the activity for 24 h [110]. 
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3.4 APPLICATION OF LIPIDS IN LYMPHATIC DELIVERY 
 Siram et al., 2014 worked to target and increase its retention time of 
diethylcarbamazine citrate (DEC). The influence of various excipients on the size, 
shape, texture, surface charge, physical nature of the entrapped drug, entrapment 
efficiency and in vitro drug release of SLNs was also studied in detail. 
Additionally, in vivo animal studies were also performed to estimate the drug 
concentration in blood and lymph after oral administration. The results indicated 
an average size in the range of 27.25 ± 3.43 nm to 179 ± 3.08 nm among all the 
batches of the formulations. In vivo studies in rats showed a 4 fold enhancement in 
the amount of DEC that has reached the lymphatics after oral administration by 
SLNs [60]. 
 Mishra et al., 2015 prepared solid lipid nanoparticles of Praziquantel for 
targeting the intestinal lymphatics and also tested them by performing suitable  
in vivo studies. The SLNs were prepared by hot homogenization followed by 
ultrasonication using triglycerides, lecithin and different surfactants. In vivo 
results in rats indicated a 6 fold increase in AUC0-∞ after intraduodenal 
administration of SLNs loaded with Praziquantel in rats when compared to 
Praziquantel in saline. Absorption of Praziquantel through the intestinal 
lymphatics was confirmed using cycloheximide [61]. 
 Mu et al., 2013 discussed on the lipid based formulations used in oral 
delivery of lipophilic drugs (poorly water soluble drugs). They also described 
various lipid based products available in the market. They gave information about 
the different types of lipids which vary by their physiochemical properties and 
chemical structures. They also gave an overview on the digestion and absorption 
of lipids in vivo [111].  
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 Porter et al., 2001 provided elaborate information on the intestinal 
lymphatic drug transport. They provided information on the mechanism of access 
of drugs to the intestinal lymph and described the role of lipid in the digestion and 
absorption. The ability of various lipid carriers to stimulate lymphatic drug 
transport was discussed with respect to the class, chain length and degree of 
saturation of the lipids. They gave future directions for performing intestinal 
lymphatic transport studies in cell culture model and genetically modified  
animals [112]. 
 Khan et al., 2013 reviewed lipid based nanoformulations for lymphatic 
delivery. They mentioned the lymphatic system and the complexities involved in 
targeting the drugs to it. Lipid based formulations like solid lipid nanoparticles 
and nanostructured lipid carriers, were described with a special focus to deliver 
drugs to the lymphatics. Important factors like particle size, surface charge, types 
of lipid and concentration of the emulsifier molecular weight, and hydrophobicity 
were discussed in detail. Various in vitro and in vivo models for studying the drug 
transport in the lymphatic system were also mentioned [14]. 
 Shah et al., 2013 prepared SLNs of carvedilol for lymphatic targeting. 
Carvedilol SLNs were prepared using Compritol 888 ATO and Poloxamer 188 as 
the lipid carrier and surfactant by hot homogenisation method. In vitro cell line 
studies using Caco-2 cell line exhibited a higher uptake for carvedilol SLNs when 
compared to its free form. These results indicated higher uptake to the intestinal 
lymphatics [113]. 
 Driscoll et al., 2002 discussed on the various lipid-based formulations for 
the delivery of drugs to the intestinal lymphatics. Impact of various lipid based 
vehicles and their components used for preparing them, various physicochemical 
properties of the drugs, different animal models and experimental techniques have 
been described in detail. This review also described the success and limitations of 
lipid-based vehicles for lymphatic targeting and showcased potential areas of 
future research [114]. 
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 Shete et al., 2013 developed long chain lipid based NLCs for tamoxifen to 
target them to the lymphatics and lymph nodes. They performed systematic 
preformulation studies, formulated them and characterization them. Solubility of 
the drug was screened in the oils, surfactants and co-surfactants to identify 
suitable components. NLCs of the drug showed a good dissolution profile when 
compared to its free form [115]. 
 Cai et al., 2011 reviewed lymphatic drug delivery using solid lipid 
nanoparticles and liposomes. Various routes of delivery like subcutaneous, 
intestinal, and pulmonary routes has been described and their applications to 
improve lymphatic penetration and retention of drug molecules has been 
mentioned in detail. They also briefed the recent advances in the field of imaging 
and drug delivery using solid lipid nanoparticles and liposomes [64]. 
 Nakamura et al., 2012 prepared PEGylated liposomes by different 
techniques and also compared their characteristics. Their results showed that a 
higher stealth nature in the blood with low degradation of PEG can be inhibited by 
post-modification method. They concluded by stating that post modification 
method is advantageous in all the aspects [116]. 
 Kim et al., 1994 attempted to target methotrexate loaded differently 
charged liposomes to the lymphatics after intramuscular injection to rats. Their 
results indicated entry of liposomes injected by intramuscular route to the 
lymphatics. The concentration of the drug was 100-350 folds higher in the lymph 
when compared to the plasma concentration. Positively charged liposomes 
localized more in lymph nodes when compared to the neutral and negatively 
charged counterparts [117].  
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 Kaur et al., 2008 targeted surface-engineered zidovudine liposomes to the 
lymphatics. The surface charge of the liposomes was modified by incorporating 
stearylamine and dicetyl phosphate as charge modifier and mannose was tagged to 
the surface to enhance localization to lymphatics. The tissue distribution pattern of 
mannose modified liposomes showed a significant reduction of the free 
zidovudine concentration in serum. Fluorescent microscopy and tissue distribution 
studies showed higher concentration of the surface modified liposomes in the 
lymph nodes and spleen [11]. 
 Kinman et al., 2006 developed lipid based Indinavir nanoparticles for 
targeting the lymphatics of HIV-infected macaques. After subcutaneous 
administration, these nanoparticles enhanced the concentrations of drug by 250- 
270% higher than the plasma indinavir concentrations in both visceral and 
peripheral lymph nodes. Enhancement in anti-HIV activity was also observed in 
the animals. The results indicate that indinavir lipid nanoparticles are efficient for 
targeting to the lymphatics [44]. 
 Nune et al., 2011 mentioned the various trends and advances in the field 
of lymphatic targeting using diagnostic and drug delivery agents. They described 
the necessity of targeting various agents (dyes and drugs) to the lymphatics and 
are of the opinion that the existing tools are not up to the mark. They provided 
information on the application of novel nanocarriers like quantum dots, carbon 
nanotubes and other polymeric nanoparticles to improve the current scenario in 
delivering dyes and drugs to the lymphatics [118]. 
 Paliwal et al., 2009 studied the effect of lipid core material on 
characteristics of SLNs meant for lymphatic delivery. They hypothesized that the 
composition of SLNs alters the absorption of drugs to and through lymphatic 
route. They prepared SLNs using Compritol 888 ATO, glycerol monostearate, 
stearic acid and tristearin. In vivo studies were also performed to evaluate the 
Chapter 3  Review of Literature 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  37 
lymphatic uptake and bioavailability. Their results showed a good lymphatic 
uptake and bioavailability with the use of compritol 888 ATO, a mixture of 
different derivatives of behenic acid [55]. 
 Nishioka et al., 2001 briefed on targeting lymphatic using various 
colloidal carriers. They have discussed on the recent progress with regard to 
emulsions, nanocapsules, nanospheres and liposomes for lymphatic targeting. 
They highlighted the importance of targeting anticancer drugs to the regional 
lymph nodes through subcutaneous administration. Information about the delivery 
of diagnostic agents to the regional lymph nodes was also provided [119]. 
 Makwana et al., 2015 prepared SLNs of Efavirenz (EFV) to target the 
lymphatics and also elucidated its mechanism of uptake by blocking the flow of 
chylomicron. They prepared SLNs of EFV using Gelucire 44/14, Lipoid S 75, 
Compritol 888 ATO and Poloxamer 188 by hot homogenization technique and 
ultrasonication method. Their results of tissue distribution and lymphatic transport 
indicated that a significant amount of EFV had by-passed the hepatic portal 
system and entered the lymphatics. Thus it enhanced the oral bioavailability of 
EFV [120]. 
3.5 SOLID LIPID NANOPARTICLES AND THEIR APPLICATION IN 
 LYMPHATIC TARGETING 
 Chauhan et al., 2005 prepared solid dispersions of etoricoxib using 
different lipid carriers by spray drying technique and evaluated their properties 
using diffuse reflectance infrared fourier transform spectroscopy, differential 
scanning calorimetry, hot stage microscopy, radiograph powder diffraction, and 
dissolution studies. The absence of etoricoxib peaks in radiograph powder 
diffraction profiles of solid dispersions suggested presence of etoricoxib in an 
amorphous state. The solid dispersions showed a better in vitro dissolution profile 
when compared with pure etoricoxib, physical mixtures of drug with lipid carriers, 
and spray-dried etoricoxib [121].  
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 Fahy et al., 2011 wrote a detailed review on the classification of the lipids 
based on their structures and different tools. They provided information on Lipid 
Metabolites and Pathways Strategy (MAPS) consortium which is involved in the 
detection, quantitation and pathway reconstruction of lipids. They also discussed 
various developments by the Lipid MAPS over a period of time [122]. 
 Wang et al., 2006 studied the ability of stealth SLNs in situ to evade 
phagocytic uptake by mouse peritoneal macrophages. Fluorescent SLNs were 
prepared using rhodamine B as the marker and polyoxyethylene stearate as  
stealth agent. At all time points, phagocytic uptake of SLNs was better than stealth 
SLNs [123]. 
 Mehnert et al., 2012 published a very elaborate review on the production, 
characterization and applications of SLNs. Information pertaining to the selection 
of the ingredients, different ways to manufacture and stabilise them have been 
mentioned. Various routes of administration and their in vivo fate has been 
discussed [18]. 
 Rohit et al., 2013 worked on a technique to prepare SLNs of hydrophilic 
drugs with high entrapment efficiencies. They changed the composition of the 
lipid matrix by mixing different ratios of glyceryl monostearate, Compritol 888 
ATO and stearic acid to achieve high entrapment efficiencies for hydrophilic 
drugs. Their results showed high entrapment efficiencies when stearic acid was 
combined with Compritol 888 ATO in the ratio of 1:4 [124].  
 Muller et al., 2000 provided detailed information on solid lipid 
nanoparticles right from its origin. They stated that SLNs has the advantages of 
other nanoparticulate carriers and at the same time, does not possess their major 
disadvantages. They provided information on the current state of the art regarding 
production techniques for SLN, drug incorporation, loading capacity and drug 
release, especially focusing on drug release mechanisms. The regulatory status of 
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excipients, toxicity information, different routes of administration, sterilization 
techniques for SLNs and information pertaining to their long-term stability studies 
and industrial scale up are also discussed in detail [19]. 
3.6 IMATINIB MESYLATE 
 Bende et al., 2010 developed and validated a HPLC method for the 
estimation of imatinib mesylate plasma and tissue sample of rats. They used a 
Zorbax Extend (5 μm, 4.6 × 250 mm) double end-capped C18 column with a 
mobile phase consisting of methanol and aqueous triethyl amine (60:40, v/v) of 
pH 10.5 at a flow rate of 1 ml/min. A good recovery was observed and their 
developed method demonstrated a good linearity from 25 to 1600 ng/ml with a 
regression coefficient of 0.9995. Their method was suitable for performing in vivo 
pharmacokinetic studies [125]. 
 Marslin et al., 2015 proved that imatinib mesylate loaded poly(lactide-co-
glycolide) nanoparticles improved its anticancer activity and reduced 
cardiotoxicity. Methylthiazolyldiphenyl-tetrazolium bromide assay showed that 
poly(lactide-co-glycolide) nanoparticles of Imatinib mesylate were more cytotoxic 
to MCF-7 breast cancer cells when compared to the equivalent concentration of 
unencapsulated imatinib mesylate. There were no signs of cardiotoxicity  
in Wistar rats after orally administration of poly (lactide-co-glycolide) 
nanoparticles of Imatinb mesylate for 28 days. Histological sections of the  
hearts of Wistar rats also did not show any significant cardiotoxic  
symptoms [126]. 
 Guetens et al., 2003 quantified the Imatinib mesylate in erythrocytes and 
plasma by sediment technology and liquid chromatography–mass spectrometry. 
Imatinib mesylate and the internal standard were eluted on a Waters C18 column 
(50×2.1 mm I.D) using a mixture of methanol and ammonium acetate. Their 
developed method can be used for the quantification of Imatinib mesylate in 
plasma  [127]. 
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 Zhou et al., 2015 studied whether administration of imatinib and dasatinib 
influenced pharmacokinetic parameters in rats. They orally administered imatninb, 
dasatanib and a comibination to rats and measured various pharmacokinetic 
parameters. These results indicated that dasatinib slightly influenced the 
pharmacokinetic profile of imatinib in rats and can lead to drug-drug interactions 
if administered simultaneously [128]. 
 Gupta et al., 2015 developed and optimized nanostructured lipid carriers 
(NLCs) of imatinib base to improve their anticancer and pharmacokinetic 
properties. NLCs were prepared by hot homogenization method and optimized 
using Plackett-Burman design and central composite design. An in vivo 
pharmacokinetic study was conducted in rats after both oral and intravenous 
administration. The in vitro cytotoxicity was evaluated by MTT assay on NCI-
H727 cell-lines. The optimized NLC showed a particle size of 148.80±1.37 nm 
and zeta potential of -23.0 ±1.5 mV and showed higher bioavailability after oral 
administration [129]. 
3.7 QUILLAJA SAPONIN 
 Maier et al., 2015 studied on new phenylpropanoid sucrose esters from 
the inner bark of Quillaja saponaria, quillajasides A and B. The phenolic 
composition of aqueous extracts of the inner bark of Quillaja saponaria was 
compared with commercially available Quillaja extracts. Piscidic acid (+) and 
several p-coumaroyl sucrose esters are the major phenolics in both extracts. The 
antioxidant activity and their applicability in enzymatic browning reactions were 
also tested [88]. 
 Kralova et al., 2012 discussed on the different surfactants used in food 
industry. They focussed on the formation, structures, and properties of different 
emulsions in food. The importance of the major end points described in the 
Organisation for Economic Co-operation and Development guidelines for the 
Chapter 3  Review of Literature 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  41 
hazard assessment of food chemicals were described and the main parameters 
such acute toxicity, reproductive toxicity, sub-acute repeated studies, long-term 
studies, allergy, and mutagenicity tests were measured. They mainly focussed on 
monoglycerides, lecithins, glycolipids, fatty alcohols and fatty acids [130].  
 Martin et al., 1999 briefed about different kind of saponins and their 
industrial uses. Their structures, molecular weights and properties along with this 
uses have been described in detail [85]. 
 Yang et al., 2013 studied the stability of emulsions of food products using 
Quillaja saponin as a surfactant. They studied the suitability of this surfactant with 
Tween 80. They also studied the effect of homogenization pressure, number of 
passes, and concentration of the emulsifier on the particle size. Their results 
highlighted the applicability of Quillaja saponin in food and beverage industry 
over a long run [131]. 
 Francis et al., 2002 reviewed the biological action of saponins in animals. 
They discussed the anticarcinogenic, antioxidant, immunostimulant, membrane-
rupturing, hypocholesterolaemic, antifungal and antiviral properties of saponins. 
They also significantly affected the growth and reproduction in animals.  
They stated that the haemolytic action of saponins is due to affinity of aglycone 
moiety [132]. 
 Guclu-Ustundag et al., 2013 described the properties, applications and 
processing of saponins. Biological activities of saponins like anticancer and 
anticholesterol activity and their applications in food, cosmetics, and 
pharmaceutical industries has been described. They also described the effect of 
processing on the properties and structure of saponin [83]. 
 
Chapter 3  Review of Literature 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  42 
3.8  IMPORTANCE OF DRUG SOLUBILISATION IN THE LIPIDS 
 Bergstrom et al., 2016 discussed various computational tools for 
prediction of intestinal drug absorption, models for prediction of the suitable 
formulation strategies for B-r-o-5 compounds and models to understand the 
interplay between the drug, formulation and physiological environment. For 
B-r-o-5 compounds, non-traditional delivery strategies are required to achieve 
adequate exposure after oral administration. Molecular interaction patterns 
between the drugs and excipients, molecular dynamics simulations were 
discussed. Computational biopharmaceutical profiling can be used to identify 
formulateability during the lead optimization and early development stages [133]. 
 Silva et al., 2016 prepared lipid based formulations of carvedilol by 
testing its compatibility with different lipid excipients to enhance its 
bioavailability. They checked for the presence physical and chemical interactions 
between the drug and excipients using differential thermal analysis, 
thermogravimetric analysis, fourier transform infrared spectroscopy and 
isothermal stress testing. The results indicated the lipids which are incompatible 
with the drugs which also did not reduce the drug content over long term storage. 
Lipids like stearic acid, palmitic acid, glyceryl behenate, tribehenin-PEG, 
polyglyceryl- 6-isostearate and diethylene glycol monoethyl ether were suitable 
for developing lipid based formulations. They stressed the necessity of performing 
preliminary studies for proper selection of drugs [134]. 
 Umamatheswari et al., 2010 applied QSAR for the synthesis, and 
antimicrobial evaluation of novel piperidin derivatives. Their synthesized 
compounds were screened against different bacterial and fungal strains by serial 
dilution method. The results of QSAR studies indicated that increase in the 
weakly polar component of the solvent accessible surface area favoured the 
antibacterial activity, whereas an increased polarizability and decreased ionisation 
potential and hydrogen bond donor favoured antifungal activity [135]. 
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 Zheng et al., 2012 worked to identify different approaches for enhancing 
the oral bioavailability of poorly water-soluble drugs in the drug discovery stage. 
LCQ789, preclinical BCS Class II compound was used and to enhance 
bioavailability existing techniques like reduction in particle size, solid dispersions, 
lipid based formulations and co-crystals were used. High throughput screening 
and Gastroplus were used to reduce the amount of drug used. Amongst the various 
techniques used, solid dispersions and lipid based formulation showed highest 
bioavailability [136]. 
 Warren et al., 2013 explored the microstructures of lipid based 
formulations and studied their dispersion patterns in the gastrointestinal tract at 
molecular level using molecular dynamics. Their formulations contained 
glycerides derivatives as lipids and drugs like (danazol, acyclovir, ketoprofen, 
hydrocortisone, or progesterone) were used. As the water content increased, the 
lipid microstructures gradually changed from a continuous phase to a reverse 
micellar solution and consequently to lamellar lipids under the influence of 
hydrogen bonds. They stated that application molecular dynamics simulations is a 
good option to view changes of lipid based formulations at molecular levels and 
advised usage of these in silico tools during formulations [137].  
 Yang et al., 2013 showcased the importance of Van der Waals dispersion 
forces that contribute to molecular recognition of the solutes in the solution. They 
stated that properties that lead to self-assembly and molecular recognition are due 
to non-covalent interactions. In this work they have used synthetic molecular 
balances to measure interactions between apolar alkyl chains. They observed that 
solvent-solvent interactions lead to apolar association in the solution [138].  
 Jensen et al., 2010 showed that the solubility of corticosteroids in the 
lipids and their release from the matrix is dependent on the polarity of the lipids. 
The effect of composition of the lipids on their ability to solubilise and release 
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betamethasone-17-valerate (BMV) was estimated by varying the content of lipid 
monoglyceride content and the chain length of the fatty acids. The effect of 
physicochemical properties of the drug was determined by studying 5 different 
corticosteroid derivatives which differ in their lipophilicity. The results 
highlighted that the solubility of corticosteroids in the lipid phase and their release 
was greatly influenced by the distribution of drugs in the lipid matrix [139]. 
 Jorgenson et al., 2000 predicted the solubility of 150 drugs in water using 
Monte Carlo Simulations. Their results showed that descriptors like the solvent 
accessible surface area, numbers of hydrogen bonds and indices for cohesive 
interactions in solids correlated with the pharmacologically important properties 
like octanol/water partition coefficient and aqueous solubility [140]. 
 Sacchetti et al., 2012 tried to predict the solubility of drugs in the lipids 
and established a relationship of drug solubility in lipid mixtures. In their study, 
they tested the solubility of four drugs in eighteen different lipids. The results 
indicated that solubility of the drugs in the lipid mixtures can be quantified as an 
average of its solubility in the individual lipids [141].  
 Li et al., 2006 screened and characterized various lipid carriers and drug-
polymer-lipids for their interactions, which will be helpful in the rational 
designing of polymer-lipid nanoparticles. The solubility parameters of Verapamil 
HCl (VRP), Verapamil HCl-dextran complex (VRP-DS), and various lipids were 
calculated. Additionally, partition coefficients of VRP and VRP-DS in lipids were 
also determined. The thermodynamics behind the binding of VRP to DS was 
determined by isothermal titration calorimetry. The solid state properties and the 
interactions among them were characterized using differential scanning 
calorimetry and powder X-ray diffraction. They stated that the drug loading 
efficiency and drug loading capacity of a lipid matrix depends on the binding and 
the interactions of the VRP-DS complex with the lipid [142].  
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 Ortwine et al., 2013 studied on various physicochemical and DMPK in 
silico models to ease up the drug discovery and to simplify the selection of new 
drug molecules for future line of work. They have provided information on 
various physicochemical and DMPK properties, the problems associated during 
their calculation and different softwares available. The methods followed  
by the companies to communicate results were also discussed in  
detail [143]. 
 Lipinski et al., 2012 performed several experiments and attempted to 
correlate with computationally predicted solubility and permeability of drugs in 
discovery and development. They predicted ‘the rule of 5’ which states that poor 
absorption or permeation is more likely if there are more than 5 H bond donors,  
10 H-bond acceptors, if the molecular weight is greater than 500 and Log P is 
greater than 5. During the development setting, solubility calculations focused on 
the prediction of the exact value and are usually difficult due to polymorphism. 
Recent works on linear free energy relationships and Log P approaches were also 
discussed and they stated that predictions are possible for closely related 
analogous series of compounds when experimental thermodynamic solubility 
measurements are also simultaneously performed [144]. 
 Golbraikh et al., 2002 highlighted the importance of q2 during the 
validation while performing quantitative structure–activity relationship modelling. 
In general a high leave-one-out cross-validated R2 (LOO q2) i.e., q2 > 0.5 is 
considered as an indicator for the high predictive ability. They highlighted the fact 
that a high value of LOO q2 is necessary, but not mandatory for a model to 
possess high predictive power. They also stressed that external validation is the 
only method to establish a reliable QSAR model [145]. 
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 Greenhalgh et al., 1999 attempted to predict the miscibility in solid 
dispersions using solubility parameters. They reported the interactions and 
possible incompatibilities in solid dispersions of hydrophobic drugs in hydrophilic 
carriers (with solubility parameters employed as a means of interpreting results). 
They stated that calculation of Hildebrand parameters is a good tool to predict 
interactions and potential incompatibilities between the drug and lipid  
carriers [146]. 
 Subashini et al., 2011 applied molecular dynamics for the simulation of 
uptake of three drugs, doxorubicin, silymarin and gliclazide in six polymers 
(alginic acid, sodium alginate, chitosan, Gantrez AN119 (methyl-vinyl– ether-co-
malic acid based), Eudragit L100 and Eudragit RSPO). Molecular dynamics 
simulation of the drug in the vicinity of the polymer molecule in the presence of 
water molecules was performed using Gromacs-forcefield, (300 ps, 300 K) and 
the interaction energies between them were calculated. These energies were 
evaluated with respect to the electric-dipole, Van der Waals and hydrogen bond 
forces. The hydrophilic interaction between nanoparticles and water was inversely 
correlated with the uptake of the drug. The molecular dynamics simulation can be 
applied in developing polymer based drug delivery systems to obtain reasonable 
approximation of drug uptake [147]. 
 Alskar et al., 2016 developed tools for the early prediction of drug 
solubility in lipids by studying more than 2,000 solubility measurements. 
Computational models were developed for in silico prediction of solubility, and 
drug loading capacity in the lipids. Drugs with a melting point below 150°C 
showed reasonable solubility in the glycerides. In silico models also showed good 
predictions of the loading capacity in the formulations without performing 
experimental studies (R2 0.79) using thermal properties and molecular information 
descriptors of the crystalline drug [133]. 
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 Chen et al., 2012 gave their perspective on the various applications of 
lipid based formulations in drug discovery. They had an opinion that structure 
activity relationship and lead optimization of a new drug candidate with required 
physicochemical properties for lipid formulations, and a good design of in vitro 
and in vivo studies during drug discovery play an important role. These will help 
in establishing a good connection with the preclinical evaluation and clinical 
development goals, and can significantly reduce the time consumed in the 
development of formulations and also increase the development of a potentially 
viable clinical formulation [148]. 
 Cheng et al., 2003 developed a rapid quantitative structure-property 
relationship model for the prediction of aqueous solubility from the molecular 
structures. Genetic algorithms and multiple linear regressions were used to 
develop the mathematical models for a diverse set of compounds including small, 
drug and drug-like molecules. Those models predicted the solubility of the 
training and test sets and those results correlated well with the experimental 
values. Using the 2-D structures as input, their model could compute solubility for 
90 000-700 000 compounds/h on a SGI Origin 2000 workstation and can be used 
in data mining and screening of a vast set of molecules [149]. 
 Patel et al., 2015 attempted to predict the solubility of drugs in lipidic 
solvent mixture using a modelling and thermodynamics. They applied the data 
gathered from the in silico modelling to develop self micro emulsifying drug 
delivery systems. They also investigated the usage of the thermodynamic model to 
study the solubility behaviour of the drugs (Clotrimazole and Fluconazole) in oils. 
Their results showed a good correlation between the predicted solubility and 
experimental solubility [150]. 
Chapter 3  Review of Literature 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  48 
 Persson et al., 2013 developed computational tools for the prediction of 
drug solubility in lipids and lipid based formulations The solubility of 30 
structurally diverse drug molecules was measured in soybean oil, Captex355, 
polysorbate 80  and PEG400 and were used as responses during the development 
of partial least squares model. Various molecular descriptors and melting point 
were used as variables for the development of the model and the results were 
validated with test sets. A strong correlation was observed between polysorbate80 
and PEG400. They observed that the solubility of drugs in medium chain 
triglycerides and long chain triglycerides can be predicted by calculating the 
various molecular descriptors [151]. 
 Chevillard et al., 2012 worked on in silico prediction of aqueous 
solubility by developing a multimodel protocol based on the similarity of 
chemical structure. They evaluated ten in silico models for prediction of aqueous 
solubility for several data sets to assess their reliability and proposed a new 
diverse data set for 150 molecules. Their “multimodel protocol”, allowed selection 
of the most accurate model for a compound and showed accurate results for 
prediction of solubility when compared with other individual models [152]. 
 Benet et al., 2011 applied biopharmaceutics drug disposition classification 
system for 927 drugs. Among the 897 parent drugs, 78.8% (707) drugs are orally 
administered. The lowest percentage solubility and a dose number were recorded. 
Other parameters like percent drug excreted unchanged in urine, LogP, and LogD 
7.4 were measured. Additionally, in silico parameters for polar surface area, 
predicted Log solubility in water, calculated LogP, and the number of hydrogen 
bond acceptors and hydrogen bond donors for the active moiety were estimated 
and a comparison was made with experimentally measured values and in silico 
values. They discussed the potential use of BDDCS to estimate the disposition 
characteristics of novel drugs in the early stages of development [153]. 
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 Ali et al., 2015 performed preformulation and physicochemical interaction 
studies for furosemide using different solid lipids like Compritol 888 ATO, 
Hydrokote C, Imwitor 491, Imwitor 372P, and Witepsol H12 using Fourier 
transform infrared, Raman, differential scanning calorimetry, X-ray diffraction, 
scanning electron microscopy. Compritol 888 ATO showed highest solubility for 
the drug. FTIR, Raman, DSC and XRD studies indicated no chemical interactions 
with the lipids used. In vitro drug release study showed the release of drug to 
follow either of Zero order release, Higuchi or Korsmeyer–Peppas model [154]. 
3.9 PREPARATION AND CHARACTERISATION OF SOLID LIPID 
 NANOPARTICLES AND CONJUGATION USING VARIOUS 
 LIGANDS 
 Chalikwar et al., 2012 formulated solid lipid nanoparticles of nimodipine 
and enhanced its oral bioavailability via lymphatic transport system. They used 
(23) factorial design was employed to optimised the best formulation and to study 
the effect of various excipients on particle size, polydispersity index, zeta 
potential, drug entrapment efficiency, drug loading efficiency and in vitro drug 
release. Pharmacokinetic studies in male Albino Wistar rats showed 2.08-fold 
increase in the relative bioavailability for SLNs than the free drug [155]. 
 Bailon et al., 2009 studied about PEG and PEGylation. They stated the 
necessity of PEGylation to improve clinically efficacy and pharmacokinetic 
profile than the existing drug molecules. They highlighted that PEGylation 
sustains the clinical response with a low dose. They also focussed different 
approaches and strategies for the development of PEGylated products [156]. 
 Venishetty et al., 2013 prepared SLNs of docetaxel and ketoconazole to 
enhance the permeability of docetaxel across the blood brain barrier. Additionally, 
their surface was modified with folic acid. These SLNs were characterized for 
size, surface charge, in vitro release, cytotoxicity, and cellular uptake in brain 
endothelial cell line. The results of the plasma and brain pharmacokinetic studies 
showed an enhanced uptake across the brain for docetaxel [62]. 
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 Garg et al., 2007 attempted to prepare azidothymidine loaded 
galactosylated liposomes with enhanced cellular uptake, reduced hematopoietic 
toxicity, and altered pharmacokinetics. Galactosylated liposomes were prepared 
and characterized in vitro to target the lectin receptors present on the 
macrophages. Their formulation maintained a higher level of drugs in tissues rich 
in galactose specific receptors and enhanced the half-life of the drug [157].  
 Yuan et al., 2008 tested the cellular uptake and cytotoxicity of paclitaxel 
of solid lipid nanoparticles in A549 cancer cells. The order of cellular uptake 
ability of solid lipid nanoparticles prepared using various lipids decreased in the 
order of glycerol tristearate> monostearin> stearic acid> Compritol 888 ATO. 
Because of low drug entrapment efficiency of glycerol tristearate solid lipid 
nanoparticles, monostearin solid lipid nanoparticles were considered best to 
improve the cytotoxicity of paclitaxel. Additionally, polyethylene glycol 
monostearate and synthesized conjugate, folic acid–stearic acid were further 
introduced into the solid lipid nanoparticles. PEG and folate modified solid lipid 
nanoparticles enhanced the cellular uptake and cytotoxicity of the solid lipid 
nanoparticles [158]. 
 Biswas et al., 2013 developed surface functionalized doxorubicin-loaded 
liposomes with octa-arginine to enhance the anticancer activity. They conjugated 
commercially available Doxil with a octa-arginine. The conjugated liposomes 
increased the intracellular and intratumoral delivery when compared to 
unmodified liposomes. It also improved the cytotoxic activity in vitro and in vivo 
The results indicated improvement in the therapeutic window of PEGylated 
liposomes with lower non-specific toxicity [159]. 
 Becker et al., 2015 prepared lipid based solid oral formulations by melt 
coating, melt granulation and melt extrusion using fluid bed coaters, spray dryers 
or extruders. They attempted to produce a bigger batch of lipid based products by 
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scaling up to pilot or production scale. They also mentioned the challenges, 
experiences and formulations which could help to efficiently choose the  
excipients [59]. 
3.10 PHARMACOKINETIC STUDIES 
 Edwards et al., 2001 provided information about various animal models 
for the study of the intestinal lymphatic drug transport. The advantages and 
disadvantages with respect to the usage of both small and large animal models and 
the various factors which have been found to influence the outcome of  
intestinal lymphatic drug transport studies with these models have also been  
discussed [160]. 
 Feeney et al., 2016., discussed the origin, progress and future perspectives 
for oral lipid-based formulations. The various advantages of lipid-based 
formulations, general properties and classification over the past fifty years were 
briefed. The ability of lipid-based formulations to promote intestinal 
solubilisation, supersaturation and absorption and the various methods employed 
to assess formulation performance, various techniques to increase drug 
lipophilicity and lipid solubility were also elaborated in detail [161].   
 Wang et al., 2015 studied to investigate the effect of orally administered 
genistein and Imatinib on the pharmacokinetics in rats. A single dose of genistein 
had no effect on the pharmacokinetics of imatinib. The results showed that 
multiple doses of genistein induced the metabolism of imatinib, whereas single 
dose of genistein had no effect [162]. 
 Boyd et al., 2001 provided a valuable protocol for the collection of lymph 
from cannulated lymphatic ducts in rats. They mentioned a step by step protocol 
on how to identify the thoracic and mesenteric lymphatic duct and a detailed 
surgical procedure to cannulate and collect lymph from them [163]. 
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 Gaur et al., 2014 tried to enhance the oral bioavailability of Efavirenz by 
encapsulating it in SLNs. The SLNs were prepared (using glyceryl monostearate 
as lipid carrier and tween 80 as surfactant) and analyzed for physical parameters, 
stability, and pharmacokinetic profile. The solid lipid nanoparticles showed a 
particle size and PDI of 124.5 ± 3.2 nm and 0.234 respectively. Pharmacokinetic 
studies showed a 5 fold increase in peak plasma concentration and 11 fold 
increase in AUC when comparison to free Efavirenz [164].  
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4. SCOPE AND PLAN OF WORK 
 
4.1  SCOPE 
 In the present scenario there are sufficient amount of anticancer drugs 
which can kill the tumor cells in the body. But, these drugs are equally toxic to the 
healthy cells of the body and cause several potential side effects, leading to 
reduced patient life and compliance. To avoid the possible side effects posed by 
the anticancer drugs, many people prefer surgical and radiation methods for the 
treatment. Though surgical removal of the tumor in breast cancer patients has 
been found to be beneficial, the incidence of recurrence of cancer to the other 
parts of the body (including breast) is very high and is attributed to metastasis of 
the cancer cells from the primary site through regional lymphatics. As metastasis 
of cancerous cells occurs in the regional lymphatics, it is essential for the drug to 
reach the regional lymphatics to arrest metastasis. In order to reach the 
lymphatics, the size of the particles should be in the range of 10- 100 nm, the 
uptake rate into the lymphatics should be high and the delivery route should be 
appropriate. SLNs can safely target and deliver anticancer drugs by subcutaneous 
administration to the regional lymphatics, the residing place of the metastatic 
cancer cells. Hence, the current doctoral research work has been planned to work 
on the development and evaluation of ligand conjugated SLNs of IM which can 
specifically target and kill the tumor cells in the lymphatics. The development of 
SLNs requires solubilisation of the drug in the lipid carrier to achieve good 
entrapment efficiencies and stability. There is no model to predict the solubility of 
drugs in lipids. Hence, examining the various properties of lipids which influence 
their ability to solubilise the drugs has also been examined and a model has been 
developed to predict the solubility of IM in lipids for the first time. The utility of 
QS, a natural surfactant obtained from the bark of Quillaja saponaria, in the 
preparation of SLNs has also been evaluated for the first time. 
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 To achieve the above mentioned specific objectives the following research 
work has been followed.  
4.2  PLAN OF WORK 
 PREFORMULATION STUDIES 
 Construction of calibration curve using UV spectroscopy 
 Bioanalytical method development using high performance liquid 
 chromatography  
 Screening of lipids for IM solubility 
 Solid state characterization using differential scanning calorimetry 
 Quantification of Maximum Solubility 
 Calculation of total solubility parameters, polarity of IM and lipids 
 Identification of descriptors and development of QSSR Model 
 Compatibility of IM with the lipids using FTIR 
 Determination of partitioning coefficient of IM in different lipids and 
water 
 CHEMICAL CONJUGATION OF STEARIC ACID AND LIGANDS 
 Chemical conjugation of hyaluronic acid-stearic acid conjugate 
 Chemical conjugation of vitamin B12-stearic acid conjugate 
 PREPARATION OF SOLID LIPID NANOPARTICLES 
 Formulation of SLNs of IM using stearic acid as lipid carrier 
 Formulation of SLNs of IM using palmitic acid as lipid carrier 
 Formulation of SLNs of IM using glyceryl palmitostearate as lipid carrier 
 Formulation of SLNs of IM using glyceryl monostearate as lipid carrier 
 Formulation of SLNs of IM using Geleol mono and  di glycerides as lipid 
 carrier 
 SURFACE MODIFICATION OF SOLID LIPID NANOPARTICLES 
 Surface modification of SLNs using hyaluronic acid 
Chapter 4  Scope & Plan of Work  
 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  55 
 IN VITRO CHARACTERISATION OF SOLID LIPID 
 NANOPARTICLES 
 Confirmation of ligand- lipid conjugate by NMR spectroscopy 
 Determination of particle size and polydispersity index by Malvern Zeta 
 Sizer 
 Determination of zeta potential by Malvern Zeta Sizer 
 Determination of particle shape and morphology by Transmission Electron 
 Microscope 
 Determination of particle surface morphology using Atomic Force 
 Microscope 
 Determination of entrapment efficiency and drug loading efficiency 
 In vitro release studies 
 In vitro haemolysis test 
 
 IN VITRO CELL LINES STUDIES 
 In vitro cytotoxicity studies 
 Apoptosis analysis using propidium iodide staining 
 
 IN VIVO ANIMAL PHARMACOKINETIC STUDIES 
 To estimate the pharmacokinetic parameters in blood 
 To estimate the pharmacokinetic parameters in lymph nodes 
 
 STABILITY STUDIES 
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5. MATERIALS AND METHODS 
 
5.1  MATERIALS 
S. No Name Source 
1  Imatinib mesylate Natco Pharmaceuticals, India 
2  Quillaja saponin Sigma Aldrich, USA 
3  Hyaluronic acid Sigma Aldrich, India 
4  Vitamin B12 Veer Chemie Organics, India 
5  Myrisitc acid Sigma Aldrich, India 
6  Palmitic acid Sigma Aldrich, India 
7  Stearic acid Sigma Aldrich, India 
8  Behenic acid Sigma Aldrich, India 
9  Glyceryl monostearate HiMedia, India 
10  Glyceryl palmitostearate Subhash Chemicals, India 
11  Precirol ATO 5® Gattefosse, France 
12  Geleol mono and di glycerides® Gattefosse, France 
13  Compritol 888 ATO® Gattefosse, France 
14  Trimyristin SD fine chemicals, India 
15  Tripalmitin SD fine chemicals, India 
16  Tristearin SD fine chemicals, India 
17  Gelucire 44/14® Gattefosse, France 
18  Gelucire 33/01® Gattefosse, France 
19  Captex 70® Gattefosse, France 
20  Sterotex NF® Abitec, USA 
Chapter 5  Materials & Methods 
 
 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  57 
S. No Name Source 
21  Sterotex HM® Abitec, USA 
22  Hydrokote 112® Abitec, USA 
23  Hydrokote M® Abitec, USA 
24  Cocoa butter MN Goodies Private limited, India 
25  Pluronic F-127® Sigma Aldrich, USA 
26  Potassium dihydrogen phosphate Himedia, India 
27  Acetonitrile-HPLC Sigma Aldrich, USA 
28  Tetra butyl methyl ether Sigma Aldrich, USA 
29  Ortho phosphoric acid Sigma Aldrich, USA 
30  Ammonium acetate HiMedia, India 
31  Acetone HiMedia, India 
32  Sodium hydroxide Himedia, India 
33  D-mannitol SD Fine chemicals, India 
34  Potassium bromide Himedia, India 
35  Sodium chloride HiMedia, India 
36  Potassium chloride HiMedia, India 
37  Disodium hydrogen phosphate  HiMedia Mumbai 
38  
Dialysis membrane  
(Mw.Wt-12,000-14,000 Daltons) 
HiMedia, India 
39  Dialysis membrane clips HiMedia, India 
40  Tri sodium citrate HiMedia, India 
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5.2  INSTRUMENTS 
S. No. NAME OF THE INSTRUMENT MANUFACTURER 
1 High Speed homogenizer Pro Scientific 
2 Malvern Zeta Sizer ZS 90 Malvern instruments 
3 Ultrasonic homogenizer Sonics 
4 Lyophilizer Lyodel 
5 Centrifuge Eppendrof 
6 Bath Sonicator PCI, Mumbai 
7 Inverted Phase Contrast Microscope Nikon 
8 Transmission Electron Microscope JOEL TEM 2100 
9 Atomic Force Microscope NTMDT, NTEGRA Prima 
10 Digital Weighing Balance Shimadzu 
11 Magnetic stirrer 
Remi equipments Ltd., 
Mumbai 
12 UV-Visible Spectrophotometer UV-1650 PC Shimadzu 
13 FTIR Spectrophotometer 8400 S Shimadzu 
14 IR Hydraulic Pellet Press 
M 15 Techno Search 
Instruments 
15 Differential Scanning Calorimeter TA instruments 
16 
High Pressure Liquid 
Chromatography 
Waters 
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5.3  IMATINIB MESYLATE (IM) 
 
Chemical name  :  Methanesulfonic acid;4-[(4-methylpiperazin-1-yl) 
methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl) 
amino]phenyl] benzamide 
Empirical formula : C30H35N7O4S 
Molecular weight : 589.715 g/mol 
Structure :  The structure of IM in shown in Figure 4. 
 
Figure 4. Structure of IM 
 
Colour:  
 White to off white to brownish or yellowish tinged crystalline powder 
 
Solubility:  
 Soluble in aqueous buffers ≤ pH 5.5, but very slightly soluble in neutral to 
alkaline aqueous buffers; freely soluble to very soluble in dimethyl sulfoxide, 
methanol, and ethanol; insoluble in n-octanol, acetone, and acetonitrile. 
 
Mechanism of action:  
Imatinib is a 2-phenyl amino pyrimidine derivative which functions as a 
specific inhibitor of a group of tyrosine kinase enzymes present in the body. It 
occupies the tyrosine kinase active site, which leads to a decrease in the activity. 
Although there are a large number of tyrosine kinase enzymes in the body, 
Imatinib is specific for the tyrosine kinase domain in Abelson proto-oncogene 
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(abl), c-kit and platelet-derived growth factor receptor (PDGFR). In breast cancer, 
the fusion of abl with bcr (breakpoint cluster region), bcr-abl is observed. IM 
specifically decreases the bcr-abl activity and prevents progression of cancers. 
Imatinib does also inhibit other targets like c-kit and PDGF-R, ABL2, DDR1 and 
NQO2. 
 
Bioavailability:  
 98% 
Absorption:  
 Readily absorbed following oral administration. 
Cmax:  
 2-4 hours  
Distribution: 
  Widely distributed throughout all body compartments, except adipose 
tissue 
Peak serum concentration:  
 80 to 200 nanograms per ml after a single 50-mg dose. 
 
Half life:  
 18 hours 
Excretion:  
 Bile and feces 
Dosage forms:  
 Tablets 
Toxicity and side effects:   
 Usage of IM is associated with temporary elevations in serum 
aminotransferase levels and instances of severe acute liver injury which can be 
severe, which can lead to fatalities. Additionally, acute hepatitis and reactivation 
of an underlying hepatitis B is also observed. 
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5.4  QUILLAJA SAPONIN (QS) 
Source :  Inner bark of Quillaja saponaria 
Synonyms :  EINECS 215-731-2, HSDB 2171, soap bark saponin 
Chemical name :  soap bark saponin 
Empirical formula :  beta-D-Glucopyranosiduroni acid, (3 beta, 4 alpha, 
16alpha)-17-carboxy-16-hydroxy-23-oxo-28 
norolean-12-en-3-yl 
Molecular weight :  2284.406 g/mol 
Structural formula :  The structure of QS in shown in Figure 5. 
 
Figure 5. Structure of QS 
 
Functional category:  
 Emulsifier, solubiliser, food applications 
Melting point:  
 292°C 
Solubility:  
 Soluble in water. 
Stability and storage condition:  
 Slightly hygrscopic. 
Safety:  
 Irritant to eyes and respiratory tract; haemolytic 
Regulatory status:  
 GRAS listed and accepted for use as a food additive in Europe.  
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5.5 VITAMIN B12 
Synonyms:  
 Cyanocobalamine 
Chemical name:  
 Cyanocobalamin; Cobalamin; 68-19-9; Crystamine; Anacobin 
Empirical formula: 
 Cobalt(3+);[(2R,3S,4R,5S)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-
2-(hydroxymethyl)oxolan-3-yl][(2R)-1-[3-[(1R, 2R, 3R, 5Z, 7S, 10Z, 12S, 13S,   
15Z,  17S, 18S, 19R) -2, 13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-
oxopropyl) -3,5, 8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1H-corrin- 
24-id-3-yl]propanoylamino]propan-2-yl] phosphate;cyanide. 
Chemical formula:  
 C63H88CoN14O14P 
Molecular weight: 
 1355.388 g/mol 
Structure: The structure of vitamin B 12 is mentioned in Figure 6. 
 
Figure 6. Structure of vitamin B12 
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Functional category: 
 Water soluble vitamin, treatment of pernicious anemia 
Melting point:  300°C 
Solubility: 
 High water solubility (12500 mg/ml), soluble in alcohol; insoluble in 
acetone, chloroform and ether. 
Stability and storage conditions: 
 Hydrated crystals are stable to air, max stability in pH range 4.5-5. 
Solutions of cyanocobalamin in water or 0.9% sodium chloride are stable and can 
be autoclaved for short periods of time (15-20 minutes) at 121°C.  
 
Safety: 
 Cyanocobalamin injection is extremely safe when given by the 
intramuscular or deep subcutaneous route, but it should never be given 
intravenously. Rare occurrences of anaphylactic reaction (skin rash, itching, 
wheezing) may be observed after parenteral administration.  
Regulatory status:  
 GRAS listed and FDA approved. 
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5.6  HYALURONIC ACID 
Chemical name : Hyaluronate Tetrasaccharide; AC1MJ1T9; 
CHEMBL1697748; 
Chemical formula :   C28H44N2O23 
Empirical formula :  (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-acetamido-
2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-
acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-
yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-
hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-
trihydroxyoxane-2-carboxylic acid 
Molecular weight :  776.651 g/mol 
Structural formula :  The structure of hyaluronic acid in mentioned in 
Figure 7. 
 
Figure 7. Structure of hyaluronic acid 
 
Functional category:  
 Hyaluronic acid is a natural high-viscosity mucopolysaccharide with 
alternating beta (1-3) glucuronide and beta (1-4) glucosaminidic bonds. It is 
distributed widely throughout connective, epithelial, and neural tissues. It is used 
in treating osteoarthritis. It is also used as a dermatological agent, keratolytic, 
protectant, dermatological and wound care agent. 
 
Melting point:  
 94°C 
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Solubility: 
 Easily soluble in cold water (46.6 mg/ ml). Insoluble in organic solvents. 
Stability and storage conditions: Do not freeze; protect from light. Store at 
2 to 25°C.  
Safety:  
 Rare post market reports of immediate post injection reactions included 
extreme swelling of the lips and the whole face and symptoms of hypersensitivity 
such as anaphylactic shock. 
Regulatory status:  
 GRAS and FDA approved. 
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5.7  PALMITIC ACID 
Synonyms :  Cetylic acid; Emersol 143; Edenor C16 98-100; 1-
pentadecanecarboxylic acid; hexadecylic acid;  
Chemical name :  Hexadecanoic acid 
Empirical formula :  C16H32O2 
Molecular weight :  256.42 g/mol. 
Structure :  The structure of palmitic acid is mentioned in 
Figure 8. 
 
Figure 8. Structure of palmitic acid 
Functional category:  
 Emulsifying agent; skin penetrant; tablet and capsule lubricant. 
Melting point: 
 63-64°C 
Solubility:  
 Soluble in ethanol (95%); practically insoluble in water. 
Stability and storage conditions:  
 The bulk material should be stored in a well-closed container in a cool, 
dry, place.  
Safety:  
 Palmitic acid is used in oral and topical pharmaceutical formulations and 
is generally regarded as nontoxic and nonirritant at the levels employed as an 
excipient. However, palmitic acid is reported to be an eye and skin irritant at high 
levels and is poisonous by intravenous administration. 
Regulatory status:  
 GRAS listed. Included in the FDA Inactive Ingredients Guide (oral 
tablets). Included in nonparenteral medicines licensed in the UK.
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5.8  STEARIC ACID 
Synonyms :  Cetylacetic acid; Crodacid; E570; Edenor; Emersol; 
Hystrene; Industrene; Kortacid 1895; Pearl Steric; 
Pristerene; stereophonic acid; Tegostearic. 
Chemical name :  Octadecanoic acid 
Empirical formula :  C18H36O2 
Molecular weight :  284.47 g/mol 
Structural formula :  The structure of stearic acid is mentioned 
   in Figure 9. 
 
Figure 9. Structure of stearic acid 
 
Functional category: 
 Emulsifying agent; solubilizing agent; tablet and capsule lubricant. 
Melting point: 
 54°C 
Solubility:  
 Freely soluble in benzene, carbon tetrachloride, chloroform, and ether; 
soluble in ethanol (95%), hexane, and propylene glycol; practically insoluble in 
water. 
Stability and storage:  
 Stearic acid is a stable material; an antioxidant may also be added to it. 
The bulk material should be stored in a well-closed container in a cool, dry place. 
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Safety:  
 Stearic acid is widely used in oral and topical pharmaceutical 
formulations; it is also used in cosmetics and food products. Stearic acid is 
generally regarded as a nontoxic and non-irritant material. However, consumption 
of excessive amounts may be harmful. 
Regulatory status:  
 GRAS listed. Accepted as a food additive in Europe (fatty acids). Included 
in the FDA Inactive Ingredients Guide (sublingual tablets; oral capsules, 
solutions, suspensions, and tablets; topical and vaginal preparations). Included in 
nonparenteral medicines licensed in the UK. Included in the Canadian List of 
Acceptable Non-medicinal Ingredients. 
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5.9  GLYCERYL PALMITOSTEARATE 
Synonyms:  
 Glycerin palmitostearate; glycerol palmitostearate; 2-[(1-oxohexadecyl)-
oxy]-1,3-propanediyl dioctadecanoate and 1,2,3-propane triol. 
Chemical name:  
 Octadecanoic acid, 2,3-dihydroxypropyl ester mixed with 3-hydroxy-2-
[(1-oxohexadecyl)-oxy] propyl octadecanoate [8067-32-1] 
Empirical formula:  
 Glyceryl palmitostearate is a mixture of mono-, di-, and triglycerides of 
C16 and C18 fatty acids. 
Functional category:  
 Biodegradable material; coating agent; gelling agent; release modifying 
agent; sustained-release agent; tablet and capsule diluent; tablet and capsule 
lubricant; taste-masking agent. 
Melting point:  
 52-55°C 
Solubility:  
 Freely soluble in chloroform and dichloromethane; practically insoluble in 
ethanol (95%), mineral oil, and water. 
Stability and storage: 
 Glyceryl palmitostearate should not be stored at temperatures above  
358 ºC. For storage for periods over 1 month, glyceryl palmitostearate should be 
stored at a temperature of 5–158 ºC in an airtight container, protected from light 
and moisture. 
Safety:  
 Glyceryl palmitostearate is used in oral pharmaceutical formulations and is 
generally regarded as an essentially nontoxic and nonirritant material. 
Regulatory status:  
 GRAS listed. Included in the FDA Inactive Ingredients Guide (oral 
suspension, oral tablet). Included in nonparenteral preparations licensed in urope. 
Included in the Canadian List of Acceptable Non-medicinal Ingredients. 
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5.10 GLYCERYL MONOSTEARATE 
Synonyms:  
 Capmul GMS-50; Cutina GMS; 2,3-dihydroxypropyl octadecanoate; 
glycerine monostearate; glycerin monostearate; glycerol monostearate; glycerol 
stearate; glyceryl stearate; GMS; Imwitor 191; Imwitor 900; Kessco GMS; Lipo 
GMS 410; Lipo GMS 450; Lipo GMS 600; monoester with 1,2,3- propanetriol; 
monostearin; Myvaplex 600P; Myvatex; 1,2,3- propanetriol octadecanoate; 
Protachem GMS-450; Rita GMS; stearic acid, monoester with glycerol; stearic 
monoglyceride; Stepan GMS; Tegin; Tegin 503; Tegin 515; Tegin 4100; Tegin 
M; Unimate GMS. 
Chemical name:  
 Octadecanoic acid, monoester with 1,2,3 propanetriol 
Empirical formula: 
 C21H42O4 
Molecular weight:  
 358.6 g/mol 
Structure:  
 The structure of glyceryl monostearate is mentioned in Figure 10. 
 
Figure 10. Structure of glyceryl monostearate 
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Functional category:  
 Emollient; emulsifying agent; solubilizing agent; stabilizing agent; 
sustained-release ingredient; tablet and capsule lubricant. 
Melting point:  
 55-60°C 
Solubility:  
 Soluble in hot ethanol, ether, chloroform, hot acetone, mineral oil, and 
fixed oils. Practically insoluble in water, but may be dispersed in water with the 
aid of a small amount of soap or other surfactant. 
Stability and storage: 
 If stored at warm temperatures, glyceryl monostearate increases its acid 
value upon aging owing to the saponification of the ester with trace amounts of 
water. Effective antioxidants may be added, such as butylated hydroxytoluene and 
propyl gallate. Glyceryl monostearate should be stored in a tightly closed 
container in a cool, dry place, and protected from light. 
Safety:  
 Glyceryl monostearate is widely used in cosmetics, foods, and oral and 
topical pharmaceutical formulations and is generally regarded as a nontoxic and 
nonirritant material. 
Regulatory status:  
 It is included in the GRAS list. It is also included in the FDA Inactive 
Ingredients Guide (oral capsules and tablets; ophthalmic, otic, rectal, topical, 
transdermal, and vaginal preparations). Included in nonparenteral medicines 
licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal 
Ingredients. If glyceryl monostearate is produced from animal fats (tallow), there 
may be additional regulatory requirements that the source be free of 
contamination from bovine spongiform encephalopathy. 
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5.11 GELEOL MONO AND DI GLYCERIDES 
Synonyms: 
 Mono- and di- glyceride mixtures of stearic acid and palmitic acid; 
glyceryl mono and di stearate. 
Chemical name: 
 Mixtures of mono- and di glycerides of stearic and palmitic acid. 
Molecular weight: 
 414.9 g/mol 
Functional category:  
 Coating agent; tablet binder; tablet and capsule lubricant; thickening 
agent; washing & cleaning products, lubricants and greases, adhesives and 
sealants, polishes and waxes, fertilisers, coating products and air care products. 
Melting point:  
 65-77°C 
Solubility: 
 Soluble when heated in chloroform and dichloromethane and in many 
organic solvents; slightly soluble in hot ethanol (96%); practically insoluble in 
cold ethanol (95%), hexane, mineral oil, and water. 
Stability and storage condition:  
 It should be stored in a tightly stored container, at a temperature less than 
35°C. 
Safety:  
 It is used in cosmetics, foods and oral pharmaceutical formulations, and is 
generally regarded as a relatively non-irritant and nontoxic material. The US 
Cosmetic Ingrdients Review Expert Panel evaluated glyceryl behenate and 
concluded that it is safe for use in cosmetic formulations in present practices of 
use and concentration. 
Regulatory status:  
 GRAS listed and it is accepted for use as a food additive in Europe. It is 
included in the FDA Inactive Ingredients Database (oral capsules, tablets and 
suspensions).  
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5.12 DETERMINATION OF LAMBDA MAX (λmax) FOR IM USING UV 
SPECTROPHOTOMETER 
Five mg of pure IM was weighed accurately and transferred carefully to a 
50 ml standard flask. Sufficient volume of pH 7.4 phosphate buffer was added to 
the standard flask to obtain a stock solution of IM with a concentration 100 µg/ml. 
A suitable amount of this stock solution was transferred into a quartz cuvette and 
scanned from the wavelength of 200 to 400 nm using UV spectrophotometer. The 
wavelength at which maximum absorbance occurred was observed and noted 
down as the lambda max. 
5.13  CONSTRUCTION OF CALIBRATION CURVE FOR IM USING UV 
SPECTROPHOTOMETER AT 256 nm 
Five mg of pure of IM was weighed accurately and transferred carefully to a 
50 ml standard flask. Sufficient volume of pH 7.4 phosphate buffer was added to 
the standard flask to obtain a stock solution of IM with a concentration 100 µg/ml. 
From this stock solution, 0.2 ml, 0.4 ml, 0.6 ml, 0.8 ml, 1 ml, 1.2 ml, 1.4 ml,  
1.6 ml, 1.8 ml and 2 ml were accurately withdrawn into a 10 ml standard flask and 
made up to 10 ml using pH 7.4 phosphate buffer to produce different solutions of 
IM with concentrations of 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 µg/ml respectively. 
The absorbance of the prepared solutions was determined by UV 
spectrophotometer at 256 nm. A standard curve of absorbance vs concentration 
was obtained and the r2 value was determined.  
5.14   DEVELOPMENT OF ANALYTICAL METHOD USING HIGH 
 PERFORMANCE LIQUID CHROMATOGRAPHY 
 Quantitative and qualitative analysis of IM was carried out using reverse 
phase-high performance liquid chromatography (RP-HPLC). 
 
5.14.1 Preparation of standard stock solutions 
 Ten mg of pure IM was weighed accurately and transferred carefully to a 
10 ml standard flask. Sufficient volume of methanol was added to the standard 
flask to obtain a stock solution of IM with a concentration 1000 µg/ml to form 
primary stock solution.  
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5.14.2 Selection of detection wavelength 
 Primary stock solution was scanned from the wavelength of 200 to 400 nm 
using UV spectrophotometer. The wavelength at which maximum absorbance 
occurred was observed and noted down as the lambda max. 
5.14.3 Optimization of Chromatographic conditions 
 A RP-HPLC method was used because of its simplicity and suitability. 
Different types of columns, mobile phase, flow rate, and the influence of pH were 
examined during the development of a chromatographic method. 
A Waters 515 HPLC along with a Sunfire C8 (4.6 x 150mm, 3.5μ) column 
was used for the study and the mobile phase consisted of Acetonitrile: Water  
(0.1% formic acid) at a ratio of 30:70. The flow rate was maintained at  
0.3 ml/ min and 20 µl of the sample was injected using a rheodyne injector. An 
ultravisible detector was used and the samples were analyzed at a wavelength of 
265 nm. The method for estimation of IM was validated in terms of specificity, 
linearity and reproducibility.  
5.14.4 Extraction of IM from plasma 
 Ninety microliters of drug-free plasma was spiked with 10 μl of standard 
imatinib. The spiked sample was vortexed for 30 s followed by addition of 1 ml of 
methanol and re-vortexing for 3 min. The sample was centrifuged at 12, 000 rpm 
for 10 minutes at 4°C and an aliquot of 800 μl from supernatant was evaporated in 
a turbovap for 20 min, it is then reconstituted with 200 μl of cold acetonitrile. 
From this an aliquot of 20 μl was injected into HPLC for quantification [125]. 
Extraction efficiency 
Extraction efficiency from the rat plasma was determined by comparing 
the responses obtained from extracted sample spiked with known amount of IM 
with the extracted blank sample. The recovery was evaluated at three different 
concentrations of analyte quality control standards area and was compared against 
the mean area of respective un-extracted quality control standards area. The mean 
recovery for IM was calculated. 
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Recovery 
 The recoveries were assessed by comparing the peak area of IM extracted 
from QC samples to those of the same concentration of IM spiked into blank-
plasma post-extracts were calculated. 
5.14.5  Validation of the analytical method  
The method was validated according to guidelines set on the International 
conference on Harmonization (ICH) for the validation of analytical procedure. 
The developed method was validated in terms of specificity, linearity, accuracy, 
precision, limit of detection and limit of quantification. 
Specificity 
Specificity is the ability of a method to discriminate between the intended 
analyte and other components in the sample. A method is said to be specific when 
it shows a peak corresponding to single analyte in the presence of the 
interferences. It was carried out by comparing the standard retention time spectra 
and the sample retention time spectra. 
Linearity 
A series of concentrations (5, 10, 20, 40, 60, 80, 100 μg/ml) were prepared 
from the stock solution and their respective peak areas were plotted. A standard 
curve of peak area vs concentration was obtained and the regression equations 
were calculated. For plasma studies, 90μl of blank plasma was spiked with  
10μl of the standard stock solution to obtain concentrations in the range of  
250 ng/ml-16 μg/ml. 
Accuracy 
Samples of concentrations 10, 20 and 40 μg/ml for analysis of aqueous 
samples and 250, 1000 and 2000 ng/ml for plasma studies were analyzed in 
5-folds in three separate analytical runs for evaluation of accuracy and 
interday/intraday precision. The accuracy was calculated by dividing the observed 
concentration and the nominal concentration and multiplying by 100%.  
% Nominal = (measured concentration / Actual concentration) × 100 
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Precision 
Precision was measured by interday (on three consecutive days) and 
intraday variation by analysing 6 replicates over 3 different concentrations of IM. 
The precision was obtained from response of each of these solutions and by 
calculating percentage relative standard deviation (% RSD). 
%RSD = (SD/ mean) × 100 
Limit of Detection and Limit of Quantification (LOD and LOQ) 
 LOD is the lowest amount of analyte in a sample that can be detected but 
not necessarily quantitated under the stated experimental conditions. On the other 
hand, LOQ is the lowest amount of analyte in a sample that may be determined 
with acceptable accuracy and precision. LOD and LOQ values were determined 
from the regression curve. The residual standard deviation of a regression line or 
the standard deviation of y-intercepts of regression lines were used as the standard 
deviation. Based on the standard deviation of the response and the slope LOD and 
LOQ are calculated. 
 LOD = 3.3 σ/s 
 LQD = 10 σ/s 
 Where σ is the standard deviation of response and s is the slope of the 
calibration curve [127]. 
5.14.6  Stability 
 Stability of IM was investigated under a variety of storage and process 
conditions viz., rat plasma and deproteinized rat plasma samples at room 
temperature, at -20°c and freeze thaw cycles [125]. 
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5.15  SOLUBILITY OF IM IN VARIOUS LIPIDS 
 The lipids used in the present study were myristic acid, palmitic acid, 
stearic acid, behenic acid, glyceryl palmitostearate, Precirol ATO 5®, glyceryl 
monostearate, Geleol mono and diglycerides®, Compritol 888 ATO®, trimyristin, 
tripalmitin, tristearin, Sterotex HM®, Sterotex NF®, cocoa butter, Hydrokote M®,  
Hydrokote 112®, Captex 70®, Gelucire 44/14® and Gelucire 33/01®. To test the 
solubility of IM in these lipids, 5 mg of IM was added to 1 g of lipid and heated to 
a temperature above 10°C of its melting point in a test tube. To check the 
maximum amount of IM that could be solubilised in 1 gm of lipid, IM was slowly 
added in increments of 1 mg until no more IM could be dissolved [115].  
To confirm the solubility of IM in various lipids, the endothermic melting 
temperature of IM, bulk lipids and mixture of IM and lipids was measured in a 
differential scanning colorimeter (Universal V4.7A TA instruments). Briefly,  
10 mg of the sample was placed on an aluminium pan and scanned between 25°C 
and 300°C at a range of 5°C/ min under nitrogen gas [165].  
5.16 CALCULATION OF TOTAL SOLUBILITY PARAMETERS, 
POLARITY OF IM AND LIPIDS 
Total solubility parameter (δtotal) and polarity of a substance (Xp) for IM 
and lipids were calculated using equation 1 and equation 2 respectively [113,146].  
  ------------------------------- Equation (1) 
   ------------------------------- Equation (2) 
where, 
δtotal = total solubility parameter, 
 = contribution from dispersion forces ( ), 
 = contribution from polar force ( ), 
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 = contribution of hydrogen bonding ( ), 
 = molar attraction constant due to dispersion component, 
Fpi = molar attraction constant due to polar component, 
Ehi = hydrogen bonding energy, 
V = molar volume, 
Xp= polarity. 
5.17 IDENTIFICATION OF DESCRIPTORS AND DEVELOPMENT OF 
QUANTITATIVE STRUCTURE SOLUBILITY RELATIONSHIP 
(QSSR) MODEL 
Various descriptors (molecular and physicochemical) of the lipids and their 
statistical relationship with respect to solubilisation of IM were obtained using 
QikProp, Schrodinger [135][166]. Initially, the structures of the individual lipids 
were sketched and cleaned up in Maestro by providing the SDF files of the lipids 
as input. The structures were processed using LigPrep to obtain three dimensional 
structures and their energy was minimised using OPLS-2005. The descriptors of 
the lipids were generated using QikProp, Schrodinger. Due to small data sets, 
multiple linear regression (MLR) was used over PCA (principal component 
analysis) and PLS (partial least square) to build a statistical model which enabled 
the prediction of solubility of IM using these descriptors. For the development of 
the model, the lipids were initially divided into a training set containing 6 lipids 
(67% of the dataset) and a test set of 3 lipids (33 % of the dataset). The training 
set of lipids were used initially to develop an MLR model (Strike module, 
Schrodinger) to examine and correlate the influence of the descriptors to solubilise 
IM. The descriptors which lowered the the R2 (squared correlation coefficient) and 
Q2 (cross validated R2) were removed. The solubility of IM in lipid as % w/w was 
used as response and three separate MLR models were constructed by varying the 
number of subsets. The ability of these models to predict the solubility of IM was 
then verified using the test set of lipids. The solubility equations generated for 
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each model were also validated for their robustness using leave one out model 
(LOO). Statistically important parameters like R2; RMSE (root mean square 
error); F (Fisher’s value); P (Probability); Q2; R2m (multiple correlation 
coefficient); R2pred (predictive correlation coefficient) were calculated to validate 
the models. 
5.18 DETERMINATION OF PARTITIONING COEFFICIENT OF 
IMATINIB  MESYLATE IN DIFFERENT LIPIDS AND WATER 
In a typical partition experiment, 10 mg of IM was dispersed in a mixture of 
1 ml of double distilled water and 1 g of molten lipid (maintained at a temperature 
10ºC above the melting point of the lipid). The mixture was shaken for 60 min at 
the same temperature and then kept at room temperature for 45 min to allow 
partitioning to reach equilibrium. The aqueous phase was separated and the 
amount of IM in the aqueous solution was quantified in a UV spectrophotometer 
at 256 nm. Partition coefficient was estimated by calculating the ratio between the 
amount of IM in lipid and amount of IM in the aqueous phase [142]. 
5.19  INFRARED (IR) ABSORPTION SPECTROSCOPY 
 The purity of the drug was determined by subjecting IM for IR analysis 
using Fourier Transform Infrared Spectroscopy (FT/IR 8400S CE) Shimadzu 
spectrophotometer). The samples were prepared as KBr pellet method. Drug and 
potassium bromide are mixed in the ratio of 1:100 and a pellet is formed by 
compressing at 8 ton/mm2 pressure. The wavelength range was selected from 400 
- 2000 cm-1 in Shimadzu FT-IR spectrophotometer. The IR spectrum of pure IM 
was compared with spectrum obtained from Indian Pharmacopoeia 2007. 
 Similarly IR spectrum was obtained for each individual lipid (stearic acid, 
palmitic acid, glyceryl palmitostearate, glyceryl monostearate and Geleol mono 
and di glycerides), QS and the physical mixture of IM and lipids [167]. 
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5.20  CHEMICAL CONJUGATION OF LIPID WITH LIGANDS 
 The ligands (hyaluronic acid and vitamin B12) were chemically 
conjugated to stearic acid or stearyl amine using carbodiimide chemistry. Initially, 
20 mg of stearic acid (or stearyl amine) and 30 mg 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) was added to 5 ml of dimethyl 
formamide and allowed to react at room temperature for 1 hour. To this mixture, 
30 mg of ligand (hyaluronic acid and vitamin B 12) and 0.5 ml pyridine were 
added and reacted overnight. Twenty ml of distilled water was added to the 
reaction mixture to precipitate the stearic acid-ligand conjugates like hyaluronic 
acid-stearic acid (HA-SA) and vitamin B12-stearic acid (B12-SA). The precipitate 
was dialysed against distilled water for 3 days using cellulose membrane (8000 
molecular weight cut off) to remove the unreacted chemicals. Finally, the product 
was filtered using a 0.45 µm millipore filter and lyophilized [158,168]. 
5.21  PREPARATION OF IM LOADED SOLID LIPID 
 NANOPARTICLES (SLNs) 
IM loaded SLNs were prepared via a hot homogenisation method followed by 
ultrasonication. Briefly, the lipid was melted at a temperature above 5°C its 
melting point in a water bath. IM was added to the melted lipid to form a clear, 
homogeneous lipid phase. Simultaneously, an aqueous solution (10 ml) of QS 
preheated to as that of the lipid phase was dispersed in the lipid phase using a high 
shear homogeniser (Pro SC- 250). This pre-emulsion was sonicated in an 
ultrasonic homogeniser (Vibra cell, Sonics) at 40% amplitude and cooled in an ice 
bath to form IM loaded SLNs. Different batches of SLNs were prepared by 
changing the lipids, amount of QS, parameters of high speed homogenisation and 
probe sonication [60,169]. 
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5.22 PREPARATION OF SLNs ADSORBED WITH HYALURONIC ACID 
Hyaluronic acid adsorbed SLNs were prepared by electrostatic attraction. 
Briefly, 1 ml of the dispersion was slowly added under vigorous stirring at  
5,000 rpm to a hyaluronic acid solution at a concentration of 0.05%, 0.10%, 
0.15% or 0.20% w/v. The concentration of hyaluronic acid, the mass ratio of 
hyaluronic acid to SLNs, the adding rate and the stirring rate were investigated to 
obtain the optimum formulation [58,82]. 
5.23   PREPARATION OF SLNs CONJUGATED WITH LIGANDS 
 For the preparation of SLNs conjugated with ligands like hyaluronic acid 
and vitamin B 12, 50 mg the corresponding conjugates of stearic acid, HAJ-SA 
and B12-SA were added to the lipid phase during the preparation of SLNs. 
5.24  FREEZE DRYING 
 The formulations were freeze-dried using Lyodel freeze drier at a 
temperature and pressure of -30 ºC and -1 mbar, respectively, until the product 
was dried [78,170]. The freeze-dried powder was used for differential scanning 
measurements and nuclear magnetic resonance (NMR) spectroscopy. 
5.25  NMR SPECTROSCOPY 
1H NMR spectrum was used to analyze the synthesized stearic acid- ligand 
conjugates. The samples were measured at 298K with about CDCl3 solution using 
a NMR Spectrometer (AC-80, Bruker Biospin, Germany) [171]. 
5.26  DETERMINATION OF PARTICLE SIZE AND POLY DISPERSITY 
INDEX (PDI) 
The average particle size and PDI of the SLNs was measured by photon 
correlation spectroscopy using Malvern Zetasizer (Nano ZS90, Malvern 
Instruments) at 25°C [42,172].  
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5.27  DETERMINATION OF ZETA POTENTIAL 
 The zeta potential of the formulations was measured using Malvern 
Zetasizer (Nano ZS90, Malvern Instruments). The samples were placed in a glass 
cuvette (at 25°C) and a Zeta dip cell was used to find out the potential. The 
samples were diluted suitably using deionised water [173]. 
5.28  TRANSMISSION ELECTRON MICROSCOPY 
 The sample was cast on top of a carbon coated copper grid and the grid 
was air dried at room temperature. The particle shape and morphology were 
visualized at a voltage of 80 kV. The images were observed at a magnification 
value of 50,000 X [174].  
5.29  ATOMIC FORCE MICROSCOPY 
 The sample was adsorbed on the surface of silicon wafer and allowed to 
dry at room temperature. The samples were examined using Multimode Scanning 
probe microscope (NTMDT, NTEGRA prima, Russia) in semi-contact mode with 
a force constant range of 0.35- 6.06 N/m and a resonating frequency range of 47- 
150 KHz. The phase image and topology image were used to determine the 
morphology of SLN [175]. 
5.30  ENTRAPMENT EFFICIENCY 
 To calculate encapsulation efficiency, 2 ml of the formulation was 
centrifuged at 20,000 rpm for 45 min at 10 °C and the supernatant was analysed 
for free drug concentration using HPLC [176]. Blank SLNs were used as a 
control. Encapsulation efficiency was calculated using the following equation: 
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5.31  IN VITRO DRUG RELEASE 
 In vitro drug release profiles of the unconjugated and conjugated SLNs 
and IM solubilised in phosphate buffered saline (PBS) pH 7.4 was studied by 
dialysis bag method. Briefly, 1 ml sample was loaded into a dialysis bag with a 
molecular weight cut off of 12,000- 14,000 Daltons and both its ends were sealed 
with clips. The dialysis bag was then placed in a beaker containing 50 ml of PBS 
maintained at 37±1°C under stirring at 50 rpm using a magnetic stirrer. At various 
time points, 2 ml of PBS was withdrawn from the beaker. Each withdrawal was 
compensated by addition of 2 ml of fresh PBS to the beaker. The drug content of 
the collected samples was determined by a suitable analytical method [177].  
5.32  IN VITRO HAEMOLYSIS TEST  
 The in vitro haemolytic potential of QS, IM, unconjugated and conjugated 
SLNs was studied.  Distilled water and normal saline served as positive and 
negative controls respectively. Rat blood was freshly collected in a 
microcentrifuge tube containing 50 μl of trisodium citrate and centrifuged at 1500 
rpm for 15 min. After removing the supernatant containing plasma and cell debris, 
the pellet containing RBCs (red blood cells) was washed three times with normal 
saline. After the final wash, RBCs were collected by centrifugation at 1500 rpm. 
Purified RBCs were resuspended in normal saline to reach 2% (v/v) final 
concentration. The test samples were then added to test tubes containing 2.5 ml of 
2% RBC suspension and incubated for 4 h at 37 ºC. After incubation, the samples 
were centrifuged at 2500 rpm for 10 min and the supernatants were observed for 
any indication of haemolysis [178].  
5.33  IN VITRO CYTOTOXICITY STUDIES 
 In vitro cytotoxicity of IM, QS, unconjugated and conjugated SLNs 
against human breast cancer cells (MCF7) and its effect on the viability of murine 
macrophage cells (RAW 264.7) were tested by 3-[4,5-dimethylthiazol-2-yl]- 2,5-
Chapter 5  Materials & Methods 
 
 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  84 
diphenyl-tetrazoliumbromide (MTT) assay. Cell cultures were maintained in 
flasks containing Dulbecco's modified Eagle's medium supplemented with fetal 
bovine serum (FBS, 10%), glutamine (2 mM), streptomycin (200 µg/ml), 
gentamycin (400 µg/ml), penicillin (250 units/ml) and insulin (1 mg/ml) in a 
carbon dioxide incubator at 37°C with 5% CO2.    
 Prior to the experiment, 5000 cells/well were seeded in 96 well plates and 
incubated overnight for their attachment. Then, the medium was replaced with 
fresh medium containing various concentrations of the samples. After 48 h of 
incubation, 10 µl of 5 mg/ ml MTT stock was added to each well and incubated 
for 4 h. Then, 100 μl of DMSO was added to each well and the optical density 
was determined at 570 nm by a microplate reader. Cytotoxicity and cell viability 
in the presence of the samples (ISN3, B12-ISN, HAC-ISN, IGPN3, HAC-IGPN 
and IM) were compared with untreated control cells [174,179]. 
5.34  APOPTOSIS ANALYSIS 
 Apoptosis was measured by propidium iodide (PI) staining using MCF7 
cell line. At > 90% confluence, cells (1×105 cells/ml) were seeded in six-well 
plates and incubated with free IM, IGPN3, and HA-IGPN with an equivalent 
concentration of IM of 10 μg/ml for 24 hours. Cells incubated with PBS served as 
control. The cells were washed with PBS fixed in methanol: acetic acid (3:1,v/v) 
for 10 min and stained with 50 μg/ml PI for 10 min. Finally, the nuclear 
morphology of apoptotic cells with fragmented/ condensed was examined under 
laser scanning confocal microscope (Nikon Ti series; Nikon Corporation, Tokyo, 
Japan) [180]. 
5.35  STERILITY TESTING 
 Sterility testing was performed against bacteria and fungi on ISN3, B12-
ISN, HAC-ISN, IGPN3, HAC-IGPN and IM in pH 7.4 PBS using incubation 
method. A positive control containing the particular stain and negative control 
without addition of samples or strain were used also used. Thioglycollate 
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resazurine broth was used as the medium for the detection of bacteria and tripcase 
soy broth was used as medium for the detection of yeasts and fungi. 
Staphylococcus aureus, and Aspergillus Niger were used as the bacterial and 
fungal strains respectively. The respective samples (1 ml) were incubated for  
14 days at 32.5 ±2.5°C (thioglycollate resazurine medium) or at 22.5 ±2.5°C 
(tripcase medium). The turbidity of the media was then observed over a basic 
period of 14 days in comparison to positive controls. The experiment was done 
two times. 
5.36  IN VIVO PHARMACOKINETIC STUDIES 
In vivo animal studies were carried out to estimate the amount of drug that 
has reached the systemic circulation and to find out the uptake of the drug into the 
lymphatic vessels. The studies were carried out according to the guidelines of the 
Council for the Purpose of Control and Supervision of Experiments on Animals, 
Ministry of Social Justice and Empowerment, Government of India and the study 
protocol was carried out after obtaining the consent from PSG Institutional 
Animal Ethical Committee with registration No: 158/99/CPCSEA. Female Wistar 
rats weighing 280 - 310 gms have been used for the study and were categorized 
into 6 groups with 5 rats in each group. The rats were fed ad libitum with rodents 
chow allowing free access to drinking water. Prior to the study the animals were 
kept for overnight fasting but were allowed free access to water.  
5.36.1 Determination of pharmacokinetic parameters of Imatinib Mesylate in 
blood: 
The formulations were administered subcutaneously and the blood was 
collected from the retro-orbital venous plexus puncture of the rat with the aid of 
capillary tubes at 0.5, 1, 2, 4, 8, 12, 24, 36 and 72 hours post dosing. The samples 
were collected in a microcentrifuge tube containing 50 µl of tri sodium citrate and 
centrifuged at 2,500 rpm for 10 minutes. The plasma is collected and stored at -
20°C for further analysis [41]. 
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Group 1, Group 2, Group 3, Group 4, Group 5 and Group 6 consisted of 
animals used for the estimation of pharmacokinetic parameters in blood which 
were administered with ISN3, B12-ISN, HAC-ISN, IGPN3, HAC-IGPN and IM 
in pH 7.4 PBS (IM-PBS) respectively. A dose equivalent to 15 mg/ kg was 
administered subcutaneously at the mammary tissue and the blood (0.3 ml) was 
collected by retro-orbital venous plexus puncture with the aid of capillary tube at 
0.5, 1, 2, 4, 8, 12, 24, 36, 48, 60 and 72 hours post dose. The samples were 
collected in a microcentrifuge tube containing 50 µl of tri sodium citrate and 
centrifuged at 2,500 rpm for 10 minutes. The plasma samples were collected and 
stored at -80°C for quantitative analysis using HPLC. 
 
5.36.2 Determination of drug concentration of Imatinib Mesylate in sentinel 
lymph nodes: 
For the estimation of IM in the sentinel lymph nodes, three additional 
groups of rats containing 21 rats in each group were used. A dose equivalent to  
15 mg/ kg of IM was administered subcutaneously at the mammary tissue and at 
each sampling point (2, 4, 8, 12, 24, 48 and 72 hrs), three rats from each group 
were euthanized. Thereafter, two superficial lymph nodes, namely subiliac lymph 
node lying in the fold of thigh musculature adjacent to the ileac artery and 
popliteal lymph node lying near biceps femoris in the hind limb were located and 
harvested. The selection of lymph nodes was decided on the basis of their 
anatomical vicinity to the site of formulation administration. Lymph nodes 
collected at each time point were pooled separately, weighed, dipped in PBS and 
homogenised. IM was extracted from the lymph homogenate and quantified via 
HPLC. The pharmacokinetic parameters were calculated using WinNonlin  
(6.1; Phrsight, Mountain View, CA) [181]. 
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5.37  STABILITY STUDIES AS PER ICH GUIDELINES 
 Stability of formulations during storage conditions includes preservation of 
the initial particle size, prevention of degradation reactions and prevention of drug 
leakage from the lipid matrix. 
 Stability studies were performed for the formulations, ISN3, HAC-ISN, 
B12-ISN, IGPN3, HAC-IGPN and B12-IGPN.  The study was carried out as per 
the ICH guidelines, where in which, the samples were stored in room temperature 
(25 to 27°C) and in refrigerator (3 to 5°C) over a period of 12 months. The 
appearance of the formulation, particle size, zeta potential and entrapment 
efficiency were measured for every 3 months [164].  
5.38 STATISTICAL ANALYSIS 
Statistical analysis was carried out with the help of GraphPad Prism 
(version 5). Results are expressed as mean ± standard deviation (three 
independent values of the same formulation). Statistical significance was 
determined for in vitro release data by two-way analysis of variance (ANOVA). 
Bonferroni posttest was also used to compare the p values of each column at 
various individual time points. Student’s t-test was used to carry out the statistical 
analysis for in vivo animal studies and for finding out a significant relationship 
between concentration of lipid and size. In all cases, p value <0.05 was considered 
to be statistically significant. 
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6. RESULTS AND ANALYSIS 
 
6.1  DETERMINATION OF LAMBDA MAX (λmax) OF IMATINIB 
MESYLATE USING UV SPECTROPHOTOMETER 
 The wavelength at which maximum amount of radiation absorbs is called 
λmax of the compound and for IM maximum absorption was observed at 256 nm as 
shown in Figure 11.  
Figure 11. Wavelength of maximum absorbance for IM using UV 
spectrophotometer 
 
6.2  CONSTRUCTION OF CALIBRATION CURVE FOR IMATINIB  
 MESYLATE USING UV SPECTROPHOTOMETER AT 256 nm 
 Standard curve of IM was plotted using UV spectrophotometer and the 
corresponding absorbance at 256 nm was determined for various concentrations 
ranging from 4 to 18 mcg/ml. The absorbance values corresponding to the 
concentrations are shown in Table 1 and the graph obtained by plotting 
absorbance vs. concentration is shown in Figure 12.  
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Table 1. Calibration curve data for IM by UV spectroscopy 
S No 
CONCENTRATION 
(mcg/ml) 
ABSORBANCE  
(256 nm) 
1 0 0.000 
2 4 0.233 
3 6 0.336 
4 8 0.430 
5 10 0.559 
6 12 0.660 
7 16 0.871 
8 18 0.980 
 
 
Figure 12. Calibration curve for the estimation of IM by UV spectroscopy 
 
6.3  ANALYTICAL METHOD DEVELOPMENT 
6.3.1 Optimisation of process parameters 
A RP-HPLC method was developed for the estimation of IM in aqueous 
and plasma samples using a UV detector. The wavelength selected for the 
detection of IM was 256 nm. The chromatographic conditions were optimized to 
provide excellent performance for the assay of IM within a short time using a 
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simple mobile phase and appropriate flow rate. The selection of mobile phase was 
based upon the polarity of the drug. Different trails were performed by changing 
the columns, mobile phase composition, pH, flow rate and the chromatographic 
conditions were fixed. The conditions mentioned in Table 2 were optimised for 
the estimation of IM.  
Table 2. Optimised chromatographic conditions for HPLC 
PARAMETER FIXED CONDITION 
Stationary phase Sunfire C8 (4.6 x 150mm, 3.5μ 
Mobile phase Acetonitrile: Water  (0.1 % formic acid) pH- 3.4 
Mobile phase ratio Gradient run, (30:70 v/v) 
Detection wavelength 256 nm 
Flow rate 0.3 ml/min 
Sample volume 20 μl 
Needle wash Water HPLC grade 
Column temp 25°C 
 
 The method was validated as per ICH guidelines by using various 
parameters to ensure the accomplishment of its application. 
6.3.2  Method validation 
           The optimized method was validated of in terms of specificity, linearity, 
accuracy, precision, specificity, limit of detection, limit of quantification as per 
ICH guidelines. 
Specificity 
A good specificity was observed for the developed method where a good 
separation was observed without any additional peaks. The representative 
chromatograms of pure sample of IM, IM estimated in aqueous and IM in rat 
plasma is mentioned in Figure 13. 
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Figure 13. Representative chromatogram of IM in aqueous  
sample (a) and rat plasma (b) 
 
The calibration curve for IM in the aqueous and plasma samples was 
constructed by plotting a graph between peak area versus concentration and the 
corresponding regression equations were also calculated. The corresponding peak 
areas for different concentrations for aqueous and plasma samples were shown in 
Table 3 and Table 4 respectively. The calibration curve obtained by plotting peak 
area vs. concentration in aqueous and plasma samples was shown in Figure 14 and 
Figure 15 respectively. A correlation coefficient (r2) of 0.9998 and 0.9992 was 
observed for the calibration curves plotted in aqueous and plasma samples 
respectively. 
 
 
 
 
Chapter 6  Results & Analysis 
 
 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  92 
Table 3. Calibration curve data for IM in aqueous samples 
S No 
Nominal concentration 
(mcg) 
Peak area 
1. 5.000 821637.57 
2. 10.000 1612348.54 
3. 20.000 3217510.85 
4. 40.000 6116660.56 
5. 60.000 9091352.13 
6. 80.000 12155547.29 
7. 100.000 14954444.83 
 
Table 4. Calibration curve data for IM in plasma samples 
S No Nominal concentration (ng/ml) Peak area 
1. 250 15922.190 
2. 500 19788.850 
3. 1000 29600.888 
4. 2000 52821.869 
5. 4000 90336.032 
6. 8000 171643.672 
7. 16000 315960.481 
 
 
Figure 14. Calibration curve of IM in aqueous samples 
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Figure 15. Calibration curve of IM in rat plasma. 
Accuracy 
The accuracy of the proposed method for IM in aqueous and plasma 
samples are mentioned in Table 5 and Table 6. A good accuracy was observed for 
the samples. 
Table 5. Accuracy of IM in aqueous samples 
Spiked 
concentration                    
(µg/ml) 
LQC HQC 
10 40 
 
S.NO 
Calculated 
concentration 
(µg/ml) 
Accuracy 
% 
Calculated 
concentration 
(µg/mL) 
Accuracy 
% 
1 9.78 97.8 38.92 97.3 
2 9.63 96.3 39.21 98.02 
3 9.58 95.8 39.68 99.2 
4 9.8.7 98.7 39.98 99.5 
5 10.15 101.4 40.14 100.35 
Mean - 97.5 - 98.96 
SD  2  1.28 
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Table 6. Accuracy of IM in plasma samples 
S. 
No 
Spiked concentration 
(ng/ml) 
Measured concentration 
(ng/ml) 
Accuracy (%)  
± SD 
1. 250 251.8 100 ± 2 
2. 1000 1002.8 100.28 ± 1.84 
3. 2000 2012.4 100.29 ± 0.92 
 
Precision  
To check the repeatability, different concentrations of IM were used. The 
response of each of these solutions was measured and percentage relative standard 
deviation (% RSD) was calculated.  In aqueous samples, for intraday precision, 
three different concentrations were prepared (10, 20 and 40μg/ml) with five 
replicates of each, and their peak area was measured on the same day. Similarly, 
for interday precision, three different concentrations were prepared (25, 50 and  
75 μg/ml) with three replicates of each, and their corresponding peak area was 
measured on three subsequent days. The results were reported in terms of the 
relative standard deviation (RSD). The interday and intraday precision values are 
represented in Table 7. In plasma samples, for intra and interday precision 250, 
1000 and 2000 μg/ml concentrations were used and their corresponding peak 
areas were measured. The results were reported in terms of the relative standard 
deviation (RSD) in Table 7. 
Table 7. Interday and intraday precision of IM in aqueous and  
plasma samples 
 
IM 
Aqueous Plasma 
Concentration 
(μg/ml) 
% RSD 
Concentration 
(μg/ml) 
% RSD 
Interday 
10 2 250 1.60 
20 1.64 1000 1.84 
40 1.61 2000 0.92 
 
Intraday 
 
10 2 250 2.0 
20 1.91 1000 1.84 
40 1.29 2000 0.67 
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LOD and LOQ  
         The LOD and LOQ of the developed method for estimating IM in aqueous 
and plasma samples were established by injecting the low concentration of the 
standard solution using the developed RP-HPLC method. The LOD and LOQ in 
aqueous and plasma samples were found to be 14.5 ng/ml and 43.93 ng/ml 
respectively. 
6.3.3 Stability 
  The results of stability studies of IM in rat plasma in different conditions are 
represented in Table 8. The results indicated that IM was stable at room 
temperature at least 24 h and in refrigerated conditions ±4°C. Additionally, IM 
was also stable in deproteinzed plasma, after freeze-thaw cycles and after storage 
at -20C° for 6 months. 
Table 8. Stability of IM at different temperatures and after freeze 
thaw test  
 
Duration 
 
Samples 
Concentration(ng/ml) 
250 1000 
%accuracy %cv %accuracy %cv 
24 hrs 
Plasma ±4°C 94.49 1.84 97.16 0.56 
Deproteinized samples 99.54 0.73 99.38 1.30 
48 hrs Plasma ±4°C 95.23 2.12 96.55 3.14 
6 months 
At -20°C 97.32 2.46 98.64 1.22 
Samples from freeze-
thaw testing 
98.51 3.38 98.76 2.04 
6.4  SCREENING OF LIPIDS FOR IM SOLUBILITY 
The results of solubility study (Table 9) indicated that IM was soluble in 
only some of the lipids tested in the study. Formation of a clear lipid phase in the 
mixture of IM and the corresponding lipid indicate solubilisation of IM in the 
lipid. A clear lipid phase was observed when IM was dissolved in myristic acid, 
palmitic acid, stearic acid, glyceryl palmitostearate, Precirol 5 ATO, glyceryl 
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monostearate, Geleol mono and di glycerides, trimyristin, tripalmitin and 
tristearin. But, when behenic acid, Compritol 888 ATO, Sterotex HM, Sterotex 
NF, cocoa butter, Hydrokote M, Hydrokote 112, Captex 70, Gelucire 44/14 and 
Gelucire 33/01 were used to solubilise IM, a clear lipid phase was not observed 
which indicated the inability of those lipids to solubilise IM. 
Table 9. Assessment of solubility of IM in various lipids 
S No. 
Name of the lipid Solubility of 
IM 
1  Myristic acid Soluble 
2  Palmitic acid Soluble 
3  Stearic acid Soluble 
4  Behenic acid Soluble 
5  Glyceryl palmitostearate Soluble 
6  Precirol ATO 5® Soluble 
7  Glyceryl monostearate Soluble 
8  Geleol mono and di glycerides® Soluble 
9  Compritol 888 ATO® Insoluble 
10  Trimyristin Soluble 
11  Tripalmitin Soluble 
12  Tristearin Soluble 
13  
Sterotex HM® (hydrogenated soya 
bean seed oil) 
Insoluble 
14  
Sterotex NF® (hydrogenated cotton 
seed oil) 
Insoluble 
15  Cocoa butter Insoluble 
16  
Hydrokote M® (hydrogenated palm 
kernel oil) 
Insoluble 
17  
Hydrokote 112® (hydrogenated palm 
kernel oil) 
Insoluble 
18  
Captex 70® (mixture of 70% medium chain 
triglycerides) 
Insoluble 
19  
Gelucire 44/14® (mixture of lauroyl macrogol-32 
glycerides and lauroyl polyoxyl-32 glycerides) 
Insoluble 
20  
Gelucire 33/01® (mixture of glycerides and esters 
of fatty acids and poly ethylene glycol) 
Insoluble 
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6.5 SOLID STATE CHARACTERISATION USING DIFFERENTIAL 
SCANNING CALORIMETRY 
The results of the DSC were concomitant with the results obtained from the 
solubility studies. DSC thermogram of IM indicated a melting peak at 227.83ºC 
corresponding to its melting point (Figure 16). When myristic acid, palmitic acid, 
stearic acid, glyceryl palmitostearate, Precirol 5 ATO®, glyceryl monostearate, 
Geleol mono and di glycerides®, trimyristin, tripalmitin and tristearin were used as 
the lipids carriers to solubilise IM, their corresponding DSC thermograms showed 
a melting peak corresponding only to the melting point of the lipid, but did not 
show the melting peak corresponding to IM at 227.83ºC. This absence of melting 
peak of IM confirmed the ability of the above lipids to solubilise IM. However, 
thermograms of other lipids such as Compritol 888 ATO® in Figure 16 (a), 
behenic acid in Figure 16 (b), and, Sterotex HM®, Sterotex NF®, cocoa butter, 
Hydrokote M®, Hydrokote 112®, Captex 70®, Gelucire 44/14® and Gelucire 
33/01® in Figure 16 (c) showed the corresponding melting peaks of the lipids as 
well as IM confirming the inability of these lipids to solubilise IM. The melting 
points of the lipids used were mentioned in Table 10. 
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Figure 16. DSC thermograms of IM, bulk lipids and mixture of IM and lipid 
(a, b and c). 
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Table 10. Quantitative solubility of IM in the lipids and their melting points 
S No. Name of the lipid 
Solubility  
(% w/w) 
Melting 
point (ºC) 
1  Myristic acid 2.76  ± 0.11 57.8 
2  Palmitic acid 2.10 ± 0.23 62.3 
3  Stearic acid 1.94 ± 0.08 57.5 
4  Behenic acid 0.01 ± 0.01 80.9 
5  Glyceryl palmitostearate 2.93 ± 0.15 50.2 
6  Precirol ATO 5 3.17 ± 0.19 51.5 
7  Glyceryl monostearate 6.19 ± 0.22 63.7 
8  Geleol mono and di glycerides 3.31 ± 0.27 67.5 
9  Compritol 888 ATO - 74.5 
10  Trimyristin 0.97 ± 0.08 59.8 
11  Tripalmitin 0.64 ± 0.12 68 
12  Tristearin 0.45 ± 0.04 64.2 
13  
Sterotex HM 
(hydrogenated soya bean seed oil) 
- 69.1 
14  
Sterotex NF 
(hydrogenated cotton seed oil) 
- 66.2 
15  Cocoa butter - 38.7 
16  
Hydrokote M 
(hydrogenated palm kernel oil) 
- 43.2 
17  
Hydrokote 112 
(hydrogenated palm kernel oil) 
- 44.4 
18  Captex 70 - 126.5 
19  Gelucire 44/14 - 43.6 
20  Gelucire 33/01 - 54.7 
 
6.6  QUANTIFICATION OF SOLUBILITY OF IMATINIB  
 MESYLATE IN THE LIPIDS 
The maximum solubility of IM in various lipids tested in the present study 
is listed in Table 10. Among the lipids used, glyceryl monostearate was the most 
efficient to solubilise IM (6.19 ± 0.22 %). On the other hand, tristearin showed the 
lowest ability to solubilise IM (0.45 ± 0.04%). The decreasing order of the  
lipids with respect to solubilisation of IM is as follows, glyceryl monostearate> 
Geleol mono and di glycerides> Precerol ATO5> glyceryl palmitostearate> 
myristic acid> palmitic acid> stearic acid> trimyristin> tripalmitin> tristearin> 
behenic acid. 
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6.7 ESTIMATION OF TOTAL SOLUBILITY PARAMETERS, POLARITY 
OF IMATINIB   MESYLATE AND LIPIDS 
The results of calculated solubility parameters and polarities of IM and the 
lipids are shown in Table 11. The solubility parameters of the tested lipids were 
found to be in the range of 17.34 to 23.06 MP. Amongst the lipids used, glyceryl 
palmitostearate and behenic acid were found to have the highest and lowest values 
respectively. The solubility parameter for IM was found to be 32.52 MPa1/2. As 
Compritol 888 ATO, Sterotex HM, Sterotex NF, cocoa butter, Hydrokote M, 
Hydrokote 112, Captex 70, Gelucire 44/14 and Gelucire 33/01 are mixtures of 
mono, di and triglyceride derivatives of fatty acids and hydrogenated mixtures of 
fatty acids their solubility parameters were not estimated. 
Table 11. Solubility parameter and polarity of IM and lipids along with their 
difference in solubility parameters. 
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1 IM 26.14 13.46 13.86 32.52 - 0.35 
2 Myristic acid 16.42 1.64 6.26 17.65 14.87 0.13 
3 Palmitic acid 16.46 1.46 5.90 17.55 14.97 0.12 
4 Stearic acid 16.49 1.31 5.59 17.46 15.06 0.11 
5 Behenic acid 16.54 1.09 5.10 17.34 15.18 0.09 
6 Glyceryl 
palmitostearate 
17.52 2.82 13.87 23.06 9.46 0.32 
7 Precirol ATO 5® -- -- -- -- -- -- 
8 Glyceryl 
monostearate 
16.4 4.3 8.8 20.36 12.15 0.35 
9 Geleol mono and 
di glycerides® 
-- -- -- -- -- -- 
10 Compritol 888 
ATO® 
16.4 4.3 11.3 21.42 11.10 0.18 
11 Trimyristin 16.69 1.11 5.24 17.53 14.99 0.09 
12 Tripalmitin 16.70 0.98 4.94 17.44 15.08 0.08 
13 Tristearin 16.70 0.88 4.68 17.37 15.15 0.08 
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6.8 IDENTIFICATION OF DESCRIPTORS AND DEVELOPMENT OF 
QUANTIATIVE STRUCTURE SOLUBILITY RELATIONSHIP 
MODEL 
Figure 17 shows the three dimensional structures of the lipids that were 
developed using LigPrep. Although QikProp module of Schrodinger provided 
information pertaining to 51 different descriptors of the lipids used in the study, 
only those descriptors which showed good correlation with the solubility of IM 
(r2> 0.6) were used for the development of model (data not shown). Additionally, 
non-significant descriptors were removed to avoid distortions and to improve the 
efficiency of the model. Three separate models were constructed to identify the 
important descriptors which influenced the solubility of IM in the lipids viz., 
model 1, model 2 and model 3 by choosing one, two and three subsets 
respectively (Table 12). Among those, descriptors of the lipids which relate to its 
polar properties like the index of cohesive interaction in solids (AC×DN0.5/SA), 
estimated number of hydrogen bonds that would be accepted by the solute from 
water molecules in an aqueous solution (accptHB), estimated number of hydrogen 
bonds that would be donated by the solute to water molecules in an aqueous 
solution (donorHB) and solvent accessible surface area (SASA) were used for the 
model development and their corresponding descriptor values for the various 
lipids used in the study are mentioned in Table 13. The equations generated by the 
3 models (viz., model 1, model 2 and model 3) using MLR are mentioned as 
equations 3, equation 4 and equation 5 respectively. 
     
------- equation 3 
B  
---- equation 4 
           -----equation 5 
 These equations can predict the solubility of IM in lipids and additionally 
describe the major descriptors which influenced the solubilisation of IM in the 
lipids.  The statistical values pertaining to the model development is mentioned in 
Table 14. 
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Figure 17. Three dimensional molecular structures of IM and lipids. 
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Table 12. Details of the three MLR models developed 
Model 
Number of 
sub sets 
Used descriptors Observed descriptors 
Model 1 1 
AC×DN0.5/SA, accptHB, 
donorHB and SASA 
AC×DN0.5/SA 
Model 2 2 
AC×DN0.5/SA, accptHB, 
donorHB and SASA 
AC×DN0.5/SA and donorHB 
Model 3 3 
AC×DN0.5/SA, accptHB, 
donorHB and SASA 
AC×DN0.5/SA, donorHB and 
accptHB 
Table 13. Molecular and physicochemical descriptors of the lipids 
S No Name of the lipid AC×DN0.5/SA accptHB donorHB SASA 
1  Myristic acid 0.0032753 2 1 610.633 
2  Palmitic acid 0.0029556 2 1 676.678 
3  Stearic acid 0.0026928 2 1 742.716 
4  Behenic acid 0.0022862 2 1 874.804 
5  
Glyceryl 
palmitostearate 
0.0026928 2 1 742.716 
6  Glyceryl monostearate 0.0086735 5.4 2 880.467 
7  Trimyristin 0 6 0 1692.1 
8  Tripalmitin 0 6 0 1889.22 
9  Tristearin 0 6 0 2087.11 
 
Table 14. Statistical results of the three QSSR models developed to predict 
solubility of IM 
TRAINING SET TEST SET 
Factors R2 RMSE F P Q2 R2 R2M 
R2 
pred 
RMSE 
1 0.826 0.863 19.1 1.202e-02 0.65 0.949 0.936 0.912 0.275 
2 0.876 0.730 10.6 4.369e-02 0.74 0.995 0.948 0.878 0.324 
3 0.925 0.566 8.3 1.098e-01 0.63 0.917 0.895 0.525 0.642 
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(iii) 
Figure 18. Experimentally determined plot representing solubility of IM in 
lipids against predicted solubility of IM in lipids as observed in (i) model 1, 
(ii) model 2 and (iii) model 3. 
 
6.9  DETERMINATION OF PARTITIONING COEFFICIENT OF 
IMATINIB  MESYLATE IN DIFFERENT LIPIDS AND WATER 
The highest partition for IM was observed towards glyceryl palmitostearate 
(0.39 ± 0.08). The order of partition of IM in the lipids was found to be 
descending as follows; glyceryl palmitostearate (0.39 ± 0.08) > Precirol ATO 5 
(0.28 ± 0.03) > Geleol mono and di glycerides (0.26 ± 0.02) > glyceryl 
monostearate (0.33 ±0.01) > stearic acid (0.22 ± 0.02) >palmitic acid  
(0.16 ± 0.01) > myristic acid (0.12 ± 0.01). 
 
 
Chapter 6  Results & Analysis 
 
 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  107 
6.10  INFRARED (IR) ABSORPTION SPECTROSCOPY 
 The IR spectrum of pure IM in Figure 19 represents characteristic wave 
numbers at 1177 cm-1, 1418 cm-1, 1447 cm-1, 1525 cm-1, 2111 cm-1 and 3445 cm-1. 
These wave numbers are compared with the IR obtained from standard 
pharmacopeia. The IR spectrum of QS was shown in Figure 20. It showed specific 
wave numbers at 1728 cm-1 and 3389 cm-1 corresponding to the ketone group and 
alcoholic –OH groups present in the saponin. Additionally, strong bands were 
observed in the region of 1340- 1450 cm-1 and 2940 cm-1, which corresponds to 
the ketone and carboxylic acid groups present in the saponin. The IR spectrum 
corresponding to the lipids stearic acid, palmitic acid, glyceryl palmitostearate, 
glyceryl monostearate and geleol mono and diglycerides was shown in Figure 21, 
Figure 22, Figure 23, Figure 24 and Figure 25 respectively. The IR spectrum of 
stearic acid and palmitic acid prominently showed wave numbers in the regions of 
2500- 3000 cm-1 which correspond to carboxylic acid groups present in the fatty 
acids. The IR spectrum of glyceryl palmitostearate and glycerylmonostearate 
showed wave numbers in the regions of 1200 cm-1 and 1700 cm-1 representing the 
acetate and ester functional groups present in the monoglyceride derivatives. 
 
Figure 19. IR spectrum of IM: pure sample 
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Figure 20. IR spectrum of QS: pure sample 
 
Figure 21. IR spectrum of stearic acid: pure sample 
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Figure 22. IR spectrum of palmitic acid: pure sample 
 
 
Figure 23. IR spectrum of glyceryl palmitostearate: pure sample 
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Figure 24. IR spectrum of glyceryl monostearate: pure sample 
 
Figure 25. IR spectrum of Geleol mono and di glycerides: pure sample 
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IR SPECTRA OF THE PHYSICAL MIXTURES OF IMATINIB   
MESYLATE AND LIPIDS 
 The IR spectra of the physical mixtures of IM and corresponding lipids are 
shown in Figure 26 to Figure 30. Table 15 mentions the various functional groups 
pertaining to IM, lipids and their corresponding mixtures. 
 
Figure 26. IR spectrum of physical mixture: IM, QS and stearic acid 
 
Figure 27. IR spectrum of physical mixture: IM, QS and palmitic acid. 
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Figure 28. IR spectrum of physical mixture: IM, QS and 
 glyceryl palmitostearate 
 
Figure 29. IR spectrum of physical mixture: IM, QS and  
glyceryl mono stearate 
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Figure 30. IR spectrum of physical mixture: IM, QS and Geleol mono and 
diglycerides 
 
Table 15. Functional groups corresponding to IM, lipids and physical 
mixture as observed in FT-IR spectroscopy. 
Functional groups 
Peak wave number (cm-1) 
 IM Lipid Physical mixture 
C=O stretch 1177 - 1178 
Amide 1418 - 1418 
Aromatic C=C stretching 1525  - 1525 
Alkynyl C-H& C=C stretching 2111 1662 1662 
Aromatic amine (NH2)  3445 1605 1605 and 3445 
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6.11 CHEMICAL CONJUGATION OF STEARIC ACID WITH LIGANDS 
 The formation of hylauronic acid conjugated stearyl amine (HAJ-SA) and 
vitamin B12 conjugated stearic acid (B12-SA) was confirmed using IR and NMR 
spectroscopy. The NMR spectrum of stearic acid, HAJ-SA and B12-SA is shown 
in Figure 31, Figure 32 and Figure 33 respectively. Conjugation of stearic acid 
with vitamin B12 was confirmed by the formation of amide linkage between 
COOH groups of stearic acid and NH2 group of vitamin B12. Whereas 
conjugation of HA to stearyl amine was confirmed by the formation of amide 
linkage between COOH groups of HA and NH2 groups of stearyl amine. The IR 
spectrum of both the conjugates in Figure 34 and Figure 35 showed peaks at 1647 
cm-1, 1552 cm-1 and 1658 cm-1 corresponding to the formation of amide bond 
stretching and NH bending. After lyophilisation, 14.1 mg of HA-SA and 12.3 mg 
of B12-SA were obtained. 
 
Figure 31. NMR spectra of stearic acid 
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Figure 32. NMR spectra of the conjugate: HAJ-SA 
 
 
Figure 33. NMR spectra of the conjugate: B12-SA 
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Figure 34. FT-IR spectra of the conjugate: HAJ-SA 
 
Figure 35. FT-IR spectra of the conjugate: B12-SA 
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6.12 PREPARATION OF IM LOADED SOLID LIPID NANOPARTICLES 
(SLNs)  
SLNs of IM were prepared using different lipid carriers like stearic acid, 
palmitic acid, glyceryl palmitostearate, glyceryl monostearate and geleol mono 
and diglycerides as lipid carriers and QS, a non-ionic amphiphilic surfactant 
extracted from the bark of Quillaja saponaria was used as a surfactant for the 
preparation of SLNs of IM. A hot melt homogenisation method using high shear 
homogenisation and probe sonication was employed for the preparation. As each 
lipid has a characteristic composition which influences the formation of SLNs, the 
same set of parameters with respect to speed and time of homogenisation and time 
of sonication may not be suitable for all the lipids. High speeds may result in the 
formation of froth and cream, whereas low speed may not be suitable for the 
formation of nanoparticles. Table 16 represents the optimised conditions for each 
lipid during the preparation of SLNs. The compositions of various batches of 
SLNs prepared were mentioned in Table 17. 
Table 16. Optimised conditions for the formation of SLNs 
S No Lipid used 
Temperature 
maintained 
during 
formulation 
Homogenization 
speed and time 
Sonication 
time 
Code 
1  Stearic acid 75 ºC 
13, 000 rpm; 
4 min 
2 min ISN 
2  Palmitic acid 68 ºC 
14,000 rpm; 
4 min 
4 min IPN 
3  
Glyceryl 
palmitostearate 
60 ºC 
14, 000 rpm; 
6 min 
6 min IGPN 
4  
Glyceryl 
monostearate 
65 ºC 
15, 000 rpm; 
4 min 
4 min IGMN 
5  
Geleol mono 
and  di 
glycerides 
67 ºC 
15,000 rpm; 
2 min 
6 min IGEN 
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Table 17. Composition of different batches of SLNs 
Code IM (mg) Lipid (%) QS (%) 
STEARIC ACID BASED SLNs 
ISN1 20 4 0.5 
ISN2 20 4 1 
ISN3 20 4 1.5 
ISN4 20 8 0.5 
ISN5 20 8 1 
ISN6 20 8 1.5 
ISN7 20 12 0.5 
ISN8 20 12 1 
ISN9 20 12 1.5 
B12-ISN 20 4 1.5 
HAJ-ISN 20 4 1.5 
HAC-ISN 20 4 1.5 
PALMITIC ACID BASED SLNs 
IPN1 20 4 0.5 
IPN2 20 4 1 
IPN3 20 4 1.5 
IPN4 20 8 0.5 
IPN5 20 8 1 
IPN6 20 8 1.5 
IPN7 20 12 0.5 
IPN8 20 12 1 
IPN9 20 12 1.5 
GLYCERYL PALMITOSTEARATE BASED SLNs 
IGPN1 20 4 0.5 
IGPN2 20 4 1 
IGPN3 20 4 1.5 
IGPN4 20 8 0.5 
IGPN5 20 8 1 
IGPN6 20 8 1.5 
IGPN7 20 12 0.5 
IGPN8 20 12 1 
IGPN9 20 12 1.5 
B12-IGPN 20 4 1.5 
HAJ-IGPN 20 4 1.5 
HAC-IGPN 20 4 1.5 
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Code IM (mg) Lipid (%) QS (%) 
GLYCERYL MONOSTEARATE BASED SLNs 
IGMN1 20 4 0.5 
IGMN2 20 4 1 
IGMN3 20 4 1.5 
IGMN4 20 8 0.5 
IGMN5 20 8 1 
IGMN6 20 8 1.5 
IGMN7 20 12 0.5 
IGMN8 20 12 1 
IGMN9 20 12 1.5 
GELEOL MONO AND DIGLYCERIDES BASED SLNs 
IGEN1 20 4 0.5 
IGEN2 20 4 1 
IGEN3 20 4 1.5 
IGEN4 20 8 0.5 
IGEN5 20 8 1 
IGEN6 20 8 1.5 
IGEN7 20 12 0.5 
IGEN8 20 12 1 
IGEN9 20 12 1.5 
 
6.13  PHYSICAL ADSORPTION WITH HYALURONIC ACID 
HA was coated onto the surface of the nanoparticles by electrostatic 
attraction. Different concentrations of HA (0.05%, 0.10%, 0.15% or 0.20% w/v) 
were used for the coating of SLNs. After coating with HA the particle size of the 
formulations reduced.  Various concentrations have been tried in order to obtain a  
formulation without any aggregation among the particles. 
6.14  FREEZE DRYING 
Freeze dried powders of the samples were used only for performing 
differential scanning calorimetric studies. The freeze dried powdered samples is 
shown in Figure 36. 
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Figure 36. Freeze dried powder samples of ISN (a), IPN (b) and IGPN (c). 
 
6.15  DETERMINATION OF PARTICLE SIZE AND POLY DISPERSITY 
 INDEX 
 The particle size of the SLNs of stearic acid containing IM is shown in 
Table 18. The average particle size of the different batches of ISN ranged from 
143.5 ± 3.5 nm to 641.9 ± 4.2 nm. A highest particle size was obtained for 
formulation ISN7 containing 12% stearic acid and 0.5% QS. A least particle size 
was observed for formulation ISN6 containing 8% stearic acid and 1.5% QS. The 
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particle size of the ISN was influenced by the amount of stearic acid and QS. The 
PDI of the formulations was found to be below 0.25, which indicates that the 
nanoparticles are partially monodisperse. Addition of conjugates like vitamin 
B12-stearic acid (B12-ISN) and HA-stearic acid (HAJ-ISN) during the 
preparation of SLNs showed a mild increase in the particle size from 159.5 ± 4.7 
nm to 169.1 ± 3.16 nm and 173.1 ± 4.5 nm respectively. But, coating of ISN3 with 
HA (HAC-ISN3) decreased the particle size to 87.3 ± 5.9 nm.  
Table 18: Particle size, polydispersity index, zeta potential and entrapment 
efficiency of the formulations 
Code 
Average Size 
(nm ± SD) 
Polydispersity 
index (± SD) 
Zeta 
potential 
(mV ± SD) 
Entrapment 
efficiency 
(% ± SD) 
STEARIC ACID BASED SLNs 
ISN1 457.8 ± 3.8 0.183 ± 0.03 0.20 ± 1.1 66.2 ± 1.2 
ISN2 320.5 ± 2.5 0.155 ± 0.03 0.62 ± 0.1 62.7 ± 1.5 
ISN3 159.5 ± 4.7 0.127 ± 0.01 0.95 ± 0.5 61.3 ± 1.1 
ISN4 423.4 ± 3.2 0.186 ± 0.01 -0.78 ± 0.8 59.5 ± 0.9 
ISN5 269.7 ± 3.7 0.165 ± 0.01 -1.97 ± 0.1 57.0 ±1.7 
ISN6 143.5 ± 3.5 0.128 ± 0.01 -0.42 ± 1.2 54.1 ± 1.9 
ISN7 641.9 ± 4.2 0.206 ± 0.03 -1.83 ± 0.2 44.1 ± 1.9 
ISN8 447.5 ± 8.7 0.237 ± 0.03 -2.43 ± 0.4 45.0 ± 1.4 
ISN9 400.9 ± 6.2 0.162 ± 0.02 -2.23 ± 0.2 41.0 ± 1.0 
B12-ISN 169.1 ± 3.2 0.205 ± 0.01 10.2 ± 1.2 56.9 ± 1.4 
HAJ-ISN 173.1 ± 4.5 0.228 ± 0.02 -6.4 ± 0.7 50.6 ± 1.5 
HAC-ISN 87.3 ± 5.9 0.162 ± 0.01 -12.8 ± 1.7 47.8 ± 2.1 
PALMITIC ACID BASED SLNs 
IPN1 395.2 ± 5.5 0.203 ± 0.03 -1.08 ± 0.2 57.1 ± 0.3 
IPN2 310.3 ± 9.5 0.185 ± 0.01 -1.70 ± 0.6 55.6  ± 0.5 
IPN3 133.1 ± 8.4 0.128 ± 0.01 -4.29 ± 0.6 53.1 ± 0.9 
IPN4 517.8 ± 7.4 0.172 ± 0.03 -1.29 ± 0.5 48.5 ± 0.6 
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Code 
Average Size 
(nm ± SD) 
Polydispersity 
index (± SD) 
Zeta 
potential 
(mV ± SD) 
Entrapment 
efficiency 
(% ± SD) 
IPN5 301.2 ± 9.3 0.227 ± 0.02 -1.77 ± 0.9 44.4 ± 1.1 
IPN6 267.6 ± 5.9 0.262 ± 0.03 -2.73 ± 0.5 39.8 ± 0.6 
IPN7 611.0 ± 4.1 0.234 ± 0.05 -3.91 ± 0.8 44.1 ± 0.3 
IPN8 309.9 ± 5.3 0.236 ± 0.02 -2.09 ± 0.2 47.4 ± 0.7 
IPN9 283.5 ± 7.1 0.279 ± 0.02 -1.83 ± 0.3 50.4 ± 0.8 
GLYCERYL PALMITOSTEARATE BASED SLNs 
IGPN1 218.0 ± 3.2 0.247 ± 0.02 1.21 ± 0.7 51.3 ± 0.9 
IGPN2 145.3 ± 4.5 0.211 ± 0.01 0.56 ± 0.3 56.7 ± 0.8 
IGPN3 106.4 ± 4.7 0.08 ± 0.01 1.03 ± 0.14 55.1 ± 1.1 
IGPN4 269.8 ± 2.3 0.203 ± 0.01 3.37 ± 0.1 55.2 ± 1.5 
IGPN5 174.9 ± 4.3 0.172 ± 0.09 2.79 ± 0.4 58.0 ± 0.7 
IGPN6 122.8 ± 2.9 0.166 ± 0.01 2.49 ± 0.3 59.4 ± 1.3 
IGPN7 430.7 ± 2.2 0.131 ± 0.02 3.72 ± 0.2 61.7 ± 0.9 
IGPN8 326.7 ± 4.8 0.227 ± 0.02 3.37 ± 0.3 63.6 ± 0.7 
IGPN9 206.9 ± 4.1 0.125 ± 0.01 2.51 ± 0.4 65.9 ± 0.6 
B12-IGPN 118.7 ± 3.9 0.194 ± 0.02 1.63 ± 0.5 51.5 ± 1.2 
HAJ-IGPN 130.6 ± 2.7 0.212 ± 0.02 -2.3 ± 0.6 49.9 ± 2.1 
HAC-IGPN 92.1 ± 2.41 0.08 ± 0.01 -10.67 ± 1.32 43.4 ± 0.7 
GLYCERYL MONOSTEARATE BASED SLNs 
IGMN1 740.9 ± 15.6 0.155 ± 0.01 4.07 ± 0.2 54.1 ± 0.6 
IGMN2 538.0 ± 15.70 0.182 ± 0.01 3.17 ± 0.5 50.4 ± 1.0 
IGMN3 422.6 ± 8.2 0.134 ± 0.01 -2.92 ± 0.3 47.1 ± 0.7 
IGMN4 430.1 ± 9.1 0.347 ± 0.02 -13.78 ± 2.3 - 
IGMN5 296.4 ± 8.4 0.309 ± 0.01 -7.05 ± 0.8 44.1 ± 0.5 
IGMN6 168.5 ± 7.5 0.175 ± 0.01 -3.56 ± 0.2 41.9 ± 1.1 
IGMN7 360.6 ±7.5 0.371 ± 0.03 -14.96 ± 0.8 - 
IGMN8 245.3 ± 9. 0.328 ± 0.01 -6.14 ± 0.3 47.2 ± 1.1 
IGMN9 126.6 ± 6.1 0.250 ± 0.02 -3.36 ± 0.5 48.9 ± 0.6 
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Code 
Average Size 
(nm ± SD) 
Polydispersity 
index (± SD) 
Zeta 
potential 
(mV ± SD) 
Entrapment 
efficiency 
(% ± SD) 
GELEOL MONO AND DI GLYCERIDE BASED SLNs 
IGEN1 354.8 ± 7.9 0.183 ± 0.01 -2.45 ± 0.1 57.5 ± 1.2 
IGEN2 224.7 ± 8.4 0.163 ± 0.01 -2.52 ± 0.3 56.6 ± 0.9 
IGEN3 118.4 ± 5.1 0.135 ± 0.02 -2.01 ± 0.1 59.0 ± 0.3 
IGEN4 376.7 ± 6.7 0.460 ± 0.02 -11.18 ± 1.7 60.7 ± 1.2 
IGEN5 260.3 ± 10.5 0.354 ± 0.02 -4.47 ± 0.7 55.4 ± 1.3 
IGEN6 155.2 ± 7.4 0.232 ± 0.01 -2.32 ± 0.1 47.0 ± 1.2 
IGEN7 653.9 ± 8.4 0.384 ± 0.01 -12.03 ± 2.7 66.5 ± 1.3 
IGEN8 443.7 ± 9.7 0.264 ± 0.01 -6.44 ± 0.6 55.3 ± 1.0 
IGEN9 321.2 ± 11.7 0.180 ± 0.01 -3.25 ± 0.3 51.5 ± 0.7 
 
 The particle size of the SLNs of IM prepared using palmitic acid (IPN) 
ranged from 133.1 ± 8.4 nm to 611.0 ± 4.1 nm. Highest particle size was obtained 
for formulation IPN7 containing 12% stearic acid and 0.5% QS. Least particle size 
was obtained for IPN3 containing 4% stearic acid and 1.5% QS. The 
polydispersity index of the IPN ranged from 0.128 ± 0.01 to 0.279 ± 0.02. The 
particle size and polydispersity index of the formulations prepared using palmitic 
acid were also influenced by the amount of lipid carrier and surfactant used.  
When glyceryl palmitostearate was used as lipid carrier the particle of the 
IGPN was in the range of 430.7 ± 2.2 nm to 92.1 ± 2.41 nm. Least particle size 
was obtained for formulation IGPN3 containing 4% glyceryl palmitostearate and 
1.5% QS. Highest particle size of 430.7 ± 2.2 nm was obtained for formulation 
IGPLN7 containing 12% glyceryl palmitostearate and 0.5% QS. The particle size 
of the SLNs prepared after addition of B12-SA and HA-SA showed an increase in 
particle size to 118.7 ± 3.9 nm and 130.6 ± 2.7 nm respectively. But coating with 
HA reduced the particle size to 92.1 ± 2.41 nm. Table 18 represents the particle 
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size of the formulations prepared using glyceryl palmitostearate as the lipid 
carrier. The particle size distribution data and polydispersity index data obtained 
for HAC-IGPN3 using Malvern particle size analyser is represented in Figure 37. 
 SLNs of IM prepared using glyceryl monostearate as the lipid carrier 
showed particle size ranging from 126.6 ± 6.1 nm to 740.9 ± 15.6 nm. The 
polydispersity index of the formulations ranged from 0.182 ± 0.01 to 0.371 ± 0.03. 
The particle size and polydispersity index of the different batches of formulations 
was mentioned in Table 18. 
 Geleol mono and diglycerides was also used as a lipid carrier to prepare 
SLNs loaded with IM. The particle size range of the different batches of 
formulations varied from 118.4 ± 5.06 nm to 653.9 ± 8.4 nm. A highest particle 
size was obtained for formulation IGEN7 containing 12% geleol mono and 
diglycerides and 0.5% QS. Least particle was obtained for IGEN3 containing 4% 
geleol mono and diglycerides and 1.5% QS. 
 
Figure 37. Particle size distribution and polydispersity index for HAC-IGPN3 
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6.16  DETERMINATION OF ZETA POTENTIAL 
The zeta potential of all the formulations was found to be neutral (-10 mV 
to +10 mV). The zeta potential of the formulations however had a mild negative 
charge due to the ionisation of lipid carriers. After coating the surface of SLNs 
with HA, the surface charge increased to a slight negative magnitude.  Whereas 
SLNs prepared by addition of B12-SA and HA-SA did not show a major change 
in the zeta potential. Table 18 mentions the zeta potential of all the formulations 
prepared using different lipid carriers. Figure 38 represents the zeta potential of 
HAC-IGPN3. 
 
Figure 38. Zeta potential for HAC-IGPN3 
6.17  TRANSMISSION ELECTRON MICROSCOPY 
The micrographs obtained from TEM were used to visualise the morphology 
of the SLNs. ISN prepared solely with stearic acid showed quassi shaped 
nanoparticles Figure 39 ISN prepared after addition of vitaminB12-stearic acid 
conjugate and HA-stearic acid conjugate did not influence the shape of the SLNs. 
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But, additional coating of SLNs with HA showed spherical shaped nanoparticles 
(Figure 40). The TEM of ISN after conjugating with vitamin B12 is shown in 
Figure 41. Aggregation was not observed in any of the particles prepared using 
stearic acid as a lipid carrier. The morphology of the IPN showed spherical shaped 
nanoparticles with mild aggregations (Figure 42). IGPN prepared using glyceryl 
palmitostearate as lipid carrier were found to possess quasi shaped nanoparticles 
without any aggregations Figure 43. Addition of vitamin B12-stearic acid 
conjugate and HA-stearic acid conjugate did not influence the morphology of the 
nanoparticles (Figure 44). But, when IGPN were coated with HA, nests of 
spherical nanoparticles were observed Figure 45. These nests were found to be in 
the size range of 100 nm which embed nanoparticles of size less than 50 nm. 
Although these nests give an appearance of aggregation, however they are not 
actually aggregated as their individual surfaces are not destroyed. There is a 
possible reason for HA to withhold IM loaded SLNs. These nests of nanoparticles 
can play a role in staying for longer time in the lymphatics. IGMN showed 
aggregates of nanoparticles which are non spherical in shape Figure 46. IGEN 
showed particles spherical to cubical shaped structures Figure 47.  
 
 
Figure 39. Transmission electron microscope image of ISN 
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Figure 40. Transmission electron microscope image of HA-ISN 
 
Figure 41. Transmission electron microscope image of B12-ISN 
 
 
Chapter 6  Results & Analysis 
 
 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  128 
 
Figure 42. Transmission electron microscope image of IPN 
 
 
Figure 43. Transmission electron microscope image of IGPN 
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Figure 44. Transmission electron microscope image of B12-IGPN 
 
   
Figure 45. Transmission electron microscope image of IGPN-HA 
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Figure 46. Transmission electron microscope image of IGMN 
 
 
Figure 47. Transmission electron microscope image of IGEN 
6.18  ATOMIC FORCE MICROSCOPY 
Analysis of the morphology of ISN, IPN, IGPN, and HAC-IGPN from 
Figure 48, Figure 49, Figure 50 and Figure 51 respectively showed spherical 
shaped particles with a smooth topography and without any aggregations. But, 
AFM images of IGMN and IGEN in Figure 52 and Figure 53 respectively showed 
aggregated nanoparticles.  
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Figure 48. AFM phase image and topographic image of ISN 
 
Figure 49. AFM phase image and topographic image of IPN 
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Figure 50. AFM phase image and topographic image of IGPN 
 
 
Figure 51. AFM phase image and topographic image of HAC-IGPN 
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Figure 52. AFM phase image and topographic image of IGMN 
 
 
Figure 53. AFM phase image and topographic image of IGEN 
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6.19  MEASUREMENT OF ENTRAPMENT EFFICIENCY 
 The entrapment efficiency of the various formulations prepared using 
different lipids carriers was mentioned in Table 18. The overall entrapment 
efficiencies of the formulations were low. The entrapment efficiencies of the 
formulations prepared using stearic acid was found to be in the range of  
66.2 ± 1.2% to 41.0 ± 1.0 %. When palmitic acid was used, the entrapment 
efficiencies of the formulations were in the range of 39.8 ± 0.6% to 57.1 ± 0.3%. 
Formulations prepared using glyceryl palmitostearate were found to have 
entrapment efficiencies in the range of 65.9 ± 0.6% to 51.3 ± 0.9%. Different 
batches of IGM prepared using glyceryl monostearate were found to have 
entrapment efficiencies in the range of 41.9 ± 1.1% to 54.1 ± 0.6%. SLNs 
prepared using geleol mono and diglycerides as lipid carrier showed entrapment 
efficiencies ranging from 66.5 ± 1.3% to 47.0 ± 1.2%.  
6.20  DIFFERENTIAL SCANNING CALORIMETRY FOR 
 FORMULATIONS 
 The thermogram of IM in Figure 53 indicated an endothermic melting 
point of 227.8 ºC. The endothermic melting point of bulk stearic acid, palmitic 
acid and glyceryl palmitostearate was observed at 62.3ºC, 57.5 ºC and 50ºC 
respectively in Figure 54, Figure 55 and Figure 56. For QS an endothermic 
melting point was observed at 126.5ºC. The thermograms of ISN, IPN and IGPN 
did not show any endothermic melting peak for IM as observed in Figure 54, 
Figure 55 and Figure 56.  
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Figure 54. Overlay of DSC thermogram of IM: Imatinib mesylate,  
QS: quillaja saponin, SA: Bulk Stearic acid, BSN: Blank SLNs, 
 ISN3: IM loaded SLNs 
 
Figure 55. Overlay of DSC thermogram of IM: Imatinib mesylate, 
QS: quillaja saponin, PA: Bulk Palmitic acid, BPN: Blank SLNs, IPN3: IM 
loaded SLNs of palmitic acid 
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Figure 56. Overlay of DSC thermogram of IM: Imatinib mesylate, QS: 
quillaja saponin, GPS: bulk glyceryl palmitostearate, BGPN: Blank SLNs, 
IGPN: IM loaded SLNs of glyceryl palmitostearate 
 
6.21  IN VITRO DRUG RELEASE 
In vitro drug release patterns of ISN, IPN and IGPN in PBS pH 7.4 are 
shown in Figure 57, Figure 58 and Figure 59. In almost 12 hours, IM was 
completely released from all the SLNs prepared using different lipid carriers. Pure 
IM exhibited a rapid release across the dialysis membrane. Although long chain 
fatty acids like palmitic acid, stearic acid and glyceryl palmitostearate were used 
in the study, the release of IM from the lipid core was rapid due to the hydrophilic 
nature of IM. When conjugates of HAJ-SA and B12-SA were used in the 
preparation of SLNs, a comparatively sustained release profile was observed 
(Figure 57 and Figure 59). The comparative in vitro release profile using different 
lipids is shown in Figure 60. 
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Figure 57. In vitro release profile of IM from ISN in phosphate buffer saline 
pH 7.4. Values are expressed as mean ± standard deviation (n=3). 
 
Figure 58. In vitro release profile of IM from IPN in phosphate buffer saline 
pH 7.4. Values are expressed as mean ± standard deviation (n=3). 
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Figure 59. In vitro release profile of IM from IGPN in phosphate buffer saline 
pH 7.4. Values are expressed as mean ± standard deviation (n=3). 
 
 
Figure 60. Comparative in vitro release profile of IM from ISN3, IPN3 and 
IGPN3 in phosphate buffer saline pH 7.4. Values are expressed as 
mean ± standard deviation (n=3). 
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6.22  RELEASE KINETICS 
The obtained release data was fitted into various kinetic models (zero 
order, first order, Higuchi and Korsmeyer-Peppas) to find out the mechanism of 
drug release from the SLNs. The results of the release kinetics was mentioned in 
Table 19,20 and 21. 
Table 19. Mechanism of release of IM from ISN 
Code 
Zero order 
model (r2) 
First order 
model (r2) 
Higuchi 
model 
(r2) 
Korsmeyer- 
Peppas model 
(r2) n 
ISN1 0.7358 0.9778 0.9676 0.9518 0.517 
ISN2 0.6588 0.9809 0.9751 0.9631 0.465 
ISN3 0.5112 0.9894 0.9448 0.9330 0.412 
ISN4 0.7005 0.9797 0.9830 0.9735 0.484 
ISN5 0.5891 0.9810 0.9689 0.9619 0.434 
ISN6 0.5466 0.9760 0.9520 0.9389 0.423 
ISN7 0.5554 0.9630 0.9646 0.9626 0.417 
ISN8 0.4484 0.9484 0.9397 0.9473 0.381 
ISN9 0.3900 0.9483 0.9237 0.9367 0.365 
B12-ISN 0.4380 0.9793 0.9422 0.9534 0.381 
HAC-ISN 0.3071 0.9358 0.9124 0.9570 0.338 
IM -1.7513 0.9957 -0.0660 0.9631 0.465 
  
Table 20. Mechanism of release of IM from IPN 
Code 
Zero order 
model (r2) 
First order 
model (r2) 
Higuchi model 
(r2) 
Korsmeyer- Peppas model 
(r2) n 
IPN1 0.4587 0.9756 0.9477 0.9561 0.387 
IPN2 0.4016 0.9833 0.9281 0.9359 0.374 
IPN3 0.2991 0.9821 0.9080 0.9413 0.344 
IPN4 0.3121 0.9652 0.9160 0.9570 0.343 
IPN5 0.2518 0.9744 0.8936 0.9359 0.331 
IPN6 0.0681 0.9600 0.8344 0.9211 0.290 
IPN7 0.2392 0.9207 0.8937 0.9564 0.321 
IPN8 0.3435 0.9231 0.9187 0.9529 0.347 
IPN9 0.4394 0.9382 0.9416 0.9562 0.375 
IM -1.7513 0.9957 -0.0660 0.9631 0.465 
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Table 21. Mechanism of release of IM from IGPN 
Code 
Zero 
order 
model (r2) 
First order 
model (r2) 
Higuchi 
model 
(r2) 
Korsmeyer- Peppas 
model 
(r2) N 
IGPN1 0.2374 0.9331 0.8905 0.9519 0.326 
IGPN2 0.3681 0.9201 0.9323 0.9761 0.353 
IGPN3 0.5205 0.9351 0.9666 0.9822 0.398 
IGPN4 0.4302 0.9061 0.9438 0.9736 0.368 
IGPN5 0.5398 0.9153 0.9628 0.9700 0.404 
IGPN6 0.5121 0.8864 0.9556 0.9668 0.392 
IGPN7 0.5550 0.9219 0.9618 0.9634 0.412 
IGPN8 0.6322 0.9170 0.9749 0.9704 0.439 
IGPN9 0.7272 0.9321 0.9829 0.9740 0.486 
B12-IGPN 0.3313 0.9571 0.9185 0.9585 0.350 
HAC-IGPN 0.0785 0.9404 0.8401 0.9387 0.294 
IM -2.1255 0.9958 -0.2663 0.9631 0.465 
 
6.23  IN VITRO HAEMOLYSIS TEST 
 A comparative in vitro haemolytic analysis was performed for SLNs of IM 
(ISN, IPN and IGPN), QS, IM, and blank SLNs of palmitic acid, stearic acid and 
glyceryl palmitostearate. The results in Figure 61 and Figure 62 revealed that QS 
(50 µg/ml) showed haemolysis. But, SLNs of IM prepared using individual lipids 
like stearic acid and glyceryl palmitostearate, blank SLNs and IM did not induce 
haemolysis.  
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Figure 61. In vitro haemolysis assay performed in the presence of A) QS  
(50 µg/ml solution in saline); B) and C) IM (10 µg/ ml and 20 µg/ ml in saline; 
D), E) and F) ISN3 (equivalent to IM concentration of 10 µg/ ml, 20 µg/ ml 
and 30 µg/ ml and QS concentration of 150 µg/ml, 300 µg/ml and 450 µg/ml); 
G) and H) BSNs (equivalent to QS concentrations of 50 µg/ml and 150 
µg/ml); I) Negative control- Saline; J) Positive control- Distilled water. 
 
Figure 62. In vitro haemolysis assay performed in the presence of A) QS  
(50 µg/ml solution in saline); B) IM (10 µg/ ml in saline); C) and D) IPN3 
(equivalent to IM concentration of 10 µg/ ml and 20 µg/ ml and QS 
concentration of 150 µg/ml and 300 µg/ml); E) BSLNs (equivalent to QS 
concentrations of 150 µg/ml); F) B12-IPN3 (equivalent to IM concentration of 
20 µg/ ml and QS concentration of 300 µg/ml); G) HAC-IPN3 (equivalent to 
IM concentration of 20 µg/ ml and QS concentration of 300 µg/ml) H) 
Negative control- Saline; I) Positive control- Distilled water 
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6.24  IN VITRO CYTOTOXICITY STUDIES 
In vitro cytotoxicity studies were performed for IM, QS, SLNs of IM (ISN 
and IGPN), their corresponding conjugated SLNs, blank SLNs of stearic acid and 
glyceryl palmitostearate) and blank SLNs (of stearic acid and glyceryl 
palmitostearate) and IM. Figure 63 represents the results of the cytotoxicity 
studies performed for IM, QS, ISN3, blank SLNs of stearic acid, blank SLNs of 
stearic acid and IM, B12-ISN3, HAJ-ISN3 and HAC-ISN3 in MCF7 cell line. 
Figure 64 represents the results of the cytotoxicity studies performed for IM, QS, 
IGPN3, blank SLNs of glyceryl palmitostearate, blank SLNs of glyceryl 
palmitostearate and IM, B12-IGPN3, HAJ-IGPN3 and HAC-IGPN3 in MCF7 cell 
line. The IC50 values were mentioned in Table 22. 
Correspondingly, the viability of the samples were also tested in RAW 
264.7 cell line. Figure 65 and Figure 66 represents the results of the viability tests 
for the given samples. None of the samples were found to be toxic against RAW 
264.7 cell line. 
Table 22. IC50 values of various samples 
S No Name of the sample IC50 value * 
1  IM 7.39 
2  QS 8.17 
3  ISN3 1.23 
4  Blank ISN3 6.91 
5  Blank ISN3 + IM 3.11 
6  B12-ISN3 1.03 
7  HAJ-ISN3 1.17 
8  HAC-ISN3 0.76 
9  IGPN3 1.80 
10  Blank IGPN3 6.31 
11  Blank IGPN3 + IM 2.21 
12  B12-IGPN3 1.45 
13  HAJ-IGPN3 1.25 
14  HAC-IGPN3 0.91 
* QS concentration is represented by µg/ml unit, whereas all other samples 
are represented in µM concentration. 
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Figure 63. Graph showing cytotoxicity in MCF7 cells in the presence of IM, 
QS, ISN3, Blank ISN3, mixture of blank ISN3 + IM, B12- ISN3, HAJ- ISN3 
and HAC- ISN3 as revealed by MTT assay. Values are expressed as mean ± 
standard deviation (n=3). * QS concentration is represented by µg/ml unit, 
whereas all other samples are represented in µM concentration. 
 
 
Figure 64. Graph showing cytotoxicity in MCF7 cells in the presence of IM, 
IGPN3, Blank IGPN3, mixture of blank IGPN3 + IM, B12-IGPN3, HAJ-
IGPN3 and HAC-IGPN3 as revealed by MTT assay. Values are expressed as 
mean ± standard deviation (n=3).  
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Figure 65. Graph showing viability in RAW 264.7 cells in the presence of IM, 
QS, ISN3, Blank ISN3, mixture of blank ISN3 + IM, B12- ISN3, HAJ- ISN3 
and HAC- ISN3 as revealed by MTT assay. Values are expressed as mean ± 
standard deviation (n=3). * QS concentration is represented by µg/ml unit, 
whereas all other samples are represented in µM concentration. 
 
 
Figure 66. Graph showing viability in RAW 264.7 cells in the presence of IM, 
IGPN3, Blank IGPN3, mixture of blank IGPN3 + IM, B12-IGPN3, HAJ-
IGPN3 and HAC-IGPN3 as revealed by MTT assay. Values are expressed as 
mean ± standard deviation (n=3).  
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6.25 APOPTOSIS ANALYSIS 
MCF 7 cell line treated with free IM, IGPN3 and HA-IGPN3 were stained 
with propidium iodide and observed for the DNA damage. The results of the study 
after treatment with control and IM (and nanoparticles) were represented in Figure 
67. Figure 67 (b), (d), (f) and (h) represents the fluorescence images of MCF7 
cells after treatment with control, free IM, IGMN, HA-ILN treated MCF7 cells. 
Their corresponding light microscopic images are shown in Figure 67 (a), (c), (e), 
and (g). 
 
 
Figure 67. Propidium iodide staining of control (b), free IM (d), IGMN (f), 
HA-ILN treated (h) MCF7 cells showing dead cells in the later. 
Corresponding light microscopic images are shown above (a), (c), (e) and (g).  
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6.26 STERILITY TESTING 
In order to ensure the sterility of ISN3, B12-ISN, HAC-ISN, IGPN3, 
HAC-IGPN and IM in pH 7.4 PBS, the samples were tested for sterility according 
to pharmacopoeial requirements. Sterility was evaluated by the observation of the 
media containing the respective samples for the proliferation of bacteria or fungi 
during the incubation period. These results demonstrated in Figure 68 and Figure 
69 did not show any visible bacterial or fungal growth for all the batches of 
nanoparticles tested. But, the positive controls showed substantial increase of 
turbidity indicating bacterial or fungal growth. These results suggest that the 
prepared SLNs are sterile. 
 
 
 
 
 
 
Figure 68. Sterility testing indicating absence of bacterial growth after 24 
hours incubation with 1) ISN3, 2) B12-ISN, 3) HAC-ISN, 4) IGPN3, 5) HAC-
IGPN and 6) IM in pH 7.4 PBS 
 
Figure 69. Sterility testing indicating absence of fungal growth after 14 days 
incubation with 1) ISN3, 2) B12-ISN, 3) HAC-ISN, 4) IGPN3, 5) HAC-IGPN 
and 6) IM in pH 7.4 PBS 
1 2 3 4 5 6 
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6.27 IN VIVO PHARMACOKINETIC STUDIES  
Pharmacokinetic parameters of IM in blood: 
Pharmacokinetic studies were performed in female wistar rats after 
subcutaneous administration to quantify the amount of drug present in the blood at 
different time points. Various pharmacokinetic parameters like Cmax, Tmax, T1/2, 
MRT, AUC0-t, AUC0-∞, AUMC0-t, AUMC0-∞ and clearance were calculated using 
Winonlin 5.3 and the values are represented in Table 23. Figure 70 and Figure 71 
represents the plasma concentration profiles of different samples at different time 
intervals. 
Table 23. Pharmacokinetic parameters of IM in blood 
Pharmacokin
etic 
parameter 
IM IGPN3 
HA-
IGPN 
ISN3 
B12-
ISN 
HA-ISN 
T1/2 (h) 
18.331 ± 
0.5 
21.7 ± 
4.1 
49.01 ± 
4 
20.3 ± 
5.5 
25.8 ± 
0.5 
40.8 ± 
3.7 
Tmax (h) 4 12 12 8 12 12 
Cmax (μg/ml) 
1947.7 ± 
38.9 
1475.3 ± 
87.3 
1377.7 ± 
41.3 
1615.3 ± 
79.1 
1842.7  
± 45.6 
1290 ± 
37.987 
AUC0-t 
(μg/ml*h) 
34483.8 
± 
2608.7 
66796.1 
± 4135.7 
79321.6 
± 1322.3 
60167.5 
± 1468.7 
71557.2 
± 530.9 
64319.5 
± 1371.9 
AUC 0-∞ 
(μg/ml*h) 
36979.2 
± 2534.9 
73523.51 
± 5733.6 
133356 
± 4617.6 
67347.8 
± 2521.6 
84451.4 
± 877.8 
97178.8 
± 5992.9 
MRT0-∞ 
(h) 
20.4 ± 
0.2 
30.4 ± 
0.2 
35.2 ± 
0.6 
27.9 ± 
0.6 
28.5 ± 
0.2 
33.1 ± 
0.4 
Cl obs 
410.0 ± 
31.1.0 
204.9 ± 
16.1 
112.6 ± 
4.0 
222.9 ± 
8.5 
177.6 ± 
1.9 
154.8 ± 
9.9 
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Figure 70. Plasma drug concentration profile after subcutaneous 
administration of IM, ISN3, B12-ISN and HA-ISN. 
 
 
Figure 71. Plasma drug concentration profile after subcutaneous 
administration of IM, IGPN3 and HA-IGPN. 
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 The lymph nodes were isolated to quantify the amount of IM that has 
reached after subcutaneous administration (Figure 72). Table 24 represents the 
pharmacokinetic parameters of IM in the lymph nodes. Figure 73 represents the 
lymph node drug concentration profile after subcutaneous administration of IM, 
IGPN3 and HA-IGPN. 
 
         
 
 
 
Figure 72. Lymph nodes in rat 
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Figure 73. Lymph node drug concentration profile after subcutaneous 
administration of IM, IGPN3 and HA-IGPN. 
 
Table 24. Pharmacokinetic parameters of IM in lymph nodes 
Pharmacokinetic 
parameter 
IM IGPN HA-IGPN 
T1/2 (h) - 68.24 ± 4.1 53.84 ± 4 
Tmax (h) 12 4 4 
Cmax (μg/ml) 
270.7 ± 
38.9 
744 ± 87.3 984.3 ± 41.3 
AUC0-t (μg/ml*h) 
3809.3 ± 
2608.7 
31364 ± 
4135.7 
45783 ± 1322.3 
AUC 0-∞ 
(μg/ml*h) 
- 
62607.1 
 ± 5733.6 
77971.4 ± 
4617.6 
MRT0-∞ 
(h) 
-  101.1 ± 0.2 80.2 ± 0.6 
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6.28 STABILITY STUDIES 
Stability studies were carried out ISN3, HAC-ISN, B12-ISN, IGPN3, 
HAC-IGPN and B12-IGPN at room temperature (20 - 25°C) and refrigerated 
conditions (3 to 5°C) over a period of 12 months. The stability of the formulations 
were evaluated for every 3 months by checking the appearance of the 
formulations, particle size, polydispersity index, zeta potential and entrapment 
efficiency. The results over a period of 12 months are mentioned from Table 25 to 
Table 28. The results indicate that the formulations are comparatively stable for 
12 months in refrigerated conditions. 
 
Table 25. Particle size of the formulations over a period of 12 months 
Stability 
Condition 
Formulation 
code 
Average Particle size (nm) 
Month 
0 1 3 6 9 12 
Room 
temperature 
(25 °C) 
ISN3 
159.5 
± 4.7 
189.2 
± 9.3 
304.8 
± 13.8 
1132.4 
± 45.2 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
159.5 
± 4.7 
161.3 
± 3.6 
163.1 
± 4.1 
167.6 
± 5.3 
172.3 
± 5.8 
189.3 
± 8.2 
Room 
temperature 
(25 °C) 
B12-ISN 
169.1 
± 3.2 
194.5 
± 5.9 
347.7 
± 17.4 
1094.3 
± 36.2 
1489.5 
± 78.2 
-- 
Refrigerated 
temperature  
(3 to 5 °C) 
169.1 
± 3.2 
170.2 
± 2.8 
171.4 
± 3.9 
184.6 
± 4.5 
195.1 
± 6.1 
208.4 
± 7.2 
Room 
temperature 
(25 °C) 
HAC-ISN 
87.3 ± 
5.9 
203.4 
± 25.6 
610.8 
± 65.3 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
87.3 ± 
5.9 
92.4 ± 
3.8 
95.7 ± 
4.5 
103.7 
± 5.8 
117.3 
± 6.5 
124.6 
± 7.4 
Room 
temperature 
(25 °C) 
IGPN3 
106.4 
± 4.7 
126.3 
± 5.3 
178.2 
± 7.2 
589.3 
± 16.8 
1285.0 
± 
104.5 
-- 
Refrigerated 
temperature  
(3 to 5 °C) 
106.4 
± 4.7 
107.1 
± 5.3 
110.5 
± 5.2 
116.8 
± 6.3 
121.9 
± 8.1  
136.2 
± 12.7 
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Stability 
Condition 
Formulation 
code 
Average Particle size (nm) 
Month 
0 1 3 6 9 12 
Room 
temperature 
(25 °C) 
B12-IGPN 
118.7 
± 3.9 
156.8 
± 4.5 
654.8 
± 35.8 
1436.2 
± 
102.4 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
118.7 
± 3.9 
120.4 
± 2.7 
124.6 
± 3.5 
131.3 
± 4.6 
149.7 
± 5.1 
152.2 
± 6.4 
Room 
temperature 
(25 °C) 
HAC-IGPN 
92.1 ± 
2.4 
179.2 
± 4.9 
534.9  
± 39.2 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
92.1 ± 
2.4 
94.3 ± 
3.3 
96.7 ± 
4.4 
98.5 ± 
5.7 
101.8 
± 5.3 
105.1 
± 6.1 
 
Table 26. Polydispersity index of the formulations over a period of 12 months 
Stability 
Condition 
Formulation 
code 
Polydispersity index (nm) 
Month 
0 1 3 6 9 12 
Room 
temperature 
(25 °C) 
ISN3 
0.127 
± 0.01 
0.248 
± 0.09 
0.843 
± 
0.101 
1 ± 
0.0 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
0.127 
± 0.01 
0.124 
± 0.02 
0.135 
± 0.08 
0.132 
± 0.06 
0.154 
± 0.04 
0.205 
± 0.06 
Room 
temperature 
(25 °C) 
B12-ISN 
0.205 
± 0.01 
0.294 
± 0.08 
0.348 
± 
0.113 
1.0 ± 
0.0  
1.0 ± 
0.0 
-- 
Refrigerated 
temperature  
(3 to 5 °C) 
0.205 
± 0.01 
0.212 
± 0.01 
0.235 
± 0.05 
0.242 
± 0.05 
0.278 
± 0.07 
0.285 
± 0.08 
Room 
temperature 
(25 °C) 
HAC-ISN 
0.162 
± 0.01 
0.348 
± 
0.123 
1.0 ± 
0.0 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
0.162 
± 0.01 
0.159 
± 0.02 
0.173 
± 0.02 
0.178 
± 0.05 
0.241 
± 0.06 
0.256 
± 0.07 
Room 
temperature 
(25 °C) 
IGPN3 
0.08 ± 
0.01 
0.213 
± 0.05 
0.893 
± 
0.101 
1.0  ± 
0.0 
-- -- 
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Stability 
Condition 
Formulation 
code 
Polydispersity index (nm) 
Month 
0 1 3 6 9 12 
Refrigerated 
temperature  
(3 to 5 °C) 
0.08 ± 
0.01 
0.102 
± 0.02 
0.113 
± 0.02 
0.128 
± 0.06 
0.132 
± 0.05 
0.241 
± 
0.103 
Room 
temperature 
(25 °C) 
B12-IGPN 
0.194 
± 0.02 
0.231 
± 0.05 
0.764 
± 
0.178 
1.0 ± 
0.0 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
0.194 
± 0.02 
0.195 
± 0.01 
0.203 
± 0.05 
0.214 
± 0.08 
0.262 
± 0.10 
0.281 
± 0.12 
Room 
temperature 
(25 °C) 
HAC-IGPN 
0.08 ± 
0.01 
0.342 
± 0.11 
1.0 ± 
0.0 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
0.08 ± 
0.01 
0.07 ± 
0.01 
0.105 
± 0.03 
0.112 
± 0.04 
0.172 
± 0.09 
0.268 
± 
0.102 
 
Table 27. Zeta potential of the formulations over a period of 12 months 
Stability 
Condition 
Formulation 
code 
Average Particle size (nm) 
Month 
0 1 3 6 9 12 
Room 
temperature 
(25 °C) 
ISN3 
0.95 ± 
0.5 
-1.36 
± 0.7 
-15.7 
± 3.6 
-19.2  
± 7.2 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
0.95 ± 
0.5 
0.65 ± 
0.3 
-1.26 
± 0.5 
-2.27 
± 0.4 
-2.17 
± 0.6 
-3.06 
± 0.7 
Room 
temperature 
(25 °C) 
B12-ISN 
10.2 ± 
1.2 
14.7 ± 
3.5 
17.8 ± 
4.2 
18.4 ± 
3.7 
19.3 ± 
5.4 
-- 
Refrigerated 
temperature  
(3 to 5 °C) 
10.2 ± 
1.2 
8.3 ± 
0.9 
6.4 ± 
2.4 
9.4 ± 
2.7 
11.3 ± 
3.2 
14.3 ± 
5.1 
Room 
temperature 
(25 °C) 
HAC-ISN 
-12.8 
± 1.7 
-18.2 
± 3.7 
-21.3 
± 4.5 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
-12.8 
± 1.7 
-11.5 
± 4.1 
-14.3 
± 6.3 
-11.7 
± 5.8 
-15.8 
± 3.7 
-16.2 
± 4.5 
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Stability 
Condition 
Formulation 
code 
Average Particle size (nm) 
Month 
0 1 3 6 9 12 
Room 
temperature 
(25 °C) 
IGPN3 
-1.03 
± 0.14 
-21.3 
± 2.6 
-15.8 
± 6.1 
-13.2 
± 5.9 
-17.6 
± 4.2 
-- 
Refrigerated 
temperature  
(3 to 5 °C) 
-1.03 
± 0.14 
-2.4 ± 
0.8 
-4.6  ± 
1.0 
-3.1 ± 
1.2 
-5.3 ± 
1.4 
-5.8 ± 
0.7 
Room 
temperature 
(25 °C) 
B12-IGPN 
1.63 ± 
0.5 
8.4 ± 
2.7 
15.2 ± 
3.9 
17.3 ± 
4.0 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
1.63 ± 
0.5 
2.3 ± 
0.4 
2.8 ± 
1.2 
1.89 ± 
0.3 
3.4 ± 
0.5 
4.2 ± 
1.3 
Room 
temperature 
(25 °C) 
HAC-IGPN 
-10.67 
± 1.32 
-14.7 
± 2.0 
-16.2 
± 4.3 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
-10.67 
± 1.32 
-7.3 ± 
1.4 
-8.5 ± 
2.7 
-12.3 
± 4.9 
-11.7 
± 3.0 
-12.0 
± 2.1 
 
Table 28. Entrapment efficiency of formulations over a period of 12 months 
Stability 
Condition 
Formulation 
code 
Entrapment efficiency (%) 
Month 
0 1 3 6 9 12 
Room 
temperature 
(25 °C) 
ISN3 
61.3 ± 
1.1 
64.7 ± 
3.2 
62.9 ± 
5.6 
58.6 ± 
4.5 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
61.3 ± 
1.1 
61.5 ± 
1.4 
59.1 ± 
2.5 
57.3 ± 
3.6 
55.2 ± 
3.8 
53.2 ± 
4.9 
Room 
temperature 
(25 °C) 
B12-ISN 
56.9 ± 
1.4 
58.2 ± 
3.5 
54.8 ± 
4.3 
54.1 ± 
3.1 
48.2 ± 
5.3 
-- 
Refrigerated 
temperature  
(3 to 5 °C) 
56.9 ± 
1.4 
57.2 ± 
2.3 
55.2 ± 
2.6 
53.2 ± 
1.2 
52.6 ± 
2.8 
48.3 ± 
3.7 
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Stability 
Condition 
Formulation 
code 
Entrapment efficiency (%) 
Month 
0 1 3 6 9 12 
Room 
temperature 
(25 °C) 
HAC-ISN 
47.8 ± 
2.1 
45.2 ± 
2.5 
38.3 ± 
5.3 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
47.8 ± 
2.1 
46.2 ± 
1.7 
45.5 ± 
3.5 
43.6 ± 
2.7 
43.1 ± 
3.9 
42.6 ± 
2.6 
Room 
temperature 
(25 °C) 
IGPN3 
55.1 ± 
1.1 
53.7 ± 
2.1 
52.1 ± 
2.8 
45.7 ± 
2.5 
36.8 ± 
2.7 
-- 
Refrigerated 
temperature  
(3 to 5 °C) 
55.1 ± 
1.1 
54.6 ± 
2.4 
53.2 ± 
1.7 
52.4 ± 
2.2 
52.7 ± 
2.6 
51.3 ± 
3.1 
Room 
temperature 
(25 °C) 
B12-IGPN 
65.9 ± 
0.6 
60.5 ± 
1.4 
51.2 ± 
2.3 
43.1 ± 
2.7 
-- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
65.9 ± 
0.6 
64.1 ± 
1.6 
63.2 ± 
2.5 
61.6 ± 
3.1 
60.3 ± 
1.6 
58.3 ± 
1.4 
Room 
temperature 
(25 °C) 
HAC-IGPN 
43.4 ± 
0.7 
40.6 ± 
1.3 
38.3 ± 
2.4 
-- -- -- 
Refrigerated 
temperature  
(3 to 5 °C) 
43.4 ± 
0.7 
42.6 ± 
2.1 
41.5 ± 
1.4 
41.8 ± 
1.9 
40.5 ± 
1.7 
39.1 ± 
2.2 
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7. DISCUSSION 
 
7.1  PREFORMULATION AND ANALYTICAL STUDIES 
7.1.1 UV Spectroscopy: 
 The wavelength at which maximum amount of radiation is absorbed is 
called λmax and it is specific for every compound. In this study, the maximum 
absorption for Imatinib mesylate (IM) was observed at 256 nm, which was 
fixed as the λmax. A calibration curve was plotted with different concentrations 
of IM against its corresponding absorbance values. The calibration curve 
Figure 12. indicated a linear increase of absorbance when its corresponding 
concentrations values increased. The r2 value (regression coefficient) was 
found to be 0.9995.  
7.1.2  High Pressure Liquid Chromatography: 
 An analytical method was additionally developed using high pressure 
liquid chromatography to estimate the concentrations of IM in different 
pharmaceutical and biological samples. Different chromatographic variables 
i.e., columns, composition and ratio of the mobile phase, pH of the mobile 
phase and peak modifiers in mobile phase were varied and their influence on 
the elution of IM was studied. The effects of various parameters for the 
development of an optimised method were studied as follows: 
 
Effect of mobile phase ratio: 
 Initially, different ratios of acetonitrile and water viz., 50:50, 40:60, 
30:70 at pH 2.8 adjusted with formic acid were used as mobile phase. At 50:50 
ratio, IM was eluted at 4.6 minutes with fronting. When the ratio was changed 
to 40:60 ratio, the elution time was reduced to 4 minutes with mild fronting. 
Finally, when 30:70 ratio was used, IM eluted at 3.5 minutes. Hence, mobile 
phase containing 30% acetonitrile and 70% water was selected as mobile 
phase. 
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Effect of pH:   
 Initially, when the pH was adjusted using orthophosphoric acid, an 
additional peak along with the peak of IM was observed. Later, when the pH 
was adjusted to 3.4 using 0.1% formic acid, the extra peak disappeared. 
Hence, the pH of the mobile phase was adjusted to 3.4 using 0.1% formic acid. 
Effect of nature of stationary phase: 
 Different stationary phases like Phenomenex Luna C18 [(150 x 
4.6mm), 5μ], Sunfire C18 [(150 x 4.6mm), 3.5μ], Sunfire C8 [(150 x 4.6mm), 
3.5 μ] were used as columns. When Phenomenex Luna C18 was used, the drug 
did not elute and the peaks corresponding to IM were not observed. When 
Sunfire C18 was used, IM eluted at 1.1 min along with void volume. Various 
attempts to improve the retention time and peak symmetry using different 
ratios of mobile phase have been futile. Finally, when Sunfire C8 column was 
used, IM eluted at 4.6 minutes without any tailing and fronting. Hence for the 
present study, Sunfire C8 was used as the column. 
Effect of flow rate: 
 At different flow rates of 0.2 ml/ min, 0.3 ml/ min and 0.5 ml/ min, the 
retention time of IM was 4.6 min, 3.5 min, and 1.1 min respectively. When the 
flow rate was maintained at 0.3 ml/ min a symmetric and well defined peak 
was observed. Hence, for the present study, a flow rate of 0.3 ml/ min was 
selected.  
 Thus, finally a Sunfire C8 [(4.6 x 150 mm, 3.5μ] column with a mobile 
phase consisting of 30:70 of acetonitrile: water at pH 3.4 (0.1 % formic acid) 
with a flow rate of 0.3 ml/ min were optimised to estimate IM in 
pharmaceutical and biological samples. Using these conditions, a calibration 
curve for estimation of IM in pharmaceutical samples was plotted with the 
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obtained peak area for each concentration and the regression equations were 
calculated. A correlation coefficient of 0.9998 was observed Figure 14. 
Similarly, for the quantification of IM in plasma, a calibration curve against 
the peak area for each concentration was plotted and correlation co-efficient 
(r2) was found to be of 0.9992 (Figure 15). The results of the validation studies 
indicated that the developed method was accurate, precise with good LOD and 
LOQ values. There were no changes in the concentration of IM during 
interday and intraday testing and sample degradation was not observed. 
Additionally, the developed method showed good limit of detection (LOD) 
and limit of quantification (LOQ). The test for specificity indicated that that 
the peak of IM was pure without any interference. Thus the developed method 
was specific for IM. The results of the stability studies of IM in rat plasma 
indicated good stability at room temperature (25°C) and refrigerated 
temperatures (4°C) for 24 h. Additionally, IM was also stable in deproteinzed 
plasma and in freeze-thaw cycles when stored at -20 C° for 6 months. 
 
7.1.3  SCREENING FOR THE PRESENCE OF INTERACTIONS 
 USING INFRA RED SPECTROSCOPY 
 IR spectroscopic studies were performed to rule out for the presence of 
any interactions between IM and the excipients (lipids and surfactant) used in 
the study. Major wave numbers at for pure IM like 1177 cm-1, 1418 cm-1, 2111 
cm-1 and 3445 cm-1 which correspond to the ester group, amide groups, 
alkynyl stretching and aromatic amine respectively were observed. The IR 
spectrum of quillaja saponin (QS) showed specific wave numbers at 1728 cm-1 
and 3389 cm-1 corresponding to the ketone group and alcoholic –OH groups 
present in the saponin. Additionally, strong bands were observed in the region 
of 1340- 1450 cm-1 and 2940 cm-1, which corresponded to the ketone and 
carboxylic acid groups present in the saponin. The IR spectrum of stearic acid 
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and palmitic acid prominently showed wave numbers in the regions of 2500- 
3000 cm-1 which correspond to carboxylic acid groups present in the fatty 
acids. The IR spectrum of glyceryl palmitostearate and glycerylmonostearate 
showed wave numbers in the regions of 1200 cm-1 and 1700 cm-1 representing 
the acetate and ester functional groups present in the monoglyceride 
derivatives. In the physical mixture of IM and corresponding lipids (stearic 
acid, palmitic acid, glyceryl monostearate, glyceryl palmitostearate and geleol 
mono and diglycerides) the wave numbers corresponding to IM were present. 
Additionally, these wave numbers were also present in the physical mixtures 
of IM, QS and corresponding lipid. These results clearly indicate the stability 
of IM in the lipid melts and physical mixtures and rule out the presence of 
interactions between the drug and excipients used. The above mentioned lipids 
and surfactant can be used for the preparation of solid lipid nanoparticles. 
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7.2  SOLUBILITY OF IMATINIB MESYLTE IN LIPIDS: 
INFLUENCE OF MOLECULAR, CHEMICAL AND 
PHYSICOCHEMICAL PROPERTIES AND DEVELOPMENT 
OF A PREDICTORY MODEL 
 During the preparation of LBFs, solubilisation of drugs in the lipids is 
a crucial step to achieve good encapsulation efficiency and stability. Although 
lipophilic drugs can be solubilised in the lipids, finding a lipid that can 
solubilise hydrophilic drugs is a challenge [103]. Predicting the solubility of 
drugs in lipids is challenging unlike predicting their solubility in water. Water 
exists with a simple chemical structure, H2O and with an established set of 
physicochemical properties. Thus, examining the influence of the various 
physicochemical properties of the drugs on solubility in water can easily be 
performed as compared to lipids. Lipids represent a broad term encompassing 
different categories like fatty acids, partial glycerides (mono, di and 
triglycerides), mixtures of fatty acids and partial glycerides, etc [122]. Each of 
these categories additionally has several lipids which vary in their chemical 
structure and physicochemical properties. Thus, screening or prediction of 
drug solubility in lipids includes examining the influence of the chemical 
structures and physicochemical properties of both drugs and lipids. Although 
some models have been developed to predict the solubility of the drugs in the 
lipids, they examined the molecular descriptors of the drugs which influence 
their solubilisation in the lipid excipients [133,150,165]. However, the 
influence of the molecular and physicochemical descriptors of various lipids 
affecting the solubility of drug have not been reported yet to the best of our 
knowledge. In this study, the influence of various molecular and 
physicochemical descriptors of the lipids on the solubility of IM was evaluated 
and a statistical correlation was developed among them using MLR to 
theoretically quantify the amount of IM that could be solubilised.   
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 Various categories of lipids like fatty acids (myristic acid, palmitic 
acid, stearic acid, behenic acid), their mono, di and triglyceride derivatives 
(glyceryl palmitostearate,  glyceryl monostearate, trimyristin, tripalmitin, 
tristearin, cocoa butter and Captex 70®), their lipid blends and derivatives 
(Precirol ATO 5®, Geleol mono and diglycerides, Compritol 888 ATO®), 
hydrogenated derivatives of vegetable oils (Sterotex HM®, Sterotex NF®, 
Hydrokote M® and  Hydrokote 112®) and polyethylene glycol derivatives 
(Gelucire 44/14® and Gelucire 33/01®) were used to evaluate the solubility 
profile of IM. As IM is a hydrophilic compound, it is essential to identify and 
use those lipids which can entrap higher amounts of IM during the preparation 
of LBFs. The solubility pattern of IM in the lipids (Table 10) was examined by 
considering the chemical structure, composition, total solubility parameters 
and physicochemical descriptors of the lipids. 
 
7.2.1  Influence of structure, composition and polarity of lipids 
 Solubility of IM in the lipids showed a negative correlation with 
respect to the chain length of fatty acids. Additionally, the chain length also 
influenced the polarity of the lipids. Long chain fatty acids like myristic acid 
(C14), palmitic acid (C16) and stearic acid (C18) stearic acid were able to 
solubilise IM. On the other hand, an increase in the chain length to C22 
(behenic acid) showed least solubility for IM. Amongst the fatty acids used in 
the study, myristic acid showed a high solubility of 2.76 ± 0.11 % w/w 
followed by palmitic acid, stearic acid and behenic acid with a solubility of 
2.21 ± 0.23% w/w, 1.94 ± 0.08 % w/w and 0.01 ± 0.01 % w/w respectively. 
The reduction in the polarity values upon increase in the carbon chain length 
from 0.13 (myristic acid) to 0.09 (behenic acid) suggested that an increase in 
the number of alkyl groups like –CH3 and –CH2– will decrease the polarity of 
the lipids. Hence, IM was soluble in myristic acid in higher amounts than in 
palmitic acid and stearic acid and least soluble in behenic acid. Thus, to 
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solubilise hydrophilic drugs, fatty acids with a comparatively shorter carbon 
chain and which are comparatively polar in nature (i.e. hydrophilic polar 
lipids) may be the preferred choice.  
 Lipids like glyceryl monostearate and glyceryl palmitostearate are 
mono glyceride derivatives of long chain fatty acids, stearic acid and palmitic 
acid respectively and contain free hydrophilic functional groups like –OH and 
–COOH. These functional groups impart polar nature to the fatty acids and 
enable formation of a stronger hydrogen bonding with the drugs. Amongst the 
lipids used, a highest polarity value was observed for glyceryl monostearate, 
which could have been also been a factor for solubilisation of highest amount 
of IM. Additionally, the surface active nature of glyceryl monostearate could 
be attributed to solubilise highest amount of IM in the lipid matrix. Similarly, 
high solubilisation capacity for glyceryl monostearate was observed while 
testing the solubility of tamoxifen in various lipids by Shete et al 2013 [115]. 
They reported that formation of hydrogen bonds between the two hydrogen 
bond donor groups of glycerides in glyceryl monostearate and hydrogen bond 
acceptor group of tamoxifen could form a molecular complex which tends to 
further enhance the solubility of tamoxifen. When Geleol mono and 
diglycerdies was used as a lipid carrier to solubilise IM, the monoglyceride 
(40-55%) and diglyceride (30-45%) derivatives of stearic acid in the lipid 
could have possibly helped in solubilising IM. But, comparatively lesser 
amount of drug was solubilised in Geleol mono and diglycerdies than glyceryl 
monostearate. This suggested that the monoglyceride derivatives of stearic 
acid (glyceryl monostearate) are more efficient in solubilising IM than a lipid 
mixture containing mono and diglycerides of stearic acid (Geleol mono and 
diglycerides). Due to unavailability of diglycerides, we could not use them for 
our work even though it is an established fact that monoglycerides are more 
polar than diglycerides [182].  
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 The respective triglyceride derivatives of myristic acid, palmitic acid 
and stearic acid like trimyristin, tripalmitin and tristearin do not contain free –
OH and –COOH groups and are comparatively less hydrophilic than the fatty 
acids as suggested by their low polarity values. Their polarity values in Table 
11 illustrate that the polarity of the triglycerides decrease in the order of 
trimyristin, tripalmitin and tristearin. Furthermore, due to the domination of 
the dispersive forces (alkyl groups), the polarity values for the triglycerides are 
relatively less when compared to the polarity values for monoglycerides and 
fatty acids. Thus, the triglycerides such as trimyristin, tripalmitin and tristearin 
could only solubilise low amounts of IM.  
 Precirol ATO (blend of glyceryl distearate and glyceryl 
palmitostearate), a mixture containing monoglycerides, diglycerides and 
triglycerides of palmitic acid and stearic acid, facilitated solubilisation of 3.17 
± 0.19% w/w of IM, which is more than the solubility of IM in palmitic acid 
and stearic acid. However, as behenic acid could not solubilise IM, Compritol 
888 ATO® (glyceryl dibehenate and glyceryl behenate), a lipid mixture of 
mono, di and triglycerides of behenic acid could not solubilise IM either. 
 Captex 70®, a mixture of 70% medium chain triglycerides (mostly 
caprylic acid and capric acid) could not solubilise IM. Sterotex HM® and 
Sterotex NF® are hydrogenated derivatives of soya bean seed oil and cotton 
seed oil respectively which offers the lipid a high lipophilic nature. Thus, they 
could not solubilise IM. Similarly, Hydrokote 112® and Hydrokote M®, which 
are hydrogenated derivatives of palm kernel oil, could not solubilise IM in 
their matrix. Although cocoa butter is a mixture of triglycerides of stearic and 
palmitic acid, it could not solubilise IM. Gelucire 44/14® (mixture of lauroyl 
macrogol-32 glycerides and lauroyl polyoxyl-32 glycerides) and Gelucire 
33/01® are mixture of glycerides and esters of fatty acids and poly ethylene 
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glycol (polyoxylglycerides) and could not solubilise IM. Thus, the lipids 
derived from polyethylene glycol may not be favourable to solubilise a 
hydrophilic drug like IM. Owing to the hydrophilic nature of IM, lipids which 
are comparatively more hydrophilic in nature were able to solubilise the drug.   
7.2.2  Influence of solubility parameters on the ability of lipid to 
solubilise Imatinib Mesylate  
 In general, a similar magnitude of total solubility parameters for the 
drug and lipid suggests a greater miscibility between them. Hence, a least 
difference between the solubility parameters of drug and lipid could be a 
favourable choice to use. In the present study amongst the lipids used, lowest 
difference (9.46 MPa1/2) of total solubility parameters was observed with IM 
for glyceryl palmitostearate (Table 11). A comparison of the difference of the 
solubility parameters of IM with fatty acids and triglycerides do not indicate 
much difference, but, IM was comparatively more soluble in fatty acids. 
Among the fatty acids, with an increase in the carbon chain length, the values 
of the solubility parameter decreased and the corresponding difference with 
IM has increased. Although the dispersive forces increased with an increase in 
–CH2– groups, the decrease in the solubility parameters of the fatty acids 
correspond to the decrease in the polar forces and hydrogen bond forces 
(Table 11). Whereas in triglycerides, lower polar and hydrogen forces were 
observed than their fatty acids due to the domination of alkyl groups, which 
decreased their ability to solubilise hydrophilic drugs. The corresponding 
solubility values for IM also predicted lower solubility for triglycerides than 
their corresponding fatty acids (Table 10). A highest difference of 15.18 
MPa1/2 was observed for behenic acid, which showed least solubility for IM. 
Although Compritol 888 ATO® possess a low difference (11.10), it could not 
solubilise IM possibly due to the presence of low polar and hydrogen bonding 
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forces. Although the application of solubility parameters as a tool to evaluate 
the solubility of a drug yielded good results previously [113], in the current 
work it did not yield consistent results. This indicates that calculation of 
solubility parameters may not always yield useful results.  
7.2.3  Influence of molecular and physicochemical descriptors on the 
 ability of lipid to solubilise Imatinib Mesylate 
 Although 20 lipids were used to screen the solubility of IM, lipids 
which could only solubilise IM were selected to develop and validate a QSSR 
model. Figure 18 represents the graph obtained by plotting experimentally 
determined solubility of IM in lipids against predicted solubility of IM in 
lipids. Among the three models (i.e., model 1, model 2 and model 3) 
developed using the test set of lipids, only those descriptors which improved 
the efficacy and statistical significance were used. A good correlation among 
the training set of lipids was observed for model 1 (R2= 0.826), model 2 (R2= 
0.876) model 3 (R2= 0.925) with respect to the solubility of IM in the lipids. 
Also, these models showed good prediction in the test set of lipids with good 
robustness (Table 14). These models reflected the influence of descriptors of 
lipids like AC×DN0.5/SA, accptHB and donorHB and solvent accessible 
surface area (SASA) to solubilise IM. All these descriptors are related to the 
polar properties of the compounds. As IM is a hydrophilic drug, we presume 
the polar properties of the lipids to play a decision role in the solubilisation of 
IM. Although all the 3 models were statistically robust, model 1 developed 
taking one subset was a better one with a highest predictive correlation 
coefficient R2pred of 0.912. This model highlighted the role of the descriptor, 
AC×DN0.5/SA, to solubilise IM in the lipids. Additionally, all the three models 
had the descriptor AC×DN0.5/SA in common. The descriptor AC×DN0.5/SA 
represents effective cohesive index and is a measure of index of cohesive 
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interaction in the solids and directly relates to the intermolecular hydrogen 
bonding between the solute and solvent which is represented as [accptHB ×  
donorHB]/ [SA].[149] It also signifies that there should be a good balance 
between the number of hydrogen bond acceptors and hydrogen bond donors 
sites in the solvent accessible surface area to solubilise the solute.[140] As 
observed by the values of AC×DN0.5/SA in Table 13, highest value was 
observed for glyceryl monostearate. Glyceryl monostearate also had the 
highest number of accHB (5.4) and donorHB (2) which could have helped in 
solubilising highest amount of IM (with 10 acceptor hydrogen bond and 3 
donor hydrogen bonds). The triglycerides trimyristin, tristearin and tripalmitin, 
used in the study had highest number of accptHB (6) each. But, they could 
solubilise only a substantial amount of IM as they do not have any donorHB. 
Although all the lipids belonging to the category of fatty acids had same 
number of accptHB (2) and donorHB (1), lowest solubilisation capacity of IM 
was observed for behenic acid. This could be possibly due to an increase in the 
number of alkyl chains which could have additionally increased the solvent 
accessible surface area. This increase in SASA could have decreased the 
AC×DN0.5/SA leading to reduced solubilisation of IM in behenic acid. 
Although stearic acid and glyceryl palmitistearate had surprisingly similar 
values of AC×DN0.5/SA, accptHB and donorHB and SASA, highest 
solubilisation for IM was observed in glyceryl palmitostearate. The presence 
of a higher total polar surface area for glyceryl palmitostearate (135 Aº2) when 
compared to stearic acid (37.3 Aº2) could have enhanced its ability to 
solubilise IM. 
 In addition to AC×DN0.5/SA, other descriptors like accptHB and 
donorHB were also correlated with the solubility of IM as observed in 
equation 4 and equation 5. As mentioned previously, accptHB and donorHB 
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represent the number of hydrogen bonds that would be accepted by the solute 
from solvent molecules and donated by the solute to solvent molecules. These 
values of are averages taken over a number of configurations, hence they can 
exist as non-integer. The values of accptHB and donorHB are directly related 
with AC×DN0.5/SA. Hence, IM with 10.5 accptHB and 2 donorHB could 
have been efficiently solubilised in lipids with a good ratio of accptHB and 
donorHB like glyceryl monostearate and glyceryl palmitostearate. All the 
three models developed were found to be statistically robust with a good 
power of prediction (Table 14).  
7.2.4  Partitioning of drug between aqueous phase and lipid phase 
 During the preparation of LBFs like solid lipid nanoparticles, 
nanostructured lipid carriers, etc., aqueous phase (water) is usually added to 
the lipid phase containing drug. Even if the drug shows good solubility in the 
lipids phase, there are high chances for the drug to leak into the aqueous phase 
during this phase. Additionally, during cooling, the lipids crystallize, which 
lead to expulsion of drug from the lipid matrix. Hence it is beneficial to 
perform partitioning studies to finalise the lipid of choice. The results of the 
partitioning studies with all the lipids indicated highest partitioning for IM 
towards water [56].  Amongst all the lipids used in the study, IM showed 
highest partitioning towards glyceryl palmitostearate. Although the solubility 
studies showed IM to be highly soluble in glyceryl monostearate, partition 
studies did not show highest affinity for IM towards glyceryl monostearate. 
The surface active properties of glyceryl monostearate could have facilitated 
formation of micelles and improved the solubility of IM in the aqueous phase 
leading to poor retention of IM in the matrix of glyceryl monostearate. Lowest 
partition for IM was observed for myristic acid. Thus, for the preparation of 
LBFs of IM, usage of glyceryl palmitostearate as lipid carrier may yield high 
entrapment efficiency. 
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7.3  FORMATION OF LIGAND- LIPID CONJUGATES 
 Ligand-lipid conjugates of HAJ-SA and B12-SA were prepared by 
carbodiimide chemistry. Stearyl amine and stearic acid were conjugated to 
hyaluronic acid and vitamin B12 to form hyaluronic acid-stearic acid (HAJ-
SA) and vitamin B12-stearic acid (B12-SA) conjugates respectively. The –
COOH group present in the stearic acid reacted with the –NH2 groups of 
vitamin B12 to form B12-SA moiety by amide linkage. Similarly, for the 
formation HAJ-SA moiety, the –COOH group of the hyaluronic acid reacted 
with the –NH2 group present in stearyl amine by amide linkage.  
 The formation of B12-stearic acid and HA-stearic acid in both the 
cases was confirmed using NMR spectrum and IR spectrums. The NMR 
spectrum in Figure 32 and Figure 33 shows peak at 8 ppm which indicates the 
formation of amide. Similarly, the IR spectrum in Figure 34 and Figure 35 
showed wave number at 1705 cm-1, 1611 cm-1 and 3100 cm-1 which 
correspond to the amide stretching and NH bending of the formed conjugates. 
Wave numbers corresponding to the acid functional groups of either stearic 
acid or hyaluronic acid and amine functional groups of stearyl amine or 
vitamin B12 are absent in the regions of 1730 cm-1 and 3330 cm-1. These 
results indicate formation of ligand-lipid conjugates, HA-SA and B12-SA 
(Figure 34 and Figure 35).  
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7.4  SOLID LIPID NANOPARTICLES OF IMATINIB MESYLATE 
 PREPARED USING STEARIC ACID AS LIPID CARRIER 
 Initial attempts to prepare a stable emulsion by hot homogenisation 
method using 4% stearic acid as a lipid core and 0.1- 0.4% of QS as an 
emulsifier have been unsuccessful due to phase separation and improper 
coverage of QS around the stearic acid. Although the critical micelle 
concentration of QS has been reported to be 0.01% [131], a minimum of 0.5% 
QS was required to cover the stearic acid core to produce SLNs. To form a 
good stable emulsion QS should be distributed properly on the surface of 
stearic acid when heating, thereby reducing the interfacial tension and 
facilitating the formation of small droplets during homogenisation. Moreover, 
QS present around the lipid surface should prevent aggregation among the 
nanoparticles upon cooling or upon long-term storage. Gelling was not 
observed in the formulations upon cooling indicating that the particle size did 
not increase and the surfactant concentration was sufficient to cover the outer 
lipid layer and thereby prevent aggregation upon cooling, when structural 
rearrangement of the lipid structures occurs.  
 For the preparation of ligand conjugated solid lipid nanoparticles, 
previously synthesised conjugates, HAJ-SA or B12-SA were added along with 
stearic acid during the preparation of solid lipid nanoparticles. Vitamin B12 
conjugated solid lipid nanoparticles of IM using stearic acid (B12-ISN) were 
prepared by adding B12-SA (50 mg) along with stearic acid during the 
preparation of solid lipid nanoparticles. Similarly, for the preparation of 
hyaluronic acid conjugated solid lipid nanoparticles of IM using stearic acid 
(HAJ-ISN), HAJ-SA (50 mg) was added to stearic acid during the preparation 
of ISN. HA coated IM loaded solid lipid nanoparticles of stearic acid (HAC-
ISN) were prepared by dispersing ISN3 in different concentrations of 
hyaluronic acid and probe sonicating for 5 minutes. 
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 Both stearic acid and QS affected the size of ISNs. Table 17 shows the 
compositions of 9 batches of ISNs prepared by changing the amounts of 
stearic acid and QS. The size of ISNs from various batches ranged between 
143.53 ± 3.47 nm to 641.87 ± 4.16 nm (Table 18). Surface conjugated ISNs, 
B12-ISN and HAJ-ISN showed a mild increase in the particle size from 159.5 
± 4.7 nm to 169.1 ± 3.2 nm and 173.1 ± 4.5 nm respectively. HAC-ISN 
showed a reduction in the particle size from 159.5 ± 4.7 nm to 87.3 ± 5.9 nm. 
The polysaccharide nature of hyaluronic acid could have reduced the surface 
tension of the system leading to reduction in the particle size. Additionally, 
sonication of ISN3 could have provided additional energy for a significant 
reduction in the particle size of the solid lipid nanoparticles. A particle size 
below 100 nm is a prerequisite for lymphatic targeting. Hence, HAC-ISN with 
a particle size of 87.3 ± 5.9 nm can be beneficial to target the lymphatics. 
Hyaluronic acid with a concentration of 0.1% was found to be optimum for 
coating around ISN3. 
 The particle size of the ISN was dependent on the amount of stearic 
acid and QS. When the concentration of stearic acid was maintained constant, 
the particle size was reduced with an increasing QS concentration, reflecting 
the role of QS as a surfactant. Probably, the increased QS concentration 
reduced the interfacial tension by adsorbing at the interface of the melted lipid 
phase and water, which might have facilitated the formation of smaller stable 
ISNs. On the other hand, when the concentration of QS was maintained 
constant, increase in stearic acid levels (e.g. 4%, 8% and 12%) variously 
affected the particle size. Compared to the particles present in the 4% stearic 
acid, smaller and larger particles were respectively found in 8% and 12% 
stearic acid formulations. The reduction in particle size of ISNs when the 
stearic acid concentration was increased from 4% to 8% can be attributed to 
the increased surface-active properties of stearic acid due to the presence of a 
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polar head and nonpolar chain. Whereas, the increase in particle size at 12% 
stearic acid might be due to the increased viscosity of the dispersed phase. 
Thus, use of 8% stearic acid was found to be optimum to obtain particles with 
smaller size in the present study. A comparison of the emulsifying properties 
of QS, lecithin and tween 80 showed that QS was able to form smaller 
particles at low concentration because of its lower molecular weight and 
higher proportion of non-polar to polar groups [69,183]. The polydispersity 
index of the formulations (Table 18) were in the range 0.127 to 0.237 
indicating that they are moderately polydisperse, which could be attributed to 
the use of high speed homogenisation and ultrasonication methods for the 
preparation of nanoparticles. Thus, QS can be foreseen as a promising 
emulsifier for the formation of solid lipid nanoparticles. 
 TEM and AFM analysis of ISN3 showed quasi-spherical shaped 
nanoparticles (Figure 39). The central black core in the TEM image represents 
the drug entrapped in the surrounding lipid carrier. The outer corona observed 
as a bright light pattern represents the surfactant coat around the nanoparticle. 
The AFM images (Figure 48) show a smooth surface and non-aggregated 
particles. The nanoparticles of B12-ISN and HAJ-ISN did not show any 
change in their morphology. But, coating with hyaluronic acid changed the 
morphology of the nanoparticles to nests of spherical shaped nanoparticles 
Figure 40. These nests showed nanoparticles below 50 nm. Although these 
nanoparticles seemed to be aggregated, they can’t be deemed as aggregates 
because their surface still remains undamaged. These nests can be efficiently 
retained in the lymphatics by evading opsonisation and phagocytosis. 
 The zeta potential for the formulations was found to be neutral in the 
range of -2.43 ± 0.41 to 0.95 ± 0.54 mV (Table 18). Due to its non-ionic 
nature and attachment of hydrophilic sugar moieties to the lipophilic 
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backbone, QS would provide hydrophilicity and neutral charge to the particle 
surface. In spite of the neutral zeta potential of the formulations, aggregation 
among the particles was not observed because of the osmotic force created by 
the surfactant coating on the surface of nanoparticles. This net neutral charge 
can provide covertness to the particles against macrophages and thereby help 
in extending the half-life of drugs. B12-ISN showed a mild positive zeta 
potential of 10.2 ± 1.2 mV, which may be due to the ionisation of vitamin 
B12. But, the zeta potential of HAJ-ISN and HAC-ISN showed a negative zeta 
potential of -6.4 ± 0.7 mV and -12.8 ± 1.7 mV respectively. The change in the 
zeta potential of HAC-ISN from 0.95 ± 0.5 mV to -12.8 ± 1.7 mV confirmed 
coating of ISN by hyaluronic acid. Hyaluronic acid could have adsorbed on 
the surface of ISN by electrostatic attraction between the hyaluronic acid and 
the stabiliser coat present on the surface of SLNs. 
 As the surfactant shell can suppress the transition of the drug from one 
state to another state, the effect of QS on the polymorphic transition of SLNs 
and the physical form of IM in the lipid matrix using DSC was checked. The 
thermograms of IM, QS, stearic acid, BSNs and ISNs were shown in Figure 
54. Endothermic peaks at 227.8 ºC, 126.5 ºC, and 59.8 ºC were observed, 
respectively, for IM, QS and stearic acid. The absence of the melting peak of 
IM in the thermogram of the ISNs indicates that the IM entrapped in the lipid 
core was in an amorphous state. Further, the broadened peak and decreased 
melting point of stearic acid indicates loading of the drug in the lipid lattice 
structures. The decrease in the melting point of stearic acid from 60.8 ºC in 
bulk stearic acid to 58.6 ºC (BSLNs) and 57.7 ºC (ISNs) respectively reveals a 
decrease in the particle size to colloidal range and increased number of lattice 
defects in the β’ structured stearic acid. DSC thermograms were not obtained 
for the surface conjugated ISNs because the composition remained the same, 
with an exception of addition of conjugated stearic acid. 
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 The entrapment efficiency of the formulations ranged between 41 % 
(ISN9) and 66 % (ISN1). Surface modified ISN showed a reduction in the 
entrapment efficiency from 61.3 ± 1.1% (ISN3) to 56.9 ± 1.4% (B12-ISN), 
50.6 ± 1.5% (HAJ-ISN) and 47.8 ± 2.1% (HAC-ISN) respectively. For B12-
ISN and HAJ-ISN the addition of conjugate to the lipid matrix could have 
reduced the entrapment efficiency. For HAC-ISN, additional homogenisation 
could have lead to repacking of the lipid matrix which could have reduced the 
entrapment efficiency. A negative trend with increasing stearic acid and QS 
concentrations was observed. High surfactant concentration could have 
enhanced the solubility of IM resulting in the partitioning of the drug into the 
aqueous medium, thereby leading to low entrapment efficiencies in the lipid 
core. IM also shows enhanced solubility in solutions with pH less than 5.5 
[153]. Thus, 0.5% and 1.5% QS solutions with pH 4.5 and 4.3 respectively 
could have additionally enhanced the solubility leading to the partitioning of 
IM from the lipid phase to the aqueous QS solution.  
 In vitro drug release patterns of ISNs in PBS pH 7.4 are shown in 
Figure 57. A biphasic release pattern with an initial burst release of about 1 h, 
followed by a sustained release of IM from the lipid core for 10 h was 
observed. The initial burst release could be due to the free and surface 
adsorbed IM as reported in a recent study with IM nanoparticles [126]. Even 
though a long-chain fatty acid (stearic acid) was used as the lipid core, the 
release of the drug from ISN was not sustained for a longer duration due to the 
hydrophilic nature of IM. The coating of hyaluronic acid could have hindered 
the release of IM. More rapid release of the drug was observed in the 
formulations containing 1.5% of QS. HAC-ILN showed a comparatively 
sustained release profile of IM from its matrix. The r2 (regression coefficient) 
values indicated a first order release pattern of IM from the lipid matrix.  
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 It should be noted that saponins in general have an innate potential to 
cause lysis of RBCs due to their membrane lytic action, which might have 
restricted the use of QS as a surfactant in the pharmaceutical industry. A 
comparative in vitro haemolytic analysis of ISNs, QS, IM, and BSNs revealed 
that ISNs, BSNs and IM did not induce haemolysis Figure 61. Although QS 
induced haemolysis even at a low concentration (50 µg/ml) when presented 
singly, the ISNs and BSNs prepared using QS did not show haemolysis even 
at a much higher QS equivalent concentration (450 µg/ml). This is probably 
due to the fact that the lipophilic aglycone group of QS which is responsible 
for haemolysis [132] was adhered to the lipid matrix of the SLNs, exposing 
the non-haemolytic hydrophilic polysaccharide groups to the outer aqueous 
medium. In line with our observation, absence of haemolysis for anticancer 
drugs in nanoparticulate form has been previously reported [178]. When ISNs 
were tested for haemolytic activity at concentrations several folds higher (e.g., 
10, 20 and 30 µg/ ml) than its original Cmax concentration (approximately  
1 µg/ml) [184], we did not observe any haemolysis indicating that SLNs 
prepared using QS as a surfactant and IM as the drug is safe for intravenous 
administration. 
 Particle size and entrapment efficiency are two parameters which 
significantly affect the drug delivery and treatment efficacy of drug loaded 
nanoparticles. Small particles have good access into tumor cells by penetration 
through the cell membranes [185]. Equally, good entrapment efficiency is also 
desired to reduce the quantity of material for administration. So, it is desirable 
for the formulations to have smaller sized particles with good entrapment 
efficiency. Although formulation ISN6 possessed least particle size among all 
the formulations, its entrapment efficiency was low. Hence the formulation 
with the next lowest particle size and higher entrapment efficiency (ISN3) was 
selected for further investigations. As revealed by MTT assay (Figure 63), 
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HAC-ISN3 was the most cytotoxic against MCF7 cells among the 
formulations tested (IM, QS, ISN3, BSNs, BSNs- IM mixture, B12-ISN3, 
HAJ-ISN3 and HAC-ISN3). The IC50 (minimum inhibitory concentration) 
value of the samples (Table 22) decreased in the following order HAC-ISN3 
(0.76 μM) < B12-ISN3 (1.03 μM) < HAJ-ISN3 (1.17 μM) < ISN3 (1.226 μM) 
< BSNs- IM mixture (3.114 μM) < BSNs (6.91 μM) < IM (7.395 μM). The 
results signify that IM encapsulated in solid lipid nanoparticles and surface 
modified with hyaluronic acid was more efficient in killing cancer cells than 
the free IM and ISN. Probably, this is due to the enhanced cellular uptake of 
lipid nanoparticles and/or a synergistic effect between QS (IC50 value = 8.167 
μg/ml) and IM present in the ISN3 and the presence of conjugating agent 
which could have enhanced its toxicity. The anticancer property of QS might 
be the reason for the higher cytotoxic potentials of BSNs and BSNs-IM 
mixture against MCF7 cells compared to IM.  
 On the other hand, when the RAW 264.7 cells (macrophages) were 
treated with the samples (IM, QS, ISN3, BSNs, BSNs- IM mixture, B12-ISN3, 
HAJ-ISN3 and HAC-ISN3), more than 90% cells were viable indicating that 
normal cells were not affected by any formulation including IM and QS 
(Figure 65) which indicates that IM and QS specifically target cancer cells. 
Cytotoxic effect of saponins against MCF7 cells and its protective effect 
against RAW 264.7 cells have been reported [186]. Although the mechanism 
behind the specificity of QS to cancer cells is unknown, as IM, (a tyrosine 
kinase inhibitor which specifically targets cancer cells expressing tyrosine 
kinase genes) was used, RAW 264.7 cells which do not this tyrosine kinase 
inhibitor could have been spared [126]. In agreement, conjugation of aptamer 
with doxorubicin enhanced the viability of RAW 264.7 cells without affecting 
the cytotoxic effect of doxirubicin to MCF cells [187]. The results indicate 
that HAC-ISNs are more efficient in killing the cancerous cells.  
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7.5 SOLID LIPID NANOPARTICLES OF IMATINIB MESYLATE 
 PREPARED USING PALMITIC ACID AS LIPID CARRIER 
 Solid lipid nanoparticles of IM using palmitic acid (IPN) as a lipid 
carrier and QS as the surfactant were prepared by hot homogenisation 
technique using high shear homogeniser and probe sonicator. Initially, 
preliminary trial formulations of IPA were prepared by varying the parameters 
like the speed of high shear homogenization (10, 000- 15, 000 rpm), time of 
high shear homogenization (2- 10 minutes) and duration of probe sonication 
(2- 10 minutes) to obtain a stable formulation. Based on the preliminary trials 
conducted, a comparatively good stability was obtained after homogenising 
the mixture of water and lipid phases at 14, 000 rpm for 4 minutes and probe 
sonication for 4 minutes. Trails at conditions other than the optimised process 
parameters showed either an increase in the particle size of the formulations or 
frothing or phase separation. At high speeds, the surfactant coating on the 
surface of solid lipid nanoparticles (SLNs) could have been damaged or 
eroded, there by promoting aggregation and increase in the particle size.  
 Nine batches of formulations were prepared by changing the amount of 
palmitic acid (PA) and QS. The particle size of the formulations was in the 
range of 133.1 ± 8.4 nm to 611.0 ± 4.1 nm (Table 18). The influence of 
particle size of IPN on the amount of PA and QS was studied. When the 
amount of QS was increased from 0.5% to 1.5%, the particle size of the solid 
lipid nanoparticles reduced. Increased levels of QS could have reduced the 
surface tension and facilitated efficient dispersion of the lipid phase in the 
aqueous medium, thereby producing smaller sized IPNs. When the amount of 
palmitic acid was increased from 4% to 12%, the particle size of IPNs 
increased. Higher amounts of palmitic acid could have increased the viscosity 
and resistance for the lipid phase to disperse in the aqueous medium, which 
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leads to production of particles with a bigger size. Hence, higher amounts of 
palmitic acid could have increased the particle size of the IPNs. Thus, in order 
to obtain, IPNs of smaller size, it is preferable to use lower amounts of 
palmitic acid (4%) and higher amounts of QS (1.5%). 
 Due to the usage of QS, a non ionic surface stabilizer, in the 
preparation of IPNs, the zeta potential of the formulations was neutral and 
ranged from -1.08 ± 0.2 mV to -4.29 ± 0.6 mV. Although, the zeta potential is 
neutral, it will not cause any instability during storage for long time as QS is a 
surface stabiliser and provides osmotic force which prevents aggregation. This 
neutral charge can additionally impart stealth nature to the IPNs by preventing 
opsonisation and phagocytosis against macrophages. The mild negative charge 
could have been due to the ionisation of acid groups of palmitic acid [155].  
 Analysis of the morphology of the nanoparticles using TEM and AFM 
showed homogeneous, spherical shaped smooth nanoparticles with mild 
aggregations (Figure 42 and Figure 49). The particle size of the IPNs 
corroborated with that of the particle size results obtained from dynamic light 
scattering analysis i.e., less than 200 nm. Cracks or pin holes on the surface of 
nanoparticles were not seen.  
 DSC studies were performed to check the physical state of IM in IPN. 
The thermograms of IM, QS, bulk PA, BPN and IPN was represented in 
Figure 55. In the thermogram corresponding to IPN, endothermic peak of IM 
was absent. This indicated that IM was encapsulated in the lipid matrix in an 
amorphous form.  
 The ability of PA to entrap IM in its lipid matrix was low as evidenced 
by the low entrapment efficiencies. The entrapment efficiencies of the 
formulations were in the range of 39.8 ± 0.6% to 57.1 ± 0.3%. As IM is 
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hydrophilic in nature, its entrapment in the lipophilic matrix of palmitic acid 
could have been poor, justifying the low entrapment efficiencies. The 
entrapment efficiencies of IPNs were influenced by the amount of PA and QS. 
The entrapment efficiency of the formulations showed a significant decrease 
when the amount of QS was increased from 0.5% to 1.5%. Higher amounts of 
QS could have enhanced the solubility of IM in the aqueous phase, thereby 
facilitating the partitioning of IM into the aqueous medium. The entrapment 
efficiency also decreased with an increase in the amount of PA from 4% to 
12%. Higher amount of palmitic acid did not improve in the amount of IM 
entrapped in its matrix. In vitro release studies in pH 7.4 phosphate buffer 
saline showed a biphasic release pattern for IM from the IPA. The total 
amount of drug entrapped in the lipid matrix was released in almost 6-8 hours. 
In the initial hour, nearly 50% of the drug was released in all the formulations. 
This represents the burst release phase and corresponds to the free and surface 
adsorbed drug.  In the remaining 4-6 hours, a comparatively sustained release 
profile was obtained. During this phase, the amount of IM released 
corresponded to the drug entrapped in the lipid matrix. Although a long chain 
fatty acid was used in the study, the release was not sustained possibly due to 
the small size of nanoparticles, hydrophilic nature of the drug and poor 
entrapment efficiencies. Low entrapment efficiencies for hydrophilic drugs 
encapsulated in SLNs have also been reported elsewhere [31,60]. The release 
pattern of IM from the lipid matrix of IPN showed a first order release.  
 Considering the high particle size and low entrapment efficiencies for 
IPA, solid lipid nanoparticles with the addition of lipid-ligand conjugates like 
B12-SA and HA-SA were not performed. Hence, additional evaluation studies 
like in vitro cytoxicity assay and cell internalisation studies in cell lines,  
in vivo pharmacokinetic studies were not performed.  
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7.6  SOLID LIPID NANOPARTICLES OF IMATINIB MESYLATE 
PREPARED USING GLYCERYL PALMITOSTEARATE AS 
LIPID CARRIER 
 Partitioning studies showed highest partitioning for IM using glyceryl 
palmitostearate as the lipid carrier. IM loaded solid lipid nanoparticles using 
glyceryl palmitostearate (IGPN) as lipid carrier were prepared by hot 
homogenisation technique using high shear homogenisation and probe 
sonication. During the preliminary trials, 12% glyceryl palmitostearate and 
0.5% QS were used to check for their ability to form o/w emulsion. Then, 
trials were performed at different homogenisation parameters like speed (10, 
000- 15, 000 rpm) and duration of high shear homogenisation (2- 10 minutes) 
and duration of probe sonication (2- 10 minutes). Based on the stability, high 
shear homogenisation at 14, 000 rpm for 6 minutes and probe sonication for 6 
minutes were selected as optimum parameters for preparing different batches 
IGPN. When different parameters were used, instability due to an increase in 
particle size or frothing was observed. Homogenising the emulsion at high 
speeds and longer duration could have damaged the surfactant coating around 
the particle surface. This damaged surface will induce aggregation among the 
nanoparticles and leads to an increase in the particle size [167]. Hence, 
choosing optimum conditions for the preparation of solid lipid nanoparticles is 
very important. 
 Different batches of IGPNs were prepared by varying the amount of 
the lipid, glyceryl palmitostearate and surfactant, QS. B12-IGPN and HAJ-
IGPN were prepared by addition of HAJ-SA and B12-SA to the lipid, glyceryl 
palmitostearate during the process of preparation of IGPNs. Hyaluronic acid 
coated IGPN (HAC-IGPN) were prepared by dispersing IGPN in solution of 
hyaluronic acid of various concentrations. The cytoxicity and apoptosis assay 
of the IGPNs was tested against MCF 7 cell line. Finally, pharmacokinetic 
studies were performed in female Wistar rats. 
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 The average particle size of the formulations was found to be in the 
range of 92.1 ± 2.41 nm to 430.7 ± 2.2 nm (Table 18). The influence of the 
amount of glyceryl palmitostearate and QS on on the particle size was studied. 
When the amount of glyceryl palmitostearate increased, the particle size of the 
nanoparticles significantly decreased (p < 0.05). Higher amounts of glyceryl 
palmitostearate could have enhanced the surface tension, thereby leading to 
the generation of solid lipid nanoparticles with reduced particle size. Among 
the various batches of SLNs prepared using different lipids (stearic acid, 
palmitic acid, glyceryl palmitostearate, glyceryl monostearate and Geleol 
mono and di glycerides), SLNs prepared using glyceryl palmitostearate were 
found to be of smaller size. High polarity of the lipids due to the presence of 
glyceryl groups in the lipid and better solubility of the drug in the lipid could 
have allowed the lipid to disperse well during the preparation of nanoparticles 
[188]. Additionally, usage of higher homogenisation speeds could have lead to 
the generation of smaller sized nanoparticles amongst all the lipids. When the 
amount of QS was increased, the particle size of the IGPNs also increased. As 
QS is a surfactant, usage of higher amounts of QS during the preparation of 
solid lipid nanoparticles reduced the surface tension [131,189]. This reduced 
surface tension could have allowed the particles to disperse well during 
homogenisation, leading to the formation of particles with smaller size. Hence, 
for the preparation of smaller size of IGPN, it is favourable to use low level of 
glyceryl palmitostearate (4%) and high level of QS (1.5%). Ligand conjugated 
nanoparticles prepared using B12-SA and HA-SA increased the particle size 
of the nanoparticles to 118.7 ± 3.9 nm and 130.6 ± 2.7 nm respectively. 
Hyaluronic acid (HA) was coated on the surface of IGPNs by surface 
adsorption to form HAC-IGPN. The size of the nanoparticles reduced from 
106.4 ± 4.7 nm to 92.1 ± 2.4 nm after coating with HA. As HA is a 
polysaccharide, it could have lowered the surface tension by acting as a 
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surfactant [82,130,190]. This reduced surface tension could have enhanced the 
ability of the particles to disperse well during homogenisation, leading to 
production of nanoparticles with smaller size. During the process of coating of 
HA, optimisation was carried out to identify the favourable concentration of 
HA required for coating with respect to size and stability. Among the different 
trials performed, 0.1 % was found to be optimum for the preparation of HAC-
IGPN. Higher concentrations of hylauronic acid increased the particle size of 
the SLNs due to aggregation. Aggregation due to higher concentration of 
hyaluronic acid have been reported in previous instances [58,82]. 
 The morphology of the solid lipid particles of IGPN was observed 
using TEM and AFM. TEM images (Figure 43) of IGPN showed near 
spherical shaped particles without any aggregation. B12-IGPN showed 
spherical shaped particles without aggregations.  HAC-IGPNs showed nests of 
nanoparticles coated by hyaluronic acid, as observed by a dark outer coating 
containing nanoparticles (Figure 45). Each nest measured below 100 nm and 
contained 2-3 particles with a size below 50 nm. Although these nests showed 
particles which are held together by hyaluronic acid, their surfaces are not 
aggregated. These nanoparticles would be ideal to enter and reside in the 
lymphatics for longer duration. Nanoparticles which are smaller than 100 nm 
are difficult to retain in the lymphatics as they are escaped out through the 
interstitial walls of the lymphatic capillaries. But, coating with hyaluronic acid 
favoured particle pseudo aggregation among the particles without damaging 
their surface. These nests with a size greater than 100 nm can remain in the 
lymphatics for longer duration by evading opsonisation. The topographic 
images obtained using semi-contact mode of AFM showed homogenous 
lateral and vertical particles (Figure 50 and Figure 51). 
 The zeta potential of the formulations was in the range of 1.63 ± 0.5 
mV to 10.67 ± 1.32 mV. As QS is a non ionic surfactant, the zeta potential of 
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the formulations were neutral. The mild negative charge was due to the 
ionisation of fatty acid chains. Although the zeta potential of the formulations 
was neutral, aggregation may not be observed over long term storage because 
of the usage of a stearic stabilizer (QS) which can create an osmotic force and 
prevent aggregation among the nanoparticles [60,173,189]. The zeta potential 
of B12-IGPNs shifted to a mild positive charge (1.63 ± 0.5 mV) possibly due 
to modification of the surface of IGPN by B12-SA. Coating with hyaluronic 
acid reduced the zeta potential of the IGPN from -1.03 ± 0.14 mV to -10.67 ± 
1.32 mV confirming the coating of hyaluronic acid on the surface of solid lipid 
nanoparticles [58,82].  
 The physical state of IM entrapped in IGPN was confirmed using DSC. 
The thermograms of IM, QS, glyceryl palmitostearate, BGPNs and IGPNs are 
shown in Figure 56. The endothermic peaks corresponding to IM, QS and 
glyceryl palmitostearate were observed at 227.8 ºC, 126.5 ºC, and 50.8 ºC 
respectively. The absence of endothermic peak of IM in the thermogram of the 
IGPNs indicated that IM entrapped in the lipid core was in an amorphous state 
[191,192]. Additionally, the broadened peak and decreased melting point of 
glyceryl palmitostearate indicated loading of IM in the lipid lattice structures. 
The decrease in the melting point of glyceryl palmitostearate from 50.8 ºC in 
bulk glyceryl palmitostearate to 49.2 ºC (BGPNs) and 48.7 ºC (IGPNs) 
respectively reveals a decrease in the particle size to colloidal range and 
increased number of lattice defects in the β’ form of glyceryl palmitostearate. 
The entrapment efficiencies of the formulations were low which ranged from 
43.4 ± 0.7- 65.9 ± 0.6%.  The hydrophilic nature of IM, usage of high 
temperatures during the preparation and high solubility of IM in the aqueous 
phase could have lead to poor entrapment efficiencies. Among the different 
lipids used for the preparation of solid lipid nanoparticles, highest entrapment 
efficiency was observed for glyceryl palmitostearate. High solubility and high 
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partition of IM in glyceryl palmitostearate could have been the reason for high 
entrapment efficiency in glyceryl palmitostearate. The entrapment efficiency 
decreased for HAC-IGPNs. Sonication of the solid lipid nanoparticles after 
addition of IGPN could have caused a structural rearrangement of the SLNs, 
which could have promoted expulsion of IM from the lipid matrix. 
Additionally, the surface active nature of hyaluronic acid could have enhanced 
the solubility of IM in the aqueous phase. In vitro release studies of IM from 
IGPNs in pH 7.4 phosphate buffer saline showed a biphasic release pattern 
(Figure 59). In 12 hours almost all the drug entrapped in the lipid matrix was 
released. A burst release amounting to 50% of the free and surface adsorbed 
drug was observed in the first hour [167]. A sustained second phase was 
observed during which the remaining amount of drug was released. HAC-
IGPNs showed a more sustained profile possibly due to the coating of 
hyaluronic acid which could have hindered the release of IM from the lipid 
matrix. 
 Saponins are potent haemolytic agents as their membrane lytic action 
can lyse the RBCs [132]. A comparative in vitro haemolytic analysis of QS, 
IM, and BGPNs revealed that IM, IGPNs, and BGPNs did not induce 
haemolysis (Figure 62). Although QS alone induced haemolysis even at a low 
concentration (50 µg/ml), IGPNs and BGPNs prepared using QS did not show 
haemolysis even at a much higher equivalent concentration of QS (450 
µg/ml). The lipophilic aglycone moiety of QS which generally causes 
haemolysis [132] could have adhered to the lipid matrix of the SLNs. This will 
expose only the non-haemolytic hydrophilic polysaccharide groups to the 
outer aqueous medium which may have been the reason for the absence of 
haemolysis. Higher levels of IGPNs were also found to be non haemolytic 
indicating that SLNs prepared using QS as a surfactant and IM as the drug are 
safe for intravenous administration. Similar results were obtained for ISNs 
 Chapter 7            Discussion 
 
 
 
 
 
 
Development of Ligand Conjugated Nano Drug Delivery System  
to Prevent Lymphatic Metastasis of Breast Cancer  184 
(IM loaded solid lipid nanoparticles prepared using stearic acid as lipid 
carrier). When IGPNs were tested for haemolytic activity at concentrations 
several folds higher (e.g., 10 and 30 µg/ ml) than its original Cmax 
concentration (approximately 1 µg/ml) [184], haemolysis was not observed.  
  
 MTT assay was performed to evaluate the ability of IM, QS, IGPN3, 
Blank IGPN3, Blank IGPN3 + IM, B12-IGPN3, HAJ-IGPN3 and HAC-
IGPN3 to inhibit the growth of MCF7 cells. Dose dependent cell growth 
inhibition was observed for all groups and % cell viability was decreased with 
an increase in the concentration of drug. As revealed from the results of MTT 
assay (Figure 64 and Table 22), HAC-IGPN3 showed highest inhibition 
against MCF7 cells. The IC50 of the samples increased in the following order: 
HAC-IGPN3 (0.91 μM) < HAJ-IGPN3 (1.25 μM) < B12-IGPN3 (1.45 μM),  
< IGPN3 (1.80 μM) < Blank IGPN3 + IM (2.21 μM) < Blank IGPN3 (6.31 
μM) < IM (7.395 μM). These results reflect that IM encapsulated in solid lipid 
nanoparticles was more efficient in killing cancer cells than the free IM. 
Probably, this is due to the enhanced cellular uptake of lipid nanoparticles 
and/or a synergistic effect between QS (IC50 value = 8.167 μg/ml) and IM 
present in the IGPN3. Increased uptake of HA coated nanoparticles through 
CD44 mediated mechanism resulted in poor viability of cells [174]. 
Kesharwani et al. also reported poor viability of pancreatic cell lines when 
treated with HA conjugated dendrimer loaded with curcumin derivative [176]. 
HA coating further significantly improved the anticancer activity of HAC-
IGPN3 through anticipated specific CD44 targeting mechanism on over 
expressed cells and it was the most potent formulation among all with the least 
IC50 concentration. The beneficial effect of HA coating onto the surface of 
mitoxantrone polymeric nanoparticles has been reported and the authors found 
that coated particles possessed lower IC50 than uncoated nanoparticles on 
MCF-7 cells [174]. The anticancer property of QS might be the reason for the 
higher cytotoxic potentials of BGPNs and BGPNs- IM mixture against MCF7 
cells compared to IM.  
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 On the other hand, when the RAW 264.7 cells (murine macrophages) 
were treated with the samples (IM, QS, IGPN3, BGPNs, BGPNs + IM 
mixture, B12-IGPN3, HAJ-IGPN3 and HAC-IGPN3), more than 90% cells 
were viable indicating that normal cells were not affected by the samples used 
(Figure 66). These results (Table 22) indicate that IM and QS targeted only the 
cancerous cells. Cytotoxic effect of saponins against MCF7 cells and its 
protective effect against RAW 264.7 cells have been previously reported 
[186,193]. Although the mechanism behind the specificity of QS to cancer 
cells is unknown, as IM (a tyrosine kinase inhibitor which specifically targets 
cancer cells expressing tyrosine kinase genes) was used, it did not show 
toxicity against RAW 264.7 cells [178].  
 
 Propidium iodide (PI) is a fluorescent intercalating agent which can be 
used for staining dead cells [180]. In the current study, PI was used as a DNA 
stain to evaluate the DNA damage and to visualise the nucleus and other 
DNA-containing organelles. To confirm if free IM, IGPN3 and HA-IGPN 
induces apoptosis in MCF 7 cells the nuclear condensation of the DNA was 
analysed by propidium iodide (PI) staining. In the control cells, which were 
treated only with PBS, PI positive cells were not observed indicating absence 
of apoptosis. But, in the cells exposed with IGPN3 and HA-IGPN for 24 h, the 
number of PI positive cells increased (Figure 67) when compared to the cells  
treated with IM alone (Figure 67 b). As PI can’t cross the membrane of live 
cells the results indicate the death of the MCF 7 was due to apoptosis. The 
improved cytotoxicity of IGPN3 and HA-IGPN is possibly due to the smaller 
size of the SLNs.  
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7.7  SOLID LIPID NANOPARTICLES OF IMATINIB MESYLATE 
PREPARED USING GLYCERYL MONOSTEARATE AS LIPID 
CARRIER 
 The results from the experimental solubility studies, Hansen 
Hildebrand’s total solubility parameters and QSSR studies indicated 
glycerylmonostearate to show highest solubility for IM. IM loaded solid lipid 
nanoparticles of glyceryl monostearate (IGMN) were prepared by hot melt 
homogenisation using a combination of high shear homogenisation and probe 
sonication. Homogenisation at high speeds and for longer duration or probe 
sonication for longer duration can generate high kinetic energy which can 
ruptured the coating of the surfactant on the surface of the nanoparticles 
[63,194]. This ruptured particle surface can induce aggregation among the 
particles and consequently increased particle size. Additionally during these 
conditions, high amounts of heat will be generated which can further  
damage the particle surface. Hence, there should be optimum process 
parameters during the preparation of SLNs. For the preparation of IGMNs 
preliminary trials were conducted at different homogenizing conditions such 
as homogenising speeds of 10, 000 rpm- 15, 000 rpm, duration of 
homogenisation (2- 10 minutes) and duration of probe sonication (2- 10 
minutes). Considering the stability, the process parameters for preparing 
IGMNs were optimised as follows: high shear homogenising at 15, 000 rpm 
for 4 minutes and probe sonication for 6 minutes.  
 Various batches of IGMNs were prepared by changing the amount of 
GMS and QS. The particle size of different batches of IGMNs as measured by 
dynamic light scattering ranged from 126.6 ± 6.1 – 740.9 ± 15.6 nm (Table 
18). The smaller size of the nanoparticles could be attributed to the surfactant 
properties of the glyceryl monostearate [124,164], efficient solubilisation of 
IM in the lipid matrix and usage of high energy dispersive forces during the 
preparation of IGMNs. The particle size of IGMNs showed a negative 
correlation with the amount of lipid (GMS) and surfactant (QS) used. When 
the amount of QS was increased from 0.5% to 1.5%, the surface tension of the 
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medium could have reduced [131] and improved the dispersion of the lipid 
matrix in the water phase. Better dispersion of the lipid matrix could have 
facilitated reduction in the particle size of IGMNs. Due to the surface active 
properties of GMS, increased levels from 4% to 12 % could have facilitated 
reduction in the particle size similar to QS.  Thus, for the formation of IGMNs 
with least particle size, it is favourable to use high amounts of QS (4%) and 
GMS (12%). The zeta potential of the IGMNs was in the range of -14.96 ± 0.8 
mV to -2.92 ± 0.3 mV (Table 18). Due to the usage of QS, a non ionic 
surfactant in the preparation of IGMNs, the zeta potentials were neutral. The 
mild negative charges were due to the presence of ionised lipid moieties.  
 Analysis of the morphology using TEM showed aggregates of particles 
with a size around 150 nm. Size of the nanoparticles as visualised in TEM was 
found to be less when compared to the size obtained by Malvern particle size 
analyzer. Malvern particle size analyser uses the principle of dynamic light 
scattering, which measures the hydrodynamic diameter of the nanoparticles. 
But, TEM and AFM measures diameter of the dried nanoparticles. Hence, a 
smaller particle size was obtained using TEM. AFM images also showed 
clusters of nanoparticles aggregates. The results of AFM were in concordance 
with the results of TEM. 
 The entrapment efficiency of the formulations ranged from 41.9 ± 
1.1% to 54.1 ± 0.6% (Table 18). Usage of a hydrophilic drug and GMS (a 
lipid with surfactant properties) and high temperatures during the preparation 
of IGMNs could have been the reason for poor entrapment efficiency values 
[124]. GMS and high temperatures could have enhanced the solubility of IM 
in the aqueous medium and also could have facilitated its entry into the 
aqueous phase. During the storage of the formulations in refrigerated 
conditions, creaming or cracking were observed in 30 days. Hence, additional 
studies were not performed for these formulations.  
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7.8  SOLID LIPID NANOPARTICLES OF IMATINIB MESYLATE 
PREPARED USING GELEOL MONO AND DIGLYCERIDES 
AS LIPID CARRIER 
 Geleol mono and diglycerides, which is composed of mono and 
diglycerides of stearic and palmitic acid was also used to prepare solid lipid 
nanoparticles of IM. A hot melt homogenisation method using high shear 
homogenisation and probe sonication were used to prepare IM loaded solid 
lipid nanoparticles of Geleol mono and diglycerides (IGEN). Preliminary trials 
were attempted at various conditions of high shear homogenisation (speed and 
duration) and probe sonication (duration). Considering the stability and 
particle size, the working parameters were optimised to high shear 
homogenisation at 15, 000 rpm for 2 minutes and probe sonication for 6 
minutes. Different batches of IGEN were prepared by changing the amount of 
Geleol mono and diglycerides and QS. 
 The particle size of the formulations as measured by Malvern zeta sizer 
varied from 118.4 ± 5.1 nm to 653.9 ± 8.4 nm (Table 18). Although the 
composition of Geleol mono and diglycerides is majorly GMS, a particle size 
similar to the formulations prepared using GMS as a lipid carrier were not 
obtained as Geleol mono and diglycerides additionally contain diglycerides of 
stearic acid and palmitic acid apart from along with monoglycerides of stearic 
acid [195,196]. The composition of the lipid may have affected the particle 
size. The zeta potential of the formulations varied from -2.01 ± 0.1 mV to -
12.03 ± 2.7 mV.  Due to the usage of non ionic surfactant (QS) in the 
preparation of IGEN, the zeta potential of the formulations was neutral. A 
slight negative charge could be attributed to the ionisation of the fatty acid 
moieties [164,173].  
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 The morphology of the SLNs was analysed using TEM and AFM. 
TEM images showed spherical shaped particles with few aggregates in TEM 
and AFM. The particle size results as observed in TEM and AFM was in 
concordance with the results obtained by analysis of particle size using 
Malvern particle size analyser.  
 The entrapment efficiencies of the formulations ranged from 47.0 ± 
1.2% to 66.5 ± 1.3% (Table 18). Low entrapment efficiencies were poor due 
the usage of a hydrophilic drug and high speeds during homogenisation 
[65,197]. During the storage of the formulations in room temperature and 
refrigerated conditions, gelling was observed. Larger size of the nanoparticles 
and change of the physical state of the lipid carrier from amorphous to 
crystalline state could have caused expulsion of drug, which could have 
reduced the stability of the nanoparticles. Hence, additional studies were not 
performed for these formulations and usage of Geleol mono and diglycerides 
as lipid carrier for the preparation of solid lipid nanoparticles may not be 
suitable with the composition used in the current experimental studies. 
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7.9 PHARMACOKINETIC STUDIES TO QUANTIFY THE 
CONCENTRATION OF IMATINIB MESYLATE IN PLASMA 
AND SENTINAL LYMPH NODES 
 IM solubilised in pH 7.4 PBS (IM-PBS), ISN, HA-ISN, B12-ISN, 
IGPN, and HA-IGPN (sterile) were administered by subcutaneous route in 
female wistar rats to quantify the amount of IM present in the blood at 
different time points [181]. The T1/2 of IM when administered using pH 7.4 
PBS was 18.4 h. But, the T1/2 of IM increased after administering it as an 
encapsulated form in solid lipid nanoparticles. Among the formulations used, 
hyaluronic acid coated solid lipid nanoparticles enhanced the T1/2 of IM to 
nearly 42 h. B12-ISN increased the T1/2 of IM to nearly 26 h. The Cmax of IM 
administered via solid lipid nanoparticles was increased by 2-3 folds when 
compared to IM-PBS. Other parameters like AUC0-t, AUC0-∞ and AUMC0-t 
and AUMC0-∞ also increased for IM after administration with solid lipid 
nanoparticles. The results (Table 23) indicate entry of the solid lipid 
nanoparticles loaded with IM to the lymphatics before being drained into the 
systemic circulation. 
 Subcutaneous administration enabled the test substances to reach the 
interstitial area beneath the dermis of the skin [198,199]. HA-ISN and HA-
IGPN, whose particle size is below 100 nm could have been selectively 
absorbed to the regional lymphatics through the gaps present among the 
endothelial cells of the lymphatic capillaries. Additionally, the nanoparticles 
coated with hyaluronic acid bearing negative charge could have been pushed 
by the negatively charged glycosaminoglycans of the hyaluronan matrix to the 
lymphatics [94,174]. This is clearly justified by the increase in the half life, 
increase in Tmax, and decrease in Cmax of IM after administration by solid lipid 
nanoparticles. The enhanced concentration and half life of IM in the 
lymphatics can be helpful in killing the metastatic cancerous cells present in 
the lymph nodes.  
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 There was only a slight increasedin the T1/2 of IM after administering 
through ISN, B12-ISN and IGPN. As their particle size is above 100 nm, they 
could have directly entered the systemic circulation after subcutaneous 
administration. Due to the presence of non ionic surfactant coating around the 
surface of the solid lipid nanoparticles, their half life could have been 
increased, which could have consequently increased the Tmax, MRT0-∞, and 
AUC 0-∞. 
 The drug concentration profile in sentinel lymph nodes was measured 
to estimate the concentration of IM present in the lymph nodes (the residing 
place of metastatic cancer cells) at different time intervals [200,201]. At all 
time points (Table 24), the amount of IM present in the lymph nodes was 
higher when administered subcutaneously as IGPN3 and HA-IGPN when 
compared to administration of IM solution. Additional coating of hylauronic 
acid helped in the entry of higher levels of IM to the sentinel lymph nodes. 
The smaller sized nanoparticles and negatively charged matrix at the site of 
injection site could have propelled the transport of negatively charged HA-
IGPN to the sentianl lymph nodes. Higher Cmax was observed in the lymph 
nodes after administration of IGPNs and HA-IGPN when compared to the 
administration of IM in PBS solution. This clearly indicates that higher 
amounts of IM reached the sentinel lymph nodes after administration of HA-
IGPN and IGPN. 
 Thus, the results of the pharmacokinetic studies reflect the fact that 
subcutaneous administration of solid lipid nanoparticles with a particle size 
below 100 nm could be used to target the regional lymphatics, the residing 
place of metastatic cancerous cells. Additional coating with hyaluronic acid 
could be used to enhance the uptake to the lymphatics and increase its 
retention time. 
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7.10  STABILITY STUDIES 
 Stability studies were carried out ISN3, HAC-ISN, B12-ISN, IGPN3, 
HAC-IGPN and B12-IGPN at room temperature (20 - 25°C) and refrigerated 
conditions (3 to 5 °C) over a period of 12 months. The stability was indicated 
by measuring some parameters like appearance of the formulations, particle 
size, polydispersity index, zeta potential and entrapment efficiency. The 
results indicated good stability when stored at refrigerated conditions than 
when stored in room temperature. 
 During storage at room temperature, large floccules were observed for 
the all the formulations after 3 months. After 6 months, sedimentation was 
observed and some formulations dispersed upon shaking. At the end of 9 
months very large floccules were observed and were found difficult to 
disperse. The zeta potential of the formulations also gradually changed over a 
period of time. Entrapment efficiencies of the formulations also gradually 
decreased over a period of 12 months when stored at room temperature.  
 Whereas, for the formulations stored in refrigerated conditions, there 
were no floccules and sedimentation after 12 months. Very minimal increase 
in the particle size was observed (statistically insignificant). The zeta potential 
and entrapment efficiencies did not change when stored at refrigerated 
conditions. 
 During storage at room temperature, light and temperature provide 
extra energy to the nanoparticles [202,203]. This increased energy will 
enhance the Brownian motion and will consequently increase the collisions 
among them. Consequently, the outer surfactant coating will be eroded and 
leads to aggregation of particles. Thus, the particle size increases. This erosion 
of the surfactant will also change the values of zeta potentials. During storage, 
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the high energy lipid crystal matrix will transform to a low energy crystal 
form. This transformation usually causes expulsion of the drug from the 
matrix into the surrounding aqueous phase thereby leading to a reduction in 
the entrapment efficiencies of the SLNs. But, when stored at refrigerated 
conditions, which are devoid of light and high temperatures, a significant 
increase in the particle size or change in the zeta potential will not be 
observed. But, the entrapment efficiency may decrease as the lipids tend to 
change its crystalline state at any conditions. 
 Thus, it is favourable to store the SLNs at refrigerated conditions. 
Freeze drying of the SLN dispersion is also a good way to protect the particles 
against increasing particle size during storage. 
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8. SUMMARY AND CONCLUSION 
 The present work was proposed to develop ligand conjugated solid lipid 
nanoparticles of Imatinib mesylate (IM) to target the regional lymphatics of the 
breast to control metastasis of breast cancer. Efficient solubilisation of drugs in 
lipid is essential for successful development of lipid-based formulations (LBFs). 
Solubility of a drug in the lipid is a very important step in the development of 
LBFs. Examining the factors of lipids responsible for the solubility of drugs in the 
lipids and predicting the same can accelerate the development of LBFs. Through 
this research work, the role of chemical structures, polarity and various descriptors 
of the lipids which influenced in the solubilisation have been examined for the 
first time. Initially, the solubility of IM was experimentally quantified in various 
lipids. To correlate the quantitative solubility data with various forces connected 
to lipid-drug interaction, Hansen Hildebrand’s total solubility parameters were 
calculated. To develop a relationship between the various molecular and 
physicochemical descriptors of the lipids and experimental solubility of IM in 
lipids (% w/w), quantitative structure-solubility relationship (QSSR) was used. 
Using MLR, a statistically valid model to theoretically predict the solubility of IM 
in the lipids was developed. IM showed good solubility in long chain fatty acids 
with a relative short alkyl chain length than long chain fatty acids with a relatively 
longer chain length. Monoglyceride (glyceride monostearate) derived from these 
long chain fatty acids showed highest solubilisation as they are more polar, which 
facilitates solubilisation of IM by forming hydrogen bonds. The results show that 
alkyl chain length and polarity of the lipids, index of cohesive interaction in solids 
(AC×DN0.5/SA), estimated number of hydrogen bonds that would be accepted by 
the solute from water molecules in an aqueous solution (accptHB), estimated 
number of hydrogen bonds that would be donated by the solute to water molecules 
in an aqueous solution (donorHB) and solvent accessible surface area (SASA) 
collectively play a significant role in solubilising IM in the lipids. It would be 
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ideal to have a good balance between the number of hydrogen bond acceptors and 
donors to favour the solubilisation of hydrophilic drugs in the lipids. The equation 
developed using MLR predicted the amount of IM that could be soluble in lipids 
with good accuracy (R2pred = 0.912). 
 IM loaded solid lipid nanoparticles were prepared using a combination of 
high shear homogenisation and ultrasonication techniques using different lipid 
carriers (stearic acid, palmitic acid, glyceryl palmitostearate, glyceryl 
monostearate and Geleol mono and di glycerides) and quillaja saponin (QS) as a 
surfactant. Hyaluronic acid and vitamin B 12 were used to modify the surface of 
the SLNs. Nearly fifty formulations were prepared by varying the lipids and 
amount of QS. The particle size, zeta potential, surface morphology, entrapment 
efficiency and the physical state of the entrapped drug were found out. In vitro 
release studies were performed using phosphate buffer saline (pH 7.4). The 
cytotoxicity of the free IM, the encapsulated form of IM in solid lipid 
nanoparticles and its ligand conjugated form were evaluated in MCF 7 breast 
cancer cell line. Apoptosis was found out using propidium iodide staining.  
Finally, in vivo pharmacokinetic studies were performed in female wistar rats after 
subcutaneous administration to estimate the concentration of IM in blood and 
lymph. 
A least particle size of 92.1 ± 2.41 nm was observed for hyaluronic acid 
surface modified solid lipid nanoparticles of IM prepared using glyceryl 
palmitostearate as the lipid carrier (HAC-IGPN). These particles existed as nests 
containing 2-3 SLNs, with their outer surface intact. Additionally, with a neutral 
zeta potential, these nests of SLNs can reside in the lymphatics for a longer 
duration by evading opsonisation against macrophages and avoiding leakage 
outside the lymphatics. Usage of higher amount of QS generated SLNs with 
smaller size. As IM is a hydrophilic drug, the entrapment efficiencies of the 
formulations were low with a maximum of 65.9 ± 0.6% when glyceryl 
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palmitostearate were used as lipid carrier. The results of the in vitro release studies 
in phosphate buffer saline pH 7.4 showed that in almost 10 hours 100% of IM was 
released from the SLNs. 
QS has an innate potential to cause haemolysis of red blood cells due to its 
lipophilic moiety. But, when it was use in the preparation of SLNs, the lipophilic 
moiety adhered to the lipid phase of the SLNs, and thereby exposing the 
hydrophilic portion to the aqueous phase. These results showed that SLNs 
prepared using QS as a surfactant can be used for intravenous administration. The 
anticancer properties of QS, smaller size of SLNs and usage of conjugating agents 
(like hyaluronic acid and vitamin B12) showed synergistic apoptotic effect against 
MCF 7 cell line by lowering the IC50 value of IM loaded SLNs when compared to 
the free form of IM.  
The amount of IM present in the blood and lymph nodes at different time 
points was tested after subcutaneous administration of free IM and IM 
encapsulated in SLNs (unconjugated and HA conjugated). The results showed a 
higher T1/2 in blood for IM encapsulated in SLNs than the free form. Additionally, 
subcutaneous administration of SLNs assisted in delivering higher loads of 
amounts of IM to the sentinel lymph nodes when administered via SLNs. A 
particle size below 100 nm, usage of a non-ionic surfactant and adhesion of 
hyaluronic acid around the surface of SLNs could have helped in delivering higher 
amounts of IM to the lymph nodes. 
Thus, the results of the present study indicated that QSSR studies can be 
used as a tool to predict and study the role of lipids in solubilising IM. It was also 
shown for the first time that QS could be efficiently used as an emulsifier in the 
preparation of SLNs loaded with IM. Finally, subcutaneously administered 
hylauronic acid coated SLNs (loaded with IM) with a particle size below 100 nm 
can enhance the amount of IM that can reach the lymphatics. These SLNs can 
specifically target and kill the cancerous cells in the lymphatics and prevent 
metastasis to other organs. 
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9. IMPACT OF THE STUDY 
In the present scenario there are sufficient amount of anticancer drugs 
which can kill the tumor cells in the body. But, these drugs are equally toxic to the 
healthy cells of the body and cause several potential side effects, leading to 
reduced patient life and compliance. To avoid the possible side effects posed by 
the anticancer drugs, many people prefer surgical and radiation methods for the 
treatment. Though surgical removal of the tumor in breast cancer patients has 
been found to be beneficial, the incidence of recurrence of cancer to the other 
parts of the body (including breast) is very high and is attributed to metastasis of 
the cancer cells from the primary site through regional lymphatics. As metastasis 
of cancerous cells occurs in the regional lymphatics, it is essential for the drug to 
reach the regional lymphatics to arrest metastasis. In order to reach the 
lymphatics, the size of the particles should be in the range of 10- 100 nm, the 
uptake rate into the lymphatics should be high and the delivery route should be 
appropriate. Solid lipid nanoparticles (SLNs) can safely target and deliver 
anticancer drugs by subcutaneous administration to the regional lymphatics, the 
residing place of the metastatic cancer cells. Hence, the current doctoral research 
work has been planned to work on the development and evaluation of ligand 
conjugated SLNs of Imatinib mesylate (IM) which can specifically target and kill 
the tumor cells in the lymphatics. The development of SLNs requires 
solubilisation of the drug in the lipid carrier to achieve good entrapment 
efficiencies and stability. There is no model to predict the solubility of drugs in 
lipids. Hence, examining the various properties of lipids which influence their 
ability to solubilise the drugs has also been examined and a model has been 
developed to predict the solubility of IM in lipids for the first time. The utility of 
quillaja saponin (QS), a natural surfactant obtained from the bark of Quillaja 
saponaria, in the preparation of SLNs has also been evaluated for the first time. 
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Solid lipid nanoparticles of
diethylcarbamazine citrate for
enhanced delivery to the
lymphatics: in vitro and in vivo
evaluation
Karthik Siram, Vijaya Raghavan Chellan†, Tamilselvan Natarajan,
Balakumar Krishnamoorthy, Habibur Rahman Mohamed Ebrahim,
Vamshikrishna Karanam, Siva Selva Kumar Muthuswamy &
Hari Prasad Ranganathan
†PSG College of Pharmacy, Department of Pharmaceutics, Coimbatore, Tamil Nadu, India
Objectives: The major objective is to target diethylcarbamazine citrate (DEC)
to the lymphatics and to increase its retention time. The effect of various
excipients on the physicochemical characteristics of the nanoparticles was
also studied.
Materials and methods: Solid lipid nanoparticles (SLNs) of DEC were prepared
by ultrasonication by varying the concentrations of compritol 888 ATO, polox-
amer 188 and soya lecithin. The SLNs were evaluated for size, shape, texture,
surface charge, physical nature of the entrapped drug, entrapment efficiency
and in vitro drug release. In vivo animal studies were carried out to estimate
the pharmacokinetic parameters in blood and drug concentration in lymph
after oral administration.
Results: The size of the spherical particles was in the range of 27.25 ± 3.43 nm
to 179 ± 3.08 nm and a maximum entrapment efficiency of 68.63 ± 1.53% was
observed. In vitro release studies in pH 7.4 PBS displayed a rapid release and
the maximum time taken for the complete drug to release was 150 min.
In vivo studies indicated an enhancement in the amount of drug that reached
lymphatics when administered via SLNs.
Conclusion: Targeting of DEC to the lymphatics is possible through SLNs and
the retention time in the lymphatics can also be enhanced.
Keywords: diethylcarbamazine citrate, filariasis, lymphatic targeting, mesenteric lymphatic duct,
poloxamer 188, solid lipid nanoparticles
Expert Opin. Drug Deliv. [Early Online]
1. Introduction
The lymphatic system is an important repository for some diseases like filariasis [1],
tuberculosis [2], AIDS [3], metastatic cancers [4], edema [5] and so on and also plays a
role in the inflammatory processes [6]. The lymphatic system majorly modulates the
immune system, and because of the complex nature and complex roles of the
lymphatics, targeting of drugs to the lymphatics is challenging [7]. Thus, in order
to target the drugs to the lymphatics and to further increase the residence time in
the lymphatics, the moieties apart from reaching the lymphatic system should evade
opsonization by reticuloendothelial system (RES), which can be possible by
preparing particles of size > 100 nm [8].
Lymphatic filariasis is a vector-borne parasitic disease caused by three kinds of
thread-like, parasitic filarial worms: Wuchereria bancrofti, Brugia malayi or Brugia
10.1517/17425247.2014.915310 © 2014 Informa UK, Ltd. ISSN 1742-5247, e-ISSN 1744-7593 1
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Solid Lipid Nanoparticles of Albendazole for 
Enhancing Cellular Uptake and Cytotoxicity  
against U-87 MG Glioma Cell Lines 
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Abstract: Albendazole (ABZ) is an antihelminthic drug used for the treatment of several parasitic 
infestations. In addition to this, there are reports on the anticancer activity of ABZ against a wide 
range of cancer types. However, its effect on glioma has not yet been reported. In the present study, 
cytotoxicity of ABZ and ABZ loaded solid lipid nanoparticles (ASLNs) was tested in human 
glioma/astrocytoma cell line (U-87 MG). Using glyceryl trimyristate as lipid carrier and tween 80 as 
surfactant spherical ASLNs with an average size of 218.4 ± 5.1 nm were prepared by a combination 
of high shear homogenization and probe sonication methods. A biphasic in vitro release pattern of 
ABZ from ASLNs was observed, where 82% of ABZ was released in 24 h. In vitro cell line studies 
have shown that ABZ in the form of ASLNs was more cytotoxic (IC50 = 4.90 µg/mL) to U-87 MG 
cells compared to ABZ in the free form (IC50 = 13.30 µg/mL) due to the efficient uptake of the former 
by these cells. 
Keywords: albendazole; solid lipid nanoparticles; U-87 MG cells; cytotoxicity; cellular uptake 
 
1. Introduction 
Development of new drugs with increased activity against cancer cells is the major focus of the 
pharmaceutical industry. Unfortunately, many of the new drugs are often toxic to the healthy cells as 
well. Hence, there is a space for the development of drugs that are toxic only to cancer cells. Although 
albendazole (ABZ) is known for its antihelminthic activity, recent studies show that it possesses 
significant anticancer activity as well. ABZ is an affordable drug, which exhibits antihelminthic 
activity even at a very low concentration (7.5 mg/kg) [1]. The ability of ABZ to destroy the β tubulin 
structures of the helminthes has also been exploited to kill tumor cells. Activities of ABZ against 
colorectal cancer and peritoneal carcinomatosis have been demonstrated respectively using HT-29 
cell line and xenograft models [2]. Later, the ability of ABZ to inhibit cell proliferation, vascular 
endothelial growth factor and tumor growth was discovered [3]. In addition, ABZ could also arrest 

CHAPTER
7Nanomaterials in drugdelivery: existing scenario
and potential scope
Habibur Rahman1, Balakumar Krishnamoorthy1, Natarajan Tamilselvan1,
Karthik Siram1, Sridhar Karthik1 and Ranganathan Hariprasad2
1
Department of Pharmaceutics, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India
2
Department of Pharmaceutical Analysis, PSG College of Pharmacy, Coimbatore,
Tamil Nadu, India
7.1 NANOTECHNOLOGY IN DRUG DELIVERY
Nanotechnology employs engineered materials or devices in the nanometer size
range (1 1000 nm). Richard Feynman introduced the concept of nanotechnology
as an important field of future scientific research in 1959 (Feynman, 1960).
Nanotechnology applications in drug delivery are witnessed by many novel nano-
devices. There has been substantial attention to the growth of novel drug delivery
using nanotechnology. Nanoparticles (NPs) symbolize a promising drug-delivery
scheme of controlled and targeted release. The advantages of nanoparticles as
drug-delivery systems include reduced drug toxicity, time-controlled drug deliv-
ery, enhanced bioavailability, improved therapeutic efficacy, and biodistribution
(Ravi Kumar, 2000). Nanotechnology also protects sensitive drugs from degrada-
tion by environmental factors, namely, stomach acid and enzymes (Jores et al.,
2004). Polymeric nanoparticles are in the size range of 10 1000 nm (Kreuter,
2001), and can be tailored with di.verse ligands, namely, antibodies to create a
smart targeting delivery system. Polymeric nanoparticles in the size range of
300 nm or less with surfactant coatings have been proved to be able to transport
drugs across the blood brain barrier (BBB) (Schroeder et al., 1998). Recent
advancements and applications of nanotechnology in drug delivery have proven
effective for treating many diseases. Nanotechnology growth is unprecedented in
the development of nanotherapeutics such as controlled drug-delivery systems,
site-specific/targeted drug delivery, gene delivery, lipid-based delivery systems,
implants, smart/intelligent drug-delivery systems, polymeric nanosystems, colloi-
dal systems, etc.
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a  b  s  t  r  a  c  t
Quillaja  saponin  (QS)  is a non-ionic  amphiphilic  surfactant  of  natural  origin.  In the  present  study,  we
evaluated  its  potential  to  form  solid  lipid nanoparticles  (SLNs)  in  the  presence  of stearic  acid  (SA)  as a
lipid  carrier  and imatinib  mesylate  (IM)  as  a  model  drug.  IM  loaded  solid  lipid  nanoparticles  (IMSLNs)
were  prepared  using  the  hot  homogenisation  method.  Characterisation  of  IMSLNs  revealed  that  they  were
quasi-spherical  in shape,  neutrally  charged  and  143.5–641.9  nm in  size.  Haemolysis,  a toxicity  issue of QS
was not  observed  in  SLNs.  Comparative  in  vitro  cytotoxicity  analyses  performed  in human  breast  cancer
cell line  MCF7  revealed  that  IMSLNs  were  more  toxic  than  IM.  On  the other  hand,  in vitro  viability  studies
in  the  RAW264.7  cell  line  did  not  show  any  sign  of  toxicity  by  IMSLNs.  Our  results  indicate  that  QS  hold
great  potential  in nano  drug  delivery  as an  emulsiﬁer.
© 2016  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Applications of solid lipid nanoparticles (SLNs) have increased
tremendously in recent times due to their major advantages such
as biocompatibility, biodegradability, ease of preparation, poten-
tial for scale up and cost effectiveness. SLNs consist of a solid lipid
core dispersed in aqueous solutions of stabilisers or surfactants at
room temperature [1]. Stearic acid, palmitic acid, glyceryl behenate,
etc., are the commonly used lipids; whereas, poloxamers, polysor-
bates, phospholipids, bile salts, sodium oleate, cremophor EL, etc.
are commonly used as stabilisers in the preparation of SLNs. In
this communication, we report on the efﬁcient preparation of SLNs
loaded with an anticancer drug using Quillaja saponin (QS) for the
ﬁrst time.
QS is a non-ionic amphiphilic surfactant extracted from the bark
of Quillaja saponaria (Soap bark tree). QS is a glycoside (Fig. 1) with
a lipophilic backbone of quillaic acid and gypsogenic acid (a triter-
pene aglycone), to which hydrophilic polysaccharide moieties like
∗ Corresponding author at: Department of Integrative Plant Biology, Institute of
Plant Genetics of the Polish Academy of Sciences, Strzeszyn´ska 34, 60-479 Poznan´,
Poland.
E-mail address: fgre@igr.poznan.pl (G. Franklin).
1 Contributed equally to this work.
rhamnose, xylose, arabinose, galactose, fucose, and glucuronic acid
are attached [2]. Thus, QS can perform the role of a surfactant by
adsorbing at the oil and water interface to form an emulsion [3].
Despite the characterisation of the micellar properties of QS as early
as 1800 AD and approval by the US Food and Drug Administration
(FDA) [4], its application has not gained prominence in the pharma-
ceutical sector so far. In addition to its emulsifying property, QS also
possesses many bioactivities (larvicidal, antitumor, antimicrobial
etc.) and is used as a natural foaming agent in cosmetic products,
and as an adjuvant in vaccine delivery [5–7]. Furthermore, a prod-
uct based on the Q. saponaria bark extract is marketed under the
trade name Q-Naturale and approved by FDA for use as emulsiﬁer
in beverages.
The aim of the present study was  to investigate the possibility
of using QS as a surfactant in the preparation of SLNs contain-
ing an anticancer drug. Brieﬂy, we  have used stearic acid (SA), an
18-carbon fatty acid as the lipid core to encapsulate imatinib mesy-
late (IM), a hydrophilic anticancer drug. The prepared SLNs, loaded
with IM (IMSLN), were physicochemically characterised for particle
size distribution, morphology, zeta potential, crystallinity, entrap-
ment efﬁciency and drug release. In addition, they were analysed
for in vitro haemolytic activity, cytotoxicity and viability using cell
lines. Our results demonstrate that QS is an excellent stabiliser for
the preparation of SLNs without any haematotoxicity.
http://dx.doi.org/10.1016/j.colsurfb.2016.07.065
0927-7765/© 2016 Elsevier B.V. All rights reserved.
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A brief perspective on the diverging theories of 
lymphatic targeting with colloids 
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Abstract: For targeted delivery of colloids to the lymphatic system, the colloids should 
efficiently reach and remain in the lymphatics for a considerable period of time. As per the current 
knowledge, diffusion and phagocytosis are the two mechanisms through which colloids reach 
the lymphatic system. Several parameters including particle size and charge have been shown to 
affect the direct uptake of colloids by the lymphatic system. Although many researchers attached 
ligands on the surface of colloids to promote phagocytosis-mediated lymphatic delivery, another 
school of thought suggests avoidance of phagocytosis by use of carriers like polyethylene glycol 
(PEG)ylated colloids to impart stealth attributes and evade phagocytosis. In this perspective, we 
weigh up the paradoxical theories and approaches available in the literature to draw conclusions 
on the conditions favorable for achieving efficient lymphatic targeting of colloids.
Keywords: lymphatic targeting, colloids, PEGylation, phagocytosis
Introduction
The lymphatic system (lymphatics), which encompasses the circulating lymph, 
network of lymphatic pathways (lymphatic capillaries, collecting vessels, trunks, and 
ducts), and lymphatic organs (lymph nodes, thymus, bone marrow, tonsils, spleen, 
etc) is present throughout the body in conjunction with the systemic circulation. The 
lymph is formed by the transport of interstitial fluid surrounding the blood vessels 
into the lymphatic capillaries. Thus, the lipids, enzymes, and protein composition of 
lymph and plasma remain the same and vary only in concentrations.1,2 The lymphatic 
system removes foreign bodies from the body and maintains homeostasis. Apart from 
mediating the immune functions and tissue fluid balance, the lymphatics also act as a 
reservoir for human immunodeficiency virus, filariasis, tuberculosis, and metastatic 
cancer cells.3 Hence, lymphatic targeting of molecules, compounds, vaccines, and so 
on will be useful for diagnosis and therapy and eliciting immune responses. Colloids 
have emerged as an important class of drug carriers for targeted delivery into the 
complex lymphatic system.4 Targeting colloids to the lymphatics involves two major 
steps: first, the targeting material should reach the lymphatic structures and then it 
should reside there for a considerable period of time by evading the host immune traf-
ficking mechanisms. A plethora of articles on lymphatic targeting using colloids sug-
gests that several parameters such as surface charge, particle size, molecular weight, 
route of administration, nature of the colloid and its surface properties (hydrophilicity 
and lipophilicity), and so on play a role in targeting colloids to the lymphatics, and a 
discussion on each of those factors is out of focus of this perspective as it would be 
a mere repetition of the already established facts. However, the role of phagocytosis 
and polyethylene glycol (PEG) attachment to colloids (PEGylation) on lymphatic 
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